Circovirus sequences associated with piglet weight loss disease (PWD)

ABSTRACT

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

INFORMATION ON RELATED APPLICATIONS

This application is a continuation-in-part of International ApplicationNo. PCT/FR98/02634, filed Dec. 4, 1998.

The invention relates to the genome sequences and nucleotide sequencescoding for polypeptides of PWD circovirus, such as the structural andnonstructural polypeptides of said circovirus, as well as vectorsincluding said sequences and cells or animals transformed by thesevectors. The invention likewise relates to methods for detecting thesenucleic acids or polypeptides and kits for diagnosing infection by thePWD circovirus. The invention is also directed to a method for selectingcompounds capable of modulating the viral infection. The inventionfurther comprises pharmaceutical compositions, including vaccines, forthe prevention and/or the treatment of viral infections by PWDcircovirus as well as the use of a vector according to the invention forthe prevention and/or the treatment of diseases by gene therapy.

Piglet weight loss disease (PWD), alternatively called fatal pigletwasting (FPW) has been widely described in North America (Harding, J.C., 1997), and authors have reported the existence of a relationshipbetween this pathology and the presence of porcine circovirus (Daft, B.et al., 1996; Clark, E. G., 1997; Harding, J. C., 1997; Harding, J. C.and Clark, E. G., 1997; Nayar, G. P. et al., 1997). A porcine circovirushas already been demonstrated in established lines of cell culturesderived from pigs and chronically infected (Tischer, I., 1986, 1988,1995; Dulac, G. C., 1989; Edwards, S., 1994; Allan, G. M., 1995 andMcNeilly, F., 1996). This virus, during experimental infection ofpiglets, does not prove pathogenic for pigs (Tischer, I., 1986, Horner,G. W., 1991) and its nucleotide sequence has been determined andcharacterized (Tischer, I., 1982; Meehan, B. M. et al., 1997; Mankertz.,A., 1997). The porcine circovirus, called PCV virus, is part of thecircovirus genus of the circoviridae family (Murphy, F. A. et al., 1995)whose virion has a circular DNA of size between 1.7 and 2.3 kb, whichDNA comprises three open reading frames (ORF1 to ORF3), coding for areplication protein REP involved in the initiation and termination phaseof rolling circular replication (RCR) (Heyraud-Nitschke, F., et al.,1995; Harding, M. R. et al., 1993; Hanson, S. F. et al., 1995; Fontes,E. P. B. et al., 1994), coding for a capsid protein (Boulton, L. H. etal., 1997; Hackland, A. F. et al., 1994; Chu, P. W. G. et al., 1993) andcoding for a nonstructural protein called a dissemination protein(Lazarowitz., S. G. et al., 1989).

The authors of the present invention have noticed that the clinicalsigns perceptible in pigs and linked to infection by the PWD circovirusare very distinctive. These manifestations in general appear in pigs of8 to 12 weeks of age, weaned for 4 to 8 weeks. The first signs arehypotonia without it being possible to speak of prostration. Rapidly (48hours), the flanks hollow, the line of the spine becomes apparent, andthe pigs “blanch.” These signs are in general accompanied byhyperthermia, anorexia and most often by respiratory signs (coughing,dyspnea, polypnea). Transitory diarrhea can likewise appear. The diseasestate phase lasts approximately one month at the end of which the rateof mortality varies from 5 to 20%. To these mortalities, it is expedientto add a variable proportion (5-10%) of cadaveric animals which are nolonger able to present an economic future. It is to be noted thatoutside of this critical stage of the end of post-weaning, no anomalyappears on the farms. In particular, the reproductive function istotally maintained.

On the epidemiological level, the first signs of this pathology appearedat the start of 1995 in the east of the Côtes d'Armor region in France,and the farms affected are especially confined to this area of theregion. In December 1996, the number of farms concerned could not beevaluated with precision because of the absence of a specific laboratorydiagnostic method or of an epidemioligical surveillance system of thelivestock. Based on the clinical facts as well as on results ofpostmortem examinations supplied by veterinarians, it is possible toestimate this number as several dozen (80-100). The contagiousness ofthe disease is weak to moderate. Cases are being reported outside theinitial area and for the majority are following the transfer of animalscoming from farms familiar with the problem. On the other hand, acharacteristic of the condition is its strong remanence. Thus, farmswhich have been affected for a year are still affected in spite of themassive administration of therapeutics. Farms with clinical expressionare drawn from various categories of specialization (breeders/fatteners,post-weaners/fatteners) and different economic structures are concerned.In addition, the disorders appear even in farms where the rules ofanimal husbandry are respected.

Numerous postmortem examinations have been carried out either on farmsor in the laboratory. The elements of the lesional table are disparate.The most constant macroscopic lesions are pneumonia which sometimesappears in patchy form as well as hypertrophy of the lymphatic ganglia.The other lesions above all affect the thoracic viscera including,especially, pericarditis and pleurisy. However, arthritis and gastriculcers are also observed. The lesions revealed in the histologicalexamination are essentially situated at the pulmonary level(interstitial pneumonia), ganglionic level (lymphoid depletion of thelymph nodes, giant cells) and renal level (glomerulonephritis,vasculitis). The infectious agents have been the subject of wideresearch. It has been possible to exclude the intervention ofpestiviruses and Aujeszky's disease. The disorders appear in theseropositive PDRS (Porcine Dysgenic and Respiratory Syndrome, aninfection linked to an arteriovirus) herds, but it has not been possibleto establish the role of the latter in the genesis of the disorders (themajority of the farms in Brittany are PDRS seropositive).

The authors of the present invention, with the aim of identifying theetiological agent responsible for PWD, have carried out “contact” testsbetween piglets which are obviously “ill” and SPF pigs (specificpathogen-free) from CNEVA (Centre National d'Etudes Veterinaires etAlimentaires, France). These tests allow the development of signscomparable to those observed on the farm to be observed in protectedanimal houses. The discrete signs such as moderate hyperthermia,anorexia and intermittent diarrhea appeared after one week of contact.It must be noted that the PDRS virus only diffused subsequent to theclinical signs. In addition, inocculations of organ homogenates of sickanimals to healthy pigs allowed signs related to those observed on thefarms to be reproduced, although with a lower incidence, linked to thefavorable conditions of upkeep of the animals in the experimentalinstallations.

Thus, the authors of the present invention have been able to demonstratethat the pathological signs appear as a well-defined entity affectingthe pig at a particular stage of its growth.

This pathology has never been described in France. However, sparseinformation, especially Canadian, relates to similar facts.

The disorders cannot be mastered with the existing therapeutics.

The data collected both on the farm and by experimentation have allowedthe following points to be higlighted:

PWD is transmissible but its contagiousness is not very high,

its etiological origin is of infectious and probably viral nature,

PWD has a persistent character in the affected farms.

Considerable economic consequences ensue for the farms.

Thus, there is currently a significant need for a specific and sensitivediagnostic, whose production is practical and rapid, allowing the earlydetection of the infection.

A reliable, sensitive and practical test which allows the distinctionbetween strains of porcine circovirus (PCV) is thus strongly desirable.

On the other hand, a need for efficient and well-tolerated treatment ofinfections with PWD circovirus likewise remains desirable, no vaccinecurrently being available against PWD circovirus.

Concerning PWD circovirus, it will probably be necessary to understandthe role of the immune defense in the physiology and the pathology ofthe disease to develop satisfactory vaccines.

Fuller information concerning the biology of these strains, theirinteractions with their hosts, the associated infectivity phenomena andthose of escape from the immune defenses of the host especially, andfinally their implication in the development of associated pathologies,will allow a better understanding of these mechanisms. Taking intoaccount the facts which have been mentioned above and which show inparticular the limitations of combatting infection by the PWDcircovirus, it is thus essential today on the one hand to developmolecular tools, especially starting from a better genetic knowledge ofthe PWD circovirus, and likewise to perfect novel preventive andtherapeutic treatments, novel methods of diagnosis and specific,efficacious and tolerated novel vaccine strategies. This is preciselythe subject of the present invention.

SUMMARY OF THE INVENTION

The present invention relates to vaccines comprising a nucleotidesequence of the genome of Porcine circovirus type B, or a homologue orfragment thereof, and an acceptable pharmaceutical or veterinaryvehicle. In one embodiment of the invention, the nucleotide sequence isselected from SEQ ID No. 15, SEQ ID No. 19 SEQ ID No. 23, or SEQ ID No.25, or a homologue or fragment thereof. In another embodiment of theinvention, the homologue has at least 80% sequence identity to SEQ IDNo. 15, SEQ ID No. 19, SEQ ID No. 23 or SEQ ID No. 25. In yet anotherembodiment, the vaccines further comprising an adjuvant.

The present invention also relates to vaccines comprising a polypeptideencoded by a nucleotide sequence of the genome of PCVB, or a homologueor fragment thereof, and an acceptable pharmaceutical or veterinaryvehicle. In one embodiment, the homologue has at least 80% sequenceidentity to SEQ ID No. 15, SEQ ID No. 19, SEQ ID No. 23 or SEQ ID No.25. In another embodiment of the invention, the nucleotide sequence isselected from SEQ ID No. 23 or SEQ ID No. 25, or a homologue or fragmentthereof. In still another embodiment, the polypeptide has the amino acidsequence of SEQ ID No. 24 or SEQ ID No. 26. In yet another embodiment,the homologue has at least 80% sequence identity to SEQ ID No. 24 or SEQID No. 26. In another embodiment, the polypeptide has the amino acidsequence of SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, or SEQ ID No.32.

A further aspect of the invention relates to vaccines comprising avector and an acceptable pharmaceutical or veterinary vehicle, thevector comprising a nucleotide sequence of the genome of Porcinecircovirus type B, or a homologue or fragment thereof. In oneembodiment, the vaccine further comprises a gene coding for anexpression product capable of inhibiting or retarding the establishmentor development of a genetic or acquired disease.

The present invention also relates to vaccines comprising a cell and anacceptable pharmaceutical or veterinary vehicle, wherein the cell istransformed with a nucleotide sequence of the genome of Porcinecircovirus type B, or a homologue or fragment thereof.

Still further, the present invention relates to vaccines comprising apharmaceutically acceptable vehicle and a single polypetide, wherein thesingle polypeptide consists of SEQ ID No. 26.

Additionally, the present invention relates to methods of immunizing amammal against piglet weight loss disease comprising administering to amammal an effective amount of the vaccines described above.

These and other aspects of the invention will become apparent to theskilled artisan in view of the teachings contained herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Experimental scheme which has made it possible to bring aboutthe isolation and the identification of the circovirus associated withPWD of type A and B.

Test 1: experimental reproduction of the PWD by inoculation of pig organhomogenates from farms affected by PWD.

Test 2: experimental reproduction of PWD.

Test 3: experimental reproduction of PWD.

Test 4: no experimental reproduction of PWD.

FIG. 2: Organization of the genome of the circovirus associated with PWDof type A (PCVA)

strand of (+) polarity (SEQ ID No. 1);

strand of (−) polarity (SEQ ID No. 5, represented according to theorientation 3′→5′);

sequences of amino acids of proteins encoded by the two DNA strands inthe three possible reading frames SEQ ID NOS: 2-4 and 6-8 respectively.

FIG. 3: Alignment of the nucleotide sequence SEQ ID No. 1 of the PWDcircovirus of type A (PCVA) and of the MEEHAN SEQ ID No. 163 strain andMANKERTZ SEQ ID No. 164 strain circoviruses of the porcine cell lines.

FIG. 4: Alignment of the sequence of amino acids SEQ ID No. 10 of apolypeptide encoded by the nucleotide sequence SEQ ID No. 9 (ORF1) ofthe PWD circovirus of type A (PCVA) and of corresponding nucleotidesequences of the MEEHAN SEQ ID No. 165 strain and MANKERTZ SEQ ID No.166 strain circoviruses of the porcine cell lines.

FIG. 5: Alignment of the sequence of amino acids SEQ ID No. 12 of apolypeptide encoded by the nucleotide sequence SEQ ID No. 11 (ORF2) ofthe PWD circovirus of type A (PCVA) and of corresponding nucleotidesequences of the MEEHAN SEQ ID No. 167 strain and MANKERTZ SEQ ID No.168 strain circoviruses of the porcine cell lines.

FIG. 6: Alignment of the sequence of amino acids SEQ ID No. 14 of apolypeptide encoded by the nucleotide sequence SEQ ID No. 13 (ORF3) ofthe PWD circovirus of type A (PCVA) and of corresponding nucleotidesequences of the MEEHAN SEQ ID No. 169 strain and MANKERTZ SEQ ID No.170 strain circoviruses of the porcine cell lines.

FIG. 7: Western blot analysis of recombinant proteins of the PWDcircovirus of type A (PCVA).

The analyses were carried out on cell extracts of Sf9 cells obtainedafter infection with recombinant baculovirus PCF ORF 1.

FIG. 8: Organization of the genome of the circovirus associated with thePWD of type B (PCVB)

strand of (+) polarity (SEQ ID No. 15);

strand of (−) polarity (SEQ ID No. 19, represented according to theorientation 3′→5′);

sequence of amino acids of proteins encoded by the two DNA strands inthe three possible reading frames SEQ ID NOS: 16-18 and 20-22respectively.

FIG. 9: Evolution of the daily mean gain (DMG) of pig farms affected bypiglet weight loss disease (PWD), placed under experimental conditions.

FIG. 10: DMG compared for the 3 batches of pigs (F1, F3 and F4)calculated over a period of 28 days, after vaccination test.

FIG. 11: Hyperthermia greater than 41° C., expressed as a percentagecompared for the 3 batches of pigs (F1, F3 and F4) calculated per weekover a period of 28 days, after vaccination test.

FIG. 12: Membranes of peptide spots corresponding to the ORF2s revealedwith the aid of an infected pig serum, originating from a conventionalfarm.

The numbers of specific peptides of the circovirus of type B as well astheir nonreactive homologs (type A) are indicated in bold.

The nonspecific immunogenic peptides are indicated in italics.

FIG. 13: Alignment of amino acid sequences of proteins encoded by theORF2 of the PWD circovirus of type A SEQ ID No. 12 and by the ORF′2 ofthe PWD circovirus of type B SEQ ID No. 26. The position of 4 peptidescorresponding to specific epitopes of the PWD circovirus of type B isindicated on the corresponding sequence by a bold line, their homolog onthe sequence of the PWD circovirus of type A is likewise indicated by anordinary line.

FIG. 14: Charts the results of experiments that demonstrate, in terms ofpercent hyperthermia, that vaccination with ORF′1 and ORF′2 of PCV-Benhances the level of protection in swine challenged with PCV-B (Percenthyperthermia: >40.5° C., Control: not vaccinated and not challenged,ORF′1: vaccinated and challenged, ORF′2: vaccinated and challenged,ORF−: not vaccinated, challenged).

FIG. 15: Charts the results of experiments that demonstrate, in terms ofanimal growth, that vaccination with ORF′1 and ORF′2 of PCV-B enhancesthe level of protection in swine challenged with PCV-B (Control: notvaccinated and not challenged, ORF′1: vaccinated and challenged, ORF′2:vaccinated and challenged, ORF−: not vaccinated, challenged).

FIG. 16: Immunoperoxidase staining of PK15 cells at 24 hpost-transfection with the pcDNA3/ORF′2 plasmid. Expression of PCVBORF′2 was confirmed by IPMA following incubation in the presence of theswine anti-PCVB monospecific serum.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to nucleotide sequences of the genome ofPWD circovirus selected from the sequences SEQ ID No. 1, SEQ ID No. 5,SEQ ID No. 15, SEQ ID No. 19 or one of their fragments.

The nucleotide sequences of sequences SEQ ID No. 1 and SEQ ID No. 5correspond respectively to the genome sequence of the strand of (+)polarity and of the strand of (−) polarity of the PWD circovirus of typeA (or PCVA), the sequence SEQ ID No. 5 being represented according tothe orientation 5′→3′.

The nucleotide sequences of sequences SEQ ID No. 15 and SEQ ID No. 19correspond respectively to the genome sequence of the strand of (+)polarity and of the strand of (−) polarity of the PWD circovirus of typeB (or PCVB), the sequence SEQ ID No. 19 being represented according tothe orientation 5′→3′.

The present invention likewise relates to nucleotide sequences,characterized in that they are selected from:

a) a nucleotide sequence of a specific fragment of the sequence SEQ IDNo. 1, SEQ ID No. 5, SEQ ID No. 15, SEQ ID No. 19 or one of theirfragments;

b) a nucleotide sequence homologous to a nucleotide sequence such asdefined in a);

c) a nucleotide sequence complementary to a nucleotide sequence such asdefined in a) or b), and a nucleotide sequence of their correspondingRNA;

d) a nucleotide sequence capable of hybridizing under stringentconditions with a sequence such as defined in a), b) or c);

e) a nucleotide sequence comprising a sequence such as defined in a),b), c) or d); and

f) a nucleotide sequence modified by a nucleotide sequence such asdefined in a), b), c), d) or e).

Nucleotide, polynucleotide or nucleic acid sequence will be understoodaccording to the present invention as meaning both a double-stranded orsingle-stranded DNA in the monomeric and dimeric (so-called in tandem)forms and the transcription products of said DNAs.

It must be understood that the present invention does not relate to thegenomic nucleotide sequences taken in their natural environment, that isto say in the natural state. It concerns sequences which it has beenpossible to isolate, purify or partially purify, starting fromseparation methods such as, for example, ion-exchange chromatography, byexclusion based on molecular size, or by affinity, or alternativelyfractionation techniques based on solubility in different solvents, orstarting from methods of genetic engineering such as amplification,cloning and subcloning, it being possible for the sequences of theinvention to be carried by vectors.

The nucleotide sequences SEQ ID No. 1 and SEQ ID No. 15 were obtained bysequencing of the genome by the Sanger method.

Nucleotide sequence fragment according to the invention will beunderstood as designating any nucleotide fragment of the PWD circovirus,type A or B, of length of at least 8 nucleotides, preferably at least 12nucleotides, and even more preferentially at least 20 consecutivenucleotides of the sequence from which it originates.

Specific fragment of a nucleotide sequence according to the inventionwill be understood as designating any nucleotide fragment of the PWDcircovirus, type A or B, having, after alignment and comparison with thecorresponding fragments of known porcine circoviruses, at least onenucleotide or base of different nature. For example, the specificnucleotide fragments of the PWD circovirus of type A can easily bedetermined by referring to FIG. 3 of the present invention in which thenucleotides or bases of the sequence SEQ ID No. 1 (circopordfp) areshown which are of different nature, after alignment of said sequenceSEQ ID No. 1 with the other two sequences of known porcine circovirus(circopormeeh and circopormank).

Homologous nucleotide sequence in the sense of the present invention isunderstood as meaning a nucleotide sequence having at least a percentageidentity with the bases of a nucleotide sequence according to theinvention of at least 80%, preferably 90% or 95%, this percentage beingpurely statistical and it being possible to distribute the differencesbetween the two nucleotide sequences at random and over the whole oftheir length.

Specific homologous nucleotide sequence in the sense of the presentinvention is understood as meaning a homologous nucleotide sequencehaving at least one nucleotide sequence of a specific fragment, such asdefined above. Said “specific” homologous sequences can comprise, forexample, the sequences corresponding to the genomic sequence or to thesequences of its fragments representative of variants of PWD circovirusof type A or B. These specific homologous sequences can thus correspondto variations linked to mutations within strains of PWD circovirus oftype A and B, and especially correspond to truncations, substitutions,deletions and/or additions of at least one nucleotide. Said homologoussequences can likewise correspond to variations linked to the degeneracyof the genetic code.

The term “degree or percentage of sequence homology” refers to “degreeor percentage of sequence identity between two sequences after optimalalignment” as defined in the present application.

Two amino-acids or nucleotidic sequences are said to be “identical” ifthe sequence of amino-acids or nucleotidic residues, in the twosequences is the same when aligned for maximum correspondence asdescribed below. Sequence comparisons between two (or more) peptides orpolynucleotides are typically performed by comparing sequences of twooptimally aligned sequences over a segment or “comparison window” toidentify and compare local regions of sequence similarity. Optimalalignment of sequences for comparison may be conducted by the localhomology algorithm of Smith and Waterman, Ad. App. Math 2: 482 (1981),by the homology alignment algorithm of Neddleman and Wunsch, J. Mol.Biol. 48: 443 (1970), by the search for similarity method of Pearson andLipman, Proc. Natl. Acad. Sci. (U.S.A.) 85: 2444 (1988), by computerizedimplementation of these algorithms (GAP, BESTFIT, FASTA, and TFASTA inthe Wisconsin Genetics Software Package, Genetics Computer Group (GCG),575 Science Dr., Madison, Wis.), or by visual inspection.

“Percentage of sequence identity” (or degree or identity) is determinedby comparing two optimally aligned sequences over a comparison window,where the portion of the peptide or polynucleotide sequence in thecomparison window may comprise additions or deletions (i.e., gaps) ascompared to the reference sequence (which does not comprise additions ordeletions) for optimal alignment of the two sequences. The percentage iscalculated by determining the number of positions at which the identicalamino-acid residue or nucleic acid base occurs in both sequences toyield the number of matched positions, dividing the number of matchedpositions by the total number of positions in the window of comparisonand multiplying the result by 100 to yield the percentage of sequenceidentity.

The definition of sequence identity given above is the definition thatwould use one of skill in the art. The definition by itself does notneed the help of any algorithm, said algorithms being helpful only toachieve the optimal alignments of sequences, rather than the calculationof sequence identity.

From the definition given above, it follows that there is a well definedand only one value for the sequence identity between two comparedsequences which value corresponds to the value obtained for the best oroptimal alignment.

In the BLAST N or BLAST P “BLAST 2 sequence”, software which isavailable in the web site http://www.ncbi.nlm.nih.gov/gorf/b12.html, andhabitually used by the inventors and in general by the skilled man forcomparing and determining the identity between two sequences, gap costwhich depends on the sequence length to be compared is directly selectedby the software (i.e. 11.2 for substitution matrix BLOSUM-62 for length>85).

In the present description, PWD circovirus will be understood asdesignating the circoviruses associated with piglet weight loss disease(PWD) of type A (PCVA) or type B (PCVB), defined below by their genomicsequence, as well as the circoviruses whose nucleic sequences arehomologous to the sequences of PWD circoviruses of type A or B, such asin particular the circoviruses corresponding to variants of the type Aor of the type B.

Complementary nucleotide sequence of a sequence of the invention isunderstood as meaning any DNA whose nucleotides are complementary tothose of the sequence of the invention, and whose orientation isreversed (antiparallel sequence).

Hybridization under conditions of stringency with a nucleotide sequenceaccording to the invention is understood as meaning a hybridizationunder conditions of temperature and ionic strength chosen in such a waythat they allow the maintenance of the hybridization between twofragments of complementary DNA.

By way of illustration, conditions of great stringency of thehybridization step with the aim of defining the nucleotide fragmentsdescribed above are advantageously the following.

The hybridization is carried out at a preferential temperature of 65° C.in the presence of SSC buffer, 1×SSC corresponding to 0.15 M NaCl and0.05 M Na citrate. The washing steps, for example, can be the following:

2×SSC, at ambient temperature followed by two washes with 2×SSC, 0.5%SDS at 65° C.; 2×0.5×SSC, 0.5% SDS; at 65° C. for 10 minutes each.

The conditions of intermediate stringency, using, for example, atemperature of 42° C. in the presence of a 2×SSC buffer, or of lessstringency, for example a temperature of 37° C. in the presence of a2×SSC buffer, respectively require a globally less significantcomplementarity for the hybridization between the two sequences.

The stringent hybridization conditions described above for apolynucleotide with a size of approximately 350 bases will be adapted bythe person skilled in the art for oligonucleotides of greater or smallersize, according to the teaching of Sambrook et al., 1989.

Among the nucleotide sequences according to the invention, those arelikewise preferred which can be used as a primer or probe in methodsallowing the homologous sequences according to the invention to beobtained, these methods, such as the polymerase chain reaction (PCR),nucleic acid cloning and sequencing, being well known to the personskilled in the art.

Among said nucleotide sequences according to the invention, those areagain preferred which can be used as a primer or probe in methodsallowing the presence of PWD circovirus or one of its variants such asdefined below to be diagnosed.

The nucleotide sequences according to the invention capable ofmodulating, of inhibiting or of inducing the expression of PWDcircovirus gene, and/or capable of modulating the replication cycle ofPWD circovirus in the host cell and/or organism are likewise preferred.Replication cycle will be understood as designating the invasion and themultiplication of PWD circovirus, and its propagation from host cell tohost cell in the host organism.

Among said nucleotide sequences according to the invention, thosecorresponding to open reading frames, called ORF sequences, and codingfor polypeptides, such as, for example, the sequences SEQ ID No. 9(ORF1), SEQ ID No. 11 (ORF2) and SEQ ID No. 13 (ORF3) respectivelycorresponding to the nucleotide sequences between the positions 47 and985 determined with respect to the position of the nucleotides on thesequence SEQ ID No. 1, the positions 1723 and 1022 and the positions 658and 38 with respect to the position of the nucleotides on the sequenceSEQ ID No. 5 (represented according to the orientation 3′→5′), the endsbeing included, or alternatively the sequences SEQ ID No. 23 (ORF′1),SEQ ID No. 25 (ORF′2) and SEQ ID No. 27 (ORF′3), respectivelycorresponding to the sequences between the positions 51 and 995determined with respect to the position of the nucleotides on thesequence SEQ ID No. 15, the positions 1734 and 1033 and the positions670 and 357, the positions being determined with respect to the positionof the nucleotides on the sequence SEQ ID No. 19 (represented accordingto the orientation 3′→5′), the ends being included, are finallypreferred.

The nucleotide sequence fragments according to the invention can beobtained, for example, by specific amplification, such as PCR, or afterdigestion with appropriate restriction enzymes of nucleotide sequencesaccording to the invention, these methods in particular being describedin the work of Sambrook et al., 1989. Said representative fragments canlikewise be obtained by chemical synthesis when their size is not verylarge and according to methods well known to persons skilled in the art.

Modified nucleotide sequence will be understood as meaning anynucleotide sequence obtained by mutagenesis according to techniques wellknown to the person skilled in the art, and containing modificationswith respect to the normal sequences according to the invention, forexample mutations in the regulatory and/or promoter sequences ofpolypeptide expression, especially leading to a modification of the rateof expression of said polypeptide or to a modulation of the replicativecycle.

Modified nucleotide sequence will likewise be understood as meaning anynucleotide sequence coding for a modified polypeptide such as definedbelow.

The present invention relates to nucleotide sequences of PWD circovirusaccording to the invention, characterized in that they are selected fromthe sequences SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 23,SEQ ID No. 25, SEQ ID No. 27 or one of their fragments.

The invention likewise relates to nucleotide sequences characterized inthat they comprise a nucleotide sequence selected from:

a) a nucleotide sequence SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 13, SEQID No. 23, SEQ ID No. 25, SEQ ID No. 27 or one of their fragments;

b) a nucleotide sequence of a specific fragment of a sequence such asdefined in a);

c) a homologous nucleotide sequence having at least 80% identity with asequence such as defined in a) or b);

d) a complementary nucleotide sequence or sequence of RNA correspondingto a sequence such as defined in a), b) or c); and

e) a nucleotide sequence modified by a sequence such as defined in a),b), c) or d).

As far as homology with the nucleotide sequences SEQ ID No. 9, SEQ IDNo. 11, SEQ ID No. 13, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No. 27 orone of their fragments is concerned, the homologous, especiallyspecific, sequences having a percentage identity with one of thesequences SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 23, SEQID No. 25, SEQ ID No. 27 or one of their fragments of at least 80%,preferably 90% or 95%, are preferred. Said specific homologous sequencescan comprise, for example, the sequences corresponding to the sequencesORF1, ORF2, ORF3, ORF′1, ORF′2 and ORF′3 of PWD circovirus variants oftype A or of type B. In the same manner, these specific homologoussequences can correspond to variations linked to mutations withinstrains of PWD circovirus of type A or of type B and especiallycorrespond to truncations, substitutions, deletions and/or additions ofat least one nucleotide.

Among nucleotide sequences according to the invention, the sequence SEQID No. 23 which has a homology having more than 80% identity with thesequence SEQ ID No. 9, as well as the sequence SEQ ID No. 25, areespecially preferred.

Preferably, the invention relates to the nucleotide sequences accordingto the invention, characterized in that they comprise a nucleotidesequence selected from the following sequences:

a) SEQ ID No. 33 170 5′ TGTGGCGA 3′; b) SEQ ID No. 34 450 5′ AGTTTCCT3′; c) SEQ ID No. 35 1026 5′ TCATTTAGAGGGTCTTTCAG 3′; d) SEQ ID No. 361074 5′ GTCAACCT 3′; e) SEQ ID No. 37 1101 5′ GTGGTTGC 3′; f) SEQ ID No.38 1123 5′ AGCCCAGG 3′; g) SEQ ID No. 39 1192 5′ TTGGCTGG 3′; h) SEQ IDNo. 40 1218 5′ TCTAGCTCTGGT 3′; i) SEQ ID No. 41 1501 5′ ATCTCAGCTCGT3′; j) SEQ ID No. 42 1536 5′ TGTCCTCCTCTT 3′; k) SEQ ID No. 43 1563 5′TCTCTAGA 3′; l) SEQ ID No. 44 1623 5′ TGTACCAA 3′; m) SEQ ID No. 45 16865′ TCCGTCTT 3′;

and their complementary sequences.

In the list of nucleotide sequences a)-m) above, the underlinednucleotides are mutated with respect to the two known sequences ofcircovirus which are nonpathogenic to pigs. The number preceding thenucleotide sequence represents the position of the first nucleotide ofsaid sequence in the sequence SEQ ID No. 1.

The invention comprises the polypeptides encoded by a nucleotidesequence according to the invention, preferably a polypeptide whosesequence is represented by a fragment, especially a specific fragment,of one of the six sequences of amino acids represented in FIG. 2, thesesix amino acid sequences corresponding to the polypeptides which can beencoded according to one of the three possible reading frames of thesequence SEQ ID No. 1 or of the sequence SEQ ID No. 5, or a polypeptidewhose sequence is represented by a fragment, especially a specificfragment, of one of the six sequences of amino acids shown in FIG. 8,these six sequences of amino acids corresponding to the polypeptideswhich can be encoded according to one of the three possible readingframes of the sequence SEQ ID No. 15 or of the sequence SEQ ID No. 19.

The invention likewise relates to the polypeptides, characterized inthat they comprise a polypeptide selected from the amino acid sequencesSEQ ID No. 10, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 24, SEQ ID No.26, SEQ ID No. 28 or one of their fragments.

Among the polypeptides according to the invention, the polypeptide ofamino acid sequence SEQ ID No. 24 which has a homology having more than80% identity with the sequence SEQ ID No. 10, as well as the polypeptideof sequence SEQ ID No. 26, are especially preferred.

The invention also relates to the polypeptides, characterized in thatthey comprise a polypeptide selected from:

a) a specific fragment of at least 5 amino acids of a polypeptide of anamino acid sequence according to the invention;

b) a polypeptide homologous to a polypeptide such as defined in a);

c) a specific biologically active fragment of a polypeptide such asdefined in a) or b); and

d) a polypeptide modified by a polypeptide such as defined in a), b) orc).

Among the polypeptides according to the invention, the polypeptides ofamino acid sequences SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31 and SEQID No. 32 are also preferred, these polypeptides being especiallycapable of specifically recognizing the antibodies produced duringinfection by the PWD circovirus of type B. These polypeptides thus haveepitopes specific for the PWD circovirus of type B and can thus be usedin particular in the diagnostic field or as immunogenic agent to conferprotection in pigs against infection by PWD circovirus, especially oftype B.

In the present description, the terms polypeptide, peptide and proteinare interchangeable.

It must be understood that the invention does not relate to thepolypeptides in natural form, that is to say that they are not taken intheir natural environment but that they can be isolated or obtained bypurification from natural sources, or else obtained by geneticrecombination, or alternatively by chemical synthesis and that they canthus contain unnatural amino acids, as will be described below.

Polypeptide fragment according to the invention is understood asdesignating a polypeptide containing at least 5 consecutive amino acids,preferably 10 consecutive amino acids or 15 consecutive amino acids.

In the present invention, specific polypeptide fragment is understood asdesignating the consecutive polypeptide fragment encoded by a specificfragment nucleotide sequence according to the invention.

Homologous polypeptide will be understood as designating thepolypeptides having, with respect to the natural polypeptide, certainmodifications such as, in particular, a deletion, addition orsubstitution of at least one amino acid, a truncation, a prolongation, achimeric fusion, and/or a mutation. Among the homologous polypeptides,those are preferred whose amino acid sequence has at least 80%,preferably 90%, homology with the sequences of amino acids ofpolypeptides according to the invention.

Specific homologous polypeptide will be understood as designating thehomologous polypeptides such as defined above and having a specificfragment of polypeptide according to the invention.

In the case of a substitution, one or more consecutive or nonconsecutiveamino acids are replaced by “equivalent” amino acids. The expression“equivalent” amino acid is directed here at designating any amino acidcapable of being substituted by one of the amino acids of the basestructure without, however, essentially modifying the biologicalactivities of the corresponding peptides and such that they will bedefined by the following.

These equivalent amino acids can be determined either by depending ontheir structural homology with the amino acids which they substitute, oron results of comparative tests of biological activity between thedifferent polypeptides, which are capable of being carried out.

By way of example, the possibilities of substitutions capable of beingcarried out without resulting in an extensive modification of thebiological activity of the corresponding modified polypeptides will bementioned, the replacement, for example, of leucine by valine orisoleucine, of aspartic acid by glutamic acid, of glutamine byasparagine, of arginine by lysine etc., the reverse substitutionsnaturally being envisageable under the same conditions.

The specific homologous polypeptides likewise correspond to polypeptidesencoded by the specific homologous nucleotide sequences such as definedabove and thus comprise in the present definition the polypeptides whichare mutated or correspond to variants which can exist in PWD circovirus,and which especially correspond to truncations, substitutions, deletionsand/or additions of at least one amino acid residue.

Specific biologically active fragment of a polypeptide according to theinvention will be understood in particular as designating a specificpolypeptide fragment, such as defined above, having at least one of thecharacteristics of polypeptides according to the invention, especiallyin that it is:

capable of inducing an immunogenic reaction directed against a PWDcircovirus; and/or

capable of being recognized by a specific antibody of a polypeptideaccording to the invention; and/or

capable of linking to a polypeptide or to a nucleotide sequence of PWDcircovirus; and/or

capable of exerting a physiological activity, even partial, such as, forexample, a dissemination or structural (capsid) activity; and/or

capable of modulating, of inducing or of inhibiting the expression ofPWD circovirus gene or one of its variants, and/or capable of modulatingthe replication cycle of PWD circovirus in the cell and/or the hostorganism.

The polypeptide fragments according to the invention can correspond toisolated or purified fragments naturally present in a PWD circovirus orcorrespond to fragments which can be obtained by cleavage of saidpolypeptide by a proteolytic enzyme, such as trypsin or chymotrypsin orcollagenase, or by a chemical reagent, such as cyanogen bromide (CNBr)or alternatively by placing said polypeptide in a very acidicenvironment, for example at pH 2.5. Such polypeptide fragments canlikewise just as easily be prepared by chemical synthesis, from hoststransformed by an expression vector according to the inventioncontaining a nucleic acid allowing the expression of said fragments,placed under the control of appropriate regulation and/or expressionelements.

“Modified polypeptide” of a polypeptide according to the invention isunderstood as designating a polypeptide obtained by geneticrecombination or by chemical synthesis as will be described below,having at least one modification with respect to the normal sequence.These modifications will especially be able to bear on amino acids atthe origin of a specificity, of pathogenicity and/or of virulence, or atthe origin of the structural conformation, and of the capacity ofmembrane insertion of the polypeptide according to the invention. Itwill thus be possible to create polypeptides of equivalent, increased ordecreased activity, and of equivalent, narrower, or wider specificity.Among the modified polypeptides, it is necessary to mention thepolypeptides in which up to 5 amino acids can be modified, truncated atthe N- or C-terminal end, or even deleted or added.

As is indicated, the modifications of the polypeptide will especiallyhave as objective:

to render it capable of modulating, of inhibiting or of inducing theexpression of PWD circovirus gene and/or capable of modulating thereplication cycle of PWD circovirus in the cell and/or the hostorganism,

of allowing its incorporation into vaccine compositions,

of modifying its bioavailability as a compound for therapeutic use.

The methods allowing said modulations on eukaryotic or prokaryotic cellsto be demonstrated are well known to the person skilled in the art. Itis likewise well understood that it will be possible to use thenucleotide sequences coding for said modified polypeptides for saidmodulations, for example through vectors according to the invention anddescribed below, in order, for example, to prevent or to treat thepathologies linked to the infection.

The preceding modified polypeptides can be obtained by usingcombinatorial chemistry, in which it is possible to systematically varyparts of the polypeptide before testing them on models, cell cultures ormicroorganisms for example, to select the compounds which are mostactive or have the properties sought.

Chemical synthesis likewise has the advantage of being able to use:

unnatural amino acids, or

nonpeptide bonds.

Thus, in order to improve the duration of life of the polypeptidesaccording to the invention, it may be of interest to use unnatural aminoacids, for example in D form, or else amino acid analogs, especiallysulfur-containing forms, for example.

Finally; it will be possible to integrate the structure of thepolypeptides according to the invention, its specific or modifiedhomologous forms, into chemical structures of polypeptide type orothers. Thus, it may be of interest to provide at the N- and C-terminalends compounds not recognized by the proteases.

The nucleotide sequences coding for a polypeptide according to theinvention are likewise part of the invention.

The invention likewise relates to nucleotide sequences utilizable as aprimer or probe, characterized in that said sequences are selected fromthe nucleotide sequences according to the invention.

Among the pairs of nucleotide sequences utilizable as a pair of primersaccording to the invention, the pairs of primers selected from thefollowing pairs are preferred:

a) SEQ ID No. 46 5′ GTG TGC TCG ACA TTG GTG TG 3′, and    SEQ ID No. 475′ TGG AAT GTT AAC GAG CTG AG 3′; b) SEQ ID No. 46 5′ GTG TGC TCG ACATTG GTG TG 3′, and    SEQ ID No. 48 5′ CTC GCA GCC ATC TTG GAA TG 3′; c)SEQ ID No. 49 5′ CGC GCG TAA TAC GAC TCA CT 3′, and    SEQ ID No. 46 5′GTG TGC TCG ACA TTG GTG TG 3′; d) SEQ ID No. 49 5′ CGC GCG TAA TAC GACTCA CT 3′, and    SEQ ID No. 48 5′ CTC GCA GCC ATC TTG GAA TG 3′; and e)SEQ ID No. 50 5′ CCT GTC TAC TGC TGT GAG TAC CTT GT 3′, and    SEQ IDNo. 51 5′ GCA GTA GAC AGG TCA CTC CGT TGT CC 3′.

The cloning and the sequencing of the PWD circovirus, type A and B, hasallowed it to be identified, after comparative analysis with thenucleotide sequences of other porcine circoviruses, that, among thesequences of fragments of these nucleic acids, were those which arestrictly specific to the PWD circovirus of type A, of type B or of typeA and B, and those which correspond to a consensus sequence of porcinecircoviruses other than the PWD circoviruses of type A and/or B.

There is likewise a great need for nucleotide sequences utilizable as aprimer or probe specific to the whole of the other known andnonpathogenic porcine circoviruses.

Said consensus nucleotide sequences specific to all circoviruses, otherthan PWD circovirus of type A and B, are easily identifiable from FIG. 3and the sequence SEQ ID No. 15, and are part of the invention.

Among said consensus nucleotide sequences, that which is characterizedin that it is part of the following pair of primers is preferred:

a) SEQ ID No. 46 5′ GTG TGC TCG ACA TTG GTG TG 3′, and    SEQ ID No. 525′ TGG AAT GTT AAC TAC CTC AA 3′.

The invention likewise comprises a nucleotide sequence according to theinvention, characterized in that said sequence is a specific consensussequence of porcine circovirus other than PWD circovirus of type B andin that it is one of the primers of the following pairs of primers:

a) SEQ ID No. 5′ GGC GGC GCC ATC TGT AAC GGT TT 3′,    53 and    SEQ IDNo. 5′ GAT GGC GCC GAA AGA CGG GTA TC 3′.    54

It is well understood that the present invention likewise relates tospecific polypeptides of known porcine circoviruses other than PWDcircovirus, encoded by said consensus nucleotide sequences, capable ofbeing obtained by purification from natural polypeptides, by geneticrecombination or by chemical synthesis by procedures well known to theperson skilled in the art and such as described in particular below. Inthe same manner, the labeled or unlabeled mono- or polyclonal antibodiesdirected against said specific polypeptides encoded by said consensusnucleotide sequences are also part of the invention.

It will be possible to use said consensus nucleotide sequences, saidcorresponding polypeptides as well as said antibodies directed againstsaid polypeptides in procedures or sets for detection and/oridentification such as described below, in place of or in addition tonucleotide sequences, polypeptides or antibodies according to theinvention, specific to PWD circovirus type A and/or B.

These protocols have been improved for the differential detection of thecircular monomeric forms of specific replicative forms of the virion orof the DNA in replication and the dimeric forms found in so-calledin-tandem molecular constructs.

The invention additionally relates to the use of a nucleotide sequenceaccording to the invention as a primer or probe for the detection and/orthe amplification of nucleic acid sequences.

The nucleotide sequences according to the invention can thus be used toamplify nucleotide sequences, especially by the PCR technique(polymerase chain reaction) (Erlich, 1989; Innis et al., 1990; RoIfs etal., 1991; and White et al., 1997).

These oligodeoxyribonucleotide or oligoribonucleotide primersadvantageously have a length of at least 8 nucleotides, preferably of atleast 12 nucleotides, and even more preferentially at least 20nucleotides.

Other amplification techniques of the target nucleic acid can beadvantageously employed as alternatives to PCR.

The nucleotide sequences of the invention, in particular the primersaccording to the invention, can likewise be employed in other proceduresof amplification of a target nucleic acid, such as:

the TAS technique (Transcription-based Amplification System), describedby Kwoh et al. in 1989;

the 3SR technique (Self-Sustained Sequence Replication), described byGuatelli et al. in 1990;

the NASBA technique (Nucleic Acid Sequence Based Amplification),described by Kievitis et al. in 1991;

the SDA technique (Strand Displacement Amplification) (Walker et al.,1992);

the TMA technique (Transcription Mediated Amplification).

The polynucleotides of the invention can also be employed in techniquesof amplification or of modification of the nucleic acid serving as aprobe, such as:

the LCR technique (Ligase Chain Reaction), described by Landegren et al.in 1988 and improved by Barany et al. in 1991, which employs athermostable ligase;

the RCR technique (Repair Chain Reaction), described by Segev in 1992;

the CPR technique (Cycling Probe Reaction), described by Duck et al. in1990;

the amplification technique with Q-beta replicase, described by Miele etal. in 1983 and especially improved by Chu et al. in 1986, Lizardi etal. in 1988, then by Burg et al. as well as by Stone et al. in 1996.

In the case where the target polynucleotide to be detected is possiblyan RNA, for example an MRNA, it will be possible to use, prior to theemployment of an amplification reaction with the aid of at least oneprimer according to the invention or to the employment of a detectionprocedure with the aid of at least one probe of the invention, an enzymeof reverse transcriptase type in order to obtain a cDNA from the RNAcontained in the biological sample. The cDNA obtained will thus serve asa target for the primer(s) or the probe(s) employed in the amplificationor detection procedure according to the invention.

The detection probe will be chosen in such a manner that it hybridizeswith the target sequence or the amplicon generated from the targetsequence. By way of sequence, such a probe will advantageously have asequence of at least 12 nucleotides, in particular of at least 20nucleotides, and preferably of at least 100 nucleotides.

The invention also comprises the nucleotide sequences utilizable as aprobe or primer according to the invention, characterized in that theyare labeled with a radioactive compound or with a nonradioactivecompound.

The unlabeled nucleotide sequences can be used directly as probes orprimers, although the sequences are generally labeled with a radioactiveelement (³²P, ³⁵S, ³H, ¹²⁵I) or with a nonradioactive molecule (biotin,acetylaminofluorene, digoxigenin, 5-bromodeoxyuridine, fluorescein) toobtain probes which are utilizable for numerous applications.

Examples of nonradioactive labeling of nucleotide sequences aredescribed, for example, in French Patent No. 78.10975 or by Urdea et al.or by Sanchez-Pescador et al. in 1988.

In the latter case, it will also be possible to use one of the labelingmethods described in patents FR-2 422 956 and FR-2 518 755.

The hybridization technique can be carried out in various manners(Matthews et al., 1988). The most general method consists inimmobilizing the nucleic acid extract of cells on a support (such asnitrocellulose, nylon, polystyrene) and in incubating, underwell-defined conditions, the immobilized target nucleic acid with theprobe. After hybridization, the excess of probe is eliminated and thehybrid molecules formed are detected by the appropriate method(measurement of the radioactivity, of the fluorescence or of theenzymatic activity linked to the probe).

The invention likewise comprises the nucleotide sequences according tothe invention, characterized in that they are immobilized on a support,covalently or noncovalently.

According to another advantageous mode of employing nucleotide sequencesaccording to the invention, the latter can be used immobilized on asupport and can thus serve to capture, by specific hybridization, thetarget nucleic acid obtained from the biological sample to be tested. Ifnecessary, the solid support is separated from the sample and thehybridization complex formed between said capture probe and the targetnucleic acid is then detected with the aid of a second probe, aso-called detection probe, labeled with an easily detectable element.

Another subject of the present invention is a vector for the cloningand/or expression of a sequence, characterized in that it contains anucleotide sequence according to the invention.

The vectors according to the invention, characterized in that theycontain the elements allowing the expression and/or the secretion ofsaid nucleotide sequences in a determined host cell, are likewise partof the invention.

The vector must then contain a promoter, signals of initiation andtermination of translation, as well as appropriate regions of regulationof transcription. It must be able to be maintained stably in the hostcell and can optionally have particular signals specifying the secretionof the translated protein. These different elements are chosen as afunction of the host cell used. To this end, the nucleotide sequencesaccording to the invention can be inserted into autonomous replicationvectors within the chosen host, or integrated vectors of the chosenhost.

Such vectors will be prepared according to the methods currently used bythe person skilled in the art, and it will be possible to introduce theclones resulting therefrom into an appropriate host by standard methods,such as, for example, lipofection, electroporation and thermal shock.

The vectors according to the invention are, for example, vectors ofplasmid or viral origin.

A preferred vector for the expression of polypeptides of the inventionis baculovirus.

The vector pBS KS in which is inserted the in-tandem DNA sequence of thePWD circovirus type A (or DFP) as deposited at the CNCM on Jul. 3, 1997,under the number I-1891, is likewise preferred.

These vectors are useful for transforming host cells in order to cloneor to express the nucleotide sequences of the invention.

The invention likewise comprises the host cells transformed by a vectoraccording to the invention.

These cells can be obtained by the introduction into host cells of anucleotide sequence inserted into a vector such as defined above, thenthe culturing of said cells under conditions allowing the replicationand/or expression of the transfected nucleotide sequence.

The host cell can be selected from prokaryotic or eukaryotic systems,such as, for example, bacterial cells (Olins and Lee, 1993), butlikewise yeast cells (Buckholz, 1993), as well as animal cells, inparticular the cultures of mammalian cells (Edwards and Aruffo, 1993),and especially Chinese hamster ovary (CHO) cells, but likewise the cellsof insects in which it is possible to use procedures employingbaculoviruses, for example (Luckow, 1993).

A preferred host cell for the expression of the proteins of theinvention is constituted by sf9 insect cells.

A more preferred host cell according to the invention is E. coli, suchas deposited at the CNCM on Jul. 3, 1997, under the number I-1891.

The invention likewise relates to animals comprising one of saidtransformed cells according to the invention.

The obtainment of transgenic animals according to the inventionoverexpressing one or more of the genes of PWD circovirus or part of thegenes will be preferably carried out in rats, mice or rabbits accordingto methods well known to the person skilled in the art, such as by viralor nonviral transfections. It will be possible to obtain the transgenicanimals overexpressing one or more of said genes by transfection ofmultiple copies of said genes under the control of a strong promoter ofubiquitous nature, or selective for one type of tissue. It will likewisebe possible to obtain the transgenic animals by homologous recombinationin embryonic cell strains, transfer of these cell strains to embryos,selection of the affected chimeras at the level of the reproductivelines, and growth of said chimeras.

The transformed cells as well as the transgenic animals according to theinvention are utilizable in procedures for preparation of recombinantpolypeptides.

It is today possible to produce recombinant polypeptides in relativelylarge quantity by genetic engineering using the cells transformed byexpression vectors according to the invention or using transgenicanimals according to the invention.

The procedures for preparation of a polypeptide of the invention inrecombinant form, characterized in that they employ a vector and/or acell transformed by a vector according to the invention and/or atransgenic animal comprising one of said transformed cells according tothe invention, are themselves comprised in the present invention.

Among said procedures for preparation of a polypeptide of the inventionin recombinant form, the preparation procedures employing a vector,and/or a cell transformed by said vector and/or a transgenic animalcomprising one of said transformed cells, containing a nucleotidesequence according to the invention coding for a polypeptide of PWDcircovirus, are preferred.

The recombinant polypeptides obtained as indicated above can just aswell be present in glycosylated form as in nonglycosylated form and canor cannot have the natural tertiary structure.

A preferred variant consists in producing a recombinant polypeptide usedto a “carrier” protein (chimeric protein). The advantage of this systemis that it allows a stabilization of and a decrease in the proteolysisof the recombinant product, an increase in the solubility in the courseof renaturation in vitro and/or a simplification of the purificationwhen the fusion partner has an affinity for a specific ligand.

More particularly, the invention relates to a procedure for preparationof a polypeptide of the invention comprising the following steps:

a) culture of transformed cells under conditions allowing the expressionof a recombinant polypeptide of nucleotide sequence according to theinvention;

b) if need be, recovery of said recombinant polypeptide.

When the procedure for preparation of a polypeptide of the inventionemploys a transgenic animal according to the invention, the recombinantpolypeptide is then extracted from said animal.

The invention also relates to a polypeptide which is capable of beingobtained by a procedure of the invention such as described previously.

The invention also comprises a procedure for preparation of a syntheticpolypeptide, characterized in that it uses a sequence of amino acids ofpolypeptides according to the invention.

The invention likewise relates to a synthetic polypeptide obtained by aprocedure according to the invention.

The polypeptides according to the invention can likewise be prepared bytechniques which are conventional in the field of the synthesis ofpeptides. This synthesis can be carried out in homogeneous solution orin solid phase.

For example, recourse can be made to the technique of synthesis inhomogeneous solution described by Houben-Weyl in 1974.

This method of synthesis consists in successively condensing, two bytwo, the successive amino acids in the order required, or in condensingamino acids and fragments formed previously and already containingseveral amino acids in the appropriate order, or alternatively severalfragments previously prepared in this way, it being understood that itwill be necessary to protect beforehand all the reactive functionscarried by these amino acids or fragments, with the exception of aminefunctions of one and carboxyls of the other or vice-versa, which mustnormally be involved in the formation of peptide bonds, especially afteractivation of the carboxyl function, according to the methods well knownin the synthesis of peptides.

According to another preferred technique of the invention, recourse willbe made to the technique described by Merrifield.

To make a peptide chain according to the Merrifield procedure, recourseis made to a very porous polymeric resin, on which is immobilized thefirst C-terminal amino acid of the chain. This amino acid is immobilizedon a resin through its carboxyl group and its amine function isprotected. The amino acids which are going to form the peptide chain arethus immobilized, one after the other, on the amino group, which isdeprotected beforehand each time, of the portion of the peptide chainalready formed, and which is attached to the resin. When the whole ofthe desired peptide chain has been formed, the protective groups of thedifferent amino acids forming the peptide chain are eliminated and thepeptide is detached from the resin with the aid of an acid.

The invention additionally relates to hybrid polypeptides having atleast one polypeptide according to the invention, and a sequence of apolypeptide capable of inducing an immune response in man or animals.

Advantageously, the antigenic determinant is such that it is capable ofinducing a humoral and/or cellular response.

It will be possible for such a determinant to comprise a polypeptideaccording to the invention in glycosylated form used with a view toobtaining immunogenic compositions capable of inducing the synthesis ofantibodies directed against multiple epitopes. Said polypeptides ortheir glycosylated fragments are likewise part of the invention.

These hybrid molecules can be formed, in part, of a polypeptide carriermolecule or of fragments thereof according to the invention, associatedwith a possibly immunogenic part, in particular an epitope of thediphtheria toxin, the tetanus toxin, a surface antigen of the hepatitisB virus (patent FR 79 21811), the VP1 antigen of the poliomyelitis virusor any other viral or bacterial toxin or antigen.

The procedures for synthesis of hybrid molecules encompass the methodsused in genetic engineering for constructing hybrid nucleotide sequencescoding for the polypeptide sequences sought. It will be possible, forexample, to refer advantageously to the technique for obtainment ofgenes coding for fusion proteins described by Minton in 1984.

Said hybrid nucleotide sequences coding for a hybrid polypeptide as wellas the hybrid polypeptides according to the invention characterized inthat they are recombinant polypeptides obtained by the expression ofsaid hybrid nucleotide sequences are likewise part of the invention.

The invention likewise comprises the vectors characterized in that theycontain one of said hybrid nucleotide sequences. The host cellstransformed by said vectors, the transgenic animals comprising one ofsaid transformed cells as well as the procedures for preparation ofrecombinant polypeptides using said vectors, said transformed cellsand/or said transgenic animals are, of course, likewise part of theinvention.

The polypeptides according to the invention, the antibodies according tothe invention described below and the nucleotide sequences according tothe invention can advantageously be employed in procedures for thedetection and/or identification of PWD circovirus, or of porcinecircovirus other than a PWD circovirus, in a biological sample(biological tissue or fluid) capable of containing them. Theseprocedures, according to the specificity of the polypeptides, theantibodies and the nucleotide sequences according to the invention whichwill be used, will in particular be able to detect and/or to identify aPWD circovirus or a porcine circovirus other than a PWD circovirus orother than the PWD circovirus of type B.

The polypeptides according to the invention can advantageously beemployed in a procedure for the detection and/or the identification ofPWD circovirus of type A, of type B, of type A or B, or porcinecircovirus other than the PWD circovirus of type B, or of porcinecircovirus other than the PWD circovirus of type A or B, in a biologicalsample (biological tissue or fluid) capable of containing them,characterized in that it comprises the following steps:

a) contacting of this biological sample with a polypeptide or one of itsfragments according to the invention (under conditions allowing animmunological reaction between said polypeptide and the antibodiespossibly present in the biological sample);

b) demonstration of the antigen-antibody complexes possibly formed.

In the present description, PWD circovirus, except if a particularmention is indicated, will be understood as designating a PWD circovirusof type A or of type B, and porcine circovirus other than PWD, except ifa particular mention is indicated, will be understood as designating aporcine circovirus other than a PWD circovirus of type A and B.

Preferably, the biological sample is formed by a fluid, for example apig serum, whole blood or biopsies.

Any conventional procedure can be employed for carrying out such adetection of the antigen-antibody complexes possibly formed.

By way of example, a preferred method brings into play immunoenzymaticprocesses according to the ELISA technique, by immunofluorescence, orradioimmunological processes (RIA) or their equivalent.

Thus, the invention likewise relates to the polypeptides according tothe invention, labeled with the aid of an adequate label such as of theenzymatic, fluorescent or radioactive type.

Such methods comprise, for example, the following steps:

deposition of determined quantities of a polypeptide compositionaccording to the invention in the wells of a microtiter plate,

introduction into said wells of increasing dilutions of serum, or of abiological sample other than that defined previously, having to beanalyzed,

incubation of the microplate,

introduction into the wells of the microtiter plate of labeledantibodies directed against pig immunoglobulins, the labeling of theseantibodies having been carried out with the aid of an enzyme selectedfrom those which are capable of hydrolyzing a substrate by modifying theabsorption of the radiation of the latter, at least at a determinedwavelength, for example at 550 nm,

detection, by comparison with a control test, of the quantity ofhydrolyzed substrate.

The invention likewise relates to a kit or set for the detection and/oridentification of PWD circovirus, of porcine circovirus other than a PWDcircovirus or of porcine circovirus other than the PWD circovirus oftype B, characterized in that it comprises the following elements:

a polypeptide according to the invention,

if need be, the reagents for the formation of the medium favorable tothe immunological or specific reaction,

if need be, the reagents allowing the detection of the antigen-antibodycomplexes produced by the immunological reaction between thepolypeptide(s) of the invention and the antibodies possibly present inthe biological sample, these reagents likewise being able to carry alabel, or to be recognized in their turn by a labeled reagent, moreparticularly in the case where the polypeptide according to theinvention is not labeled,

if need be, a biological reference sample (negative control) devoid ofantibodies recognized by a polypeptide according to the invention,

if need be, a biological reference sample (positive control) containinga predetermined quantity of antibodies recognized by a polypeptideaccording to the invention.

The polypeptides according to the invention allow monoclonal orpolyclonal antibodies to be prepared which are characterized in thatthey specifically recognize the polypeptides according to the invention.It will advantageously be possible to prepare the monoclonal antibodiesfrom hybridomas according to the technique described by Kohler andMilstein in 1975. It will be possible to prepare the polyclonalantibodies, for example, by immunization of an animal, in particular amouse, with a polypeptide or a DNA, according to the invention,associated with an adjuvant of the immune response, and thenpurification of the specific antibodies contained in the serum of theimmunized animals on an affinity column on which the polypeptide whichhas served as an antigen has previously been immobilized. The polyclonalantibodies according to the invention can also be prepared bypurification, on an affinity column on which a polypeptide according tothe invention has previously been immobilized, of the antibodiescontained in the serum of pigs infected by a PWD circovirus.

The invention likewise relates to mono- or polyclonal antibodies ortheir fragments, or chimeric antibodies, characterized in that they arecapable of specifically recognizing a polypeptide according to theinvention.

It will likewise be possible for the antibodies of the invention to belabeled in the same manner as described previously for the nucleicprobes of the invention, such as a labeling of enzymatic, fluorescent orradioactive type.

The invention is additionally directed at a procedure for the detectionand/or identification of PWD circovirus, of porcine circovirus otherthan a PWD circovirus, or other than the PWD circovirus of type B, in abiological sample, characterized in that it comprises the followingsteps:

a) contacting of the biological sample (biological tissue or fluid) witha mono- or polyclonal antibody according to the invention (underconditions allowing an immunological reaction between said antibodiesand the polypeptides of PWD circovirus, of porcine circovirus other thana PWD circovirus, of porcine circovirus other than the PWD circovirus oftype B, possibly present in the biological sample);

b) demonstration of the antigen-antibody complex possibly formed.

Likewise within the scope of the invention is a kit or set for thedetection and/or the identification of PWD circovirus, of porcinecircovirus other than a PWD circovirus or of porcine circovirus otherthan the PWD circovirus of type B, characterized in that it comprisesthe following components:

a polyclonal or monoclonal antibody according to the invention, if needbe labeled;

if need be, a reagent for the formation of the medium favorable to thecarrying out of the immunological reaction;

if need be, a reagent allowing the detection of the antigen-antibodycomplexes produced by the immunological reaction, this reagent likewisebeing able to carry a label, or being capable of being recognized in itsturn by a labeled reagent, more particularly in the case where saidmonoclonal or polyclonal antibody is not labeled;

if need be, reagents for carrying out the lysis of cells of the sampletested.

The present invention likewise relates to a procedure for the detectionand/or the identification of PWD, of porcine circovirus other than a PWDcircovirus or of porcine circovirus other than the PWD circovirus oftype B, in a biological sample, characterized in that it employs anucleotide sequence according to the invention.

More particularly, the invention relates to a procedure for thedetection and/or the identification of PWD circovirus, of porcinecircovirus other than a PWD circovirus or of porcine circovirus otherthan the PWD circovirus of type B, in a biological sample, characterizedin that it contains the following steps:

a) if need be, isolation of the DNA from the biological sample to beanalyzed;

b) specific amplification of the DNA of the sample with the aid of atleast one primer, or a pair of primers, according to the invention;

c) demonstration of the amplification products.

These can be detected, for example, by the technique of molecularhybridization utilizing a nucleic probe according to the invention. Thisprobe will advantageously be labeled with a nonradioactive (cold probe)or radioactive element.

For the purposes of the present invention, “DNA of the biologicalsample” or “DNA contained in the biological sample” will be understoodas meaning either the DNA present in the biological sample considered,or possibly the cDNA obtained after the action of an enzyme of reversetranscriptase type on the RNA present in said biological sample.

Another aim of the present invention consists in a procedure accordingto the invention, characterized in that it comprises the followingsteps:

a) contacting of a nucleotide probe according to the invention with abiological sample, the DNA contained in the biological sample having, ifneed be, previously been made accessible to hybridization underconditions allowing the hybridization of the probe with the DNA of thesample;

b) demonstration of the hybrid formed between the nucleotide probe andthe DNA of the biological sample.

The present invention also relates to a procedure according to theinvention, characterized in that it comprises the following steps:

a) contacting of a nucleotide probe immobilized on a support accordingto the invention with a biological sample, the DNA of the sample having,if need be, previously been made accessible to hybridization, underconditions allowing the hybridization of the probe with the DNA of thesample;

b) contacting of the hybrid formed between the nucleotide probeimmobilized on a support and the DNA contained in the biological sample,if need be after elimination of the DNA of the biological sample whichhas not hybridized with the probe, with a nucleotide probe labeledaccording to the invention;

c) demonstration of the novel hybrid formed in step b).

According to an advantageous embodiment of the procedure for detectionand/or identification defined previously, this is characterized in that,prior to step a), the DNA of the biological sample is first amplifiedwith the aid of at least one primer according to the invention.

The invention is additionally directed at a kit or set for the detectionand/or the identification of PWD circovirus, of porcine circovirus otherthan the PWD circovirus or of porcine circovirus other than the PWDcircovirus of type B, characterized in that it comprises the followingelements:

a) a nucleotide probe according to the invention;

b) if need be, the reagents necessary for the carrying out of ahybridization reaction;

c) if need be, at least one primer according to the invention as well asthe reagents necessary for an amplification reaction of the DNA.

The invention likewise relates to a kit or set for the detection and/orthe identification of PWD circovirus, of porcine circovirus other than aPWD circovirus or of porcine circovirus other than the PWD circovirus oftype B, characterized in that it comprises the following components:

a) a nucleotide probe, called a capture probe, according to theinvention;

b) an oligonucleotide probe, called a revealing probe, according to theinvention,

c) if need be, at least one primer according to the invention, as wellas the reagents necessary for an amplification reaction of the DNA.

The invention also relates to a kit or set for the detection and/oridentification of PWD circovirus, of porcine circovirus other than a PWDcircovirus or of porcine circovirus other than the PWD circovirus oftype B, characterized in that it comprises the following elements:

a) at least one primer according to the invention;

b) if need be, the reagents necessary for carrying out a DNAamplification reaction;

c) if need be, a component allowing the sequence of the amplifiedfragment to be verified, more particularly an oligonucleotide probeaccording to the invention.

The invention additionally relates to the use of a nucleotide sequenceaccording to the invention, of a polypeptide according to the invention,of an antibody according to the invention, of a cell according to theinvention, and/or of an animal transformed according to the invention,for the selection of an organic or inorganic compound capable ofmodulating, inducing or inhibiting the expression of genes, and/or ofmodifying the cellular replication of PWD circovirus or capable ofinducing or of inhibiting the pathologies linked to an infection by aPWD circovirus.

The invention likewise comprises a method of selection of compoundscapable of binding to a polypeptide or one of its fragments according tothe invention, capable of binding to a nucleotide sequence according tothe invention, or capable of recognizing an antibody according to theinvention, and/or capable of modulating, inducing or inhibiting theexpression of genes, and/or of modifying the cellular replication of PWDcircovirus or capable of inducing or inhibiting the pathologies linkedto an infection by a PWD circovirus, characterized in that it comprisesthe following steps:

a) contacting of said compound with said polypeptide, said nucleotidesequence, or with a cell transformed according to the invention and/oradministration of said compound to an animal transformed according tothe invention;

b) determination of the capacity of said compound to bind to saidpolypeptide or said nucleotide sequence, or to modulate, induce orinhibit the expression of genes, or to modulate the growth or thereplication of PWD circovirus, or to induce or inhibit in saidtransformed animal the pathologies linked to an infection by PWDcircovirus (designated activity of said compound).

The compounds capable of being selected can be organic compounds such aspolypeptides or carbohydrates or any other organic or inorganiccompounds already known, or novel organic compounds elaborated bymolecular modelling techniques and obtained by chemical or biochemicalsynthesis, these techniques being known to the person skilled in theart.

It will be possible to use said selected compounds to modulate thecellular replication of PWD circovirus and thus to control infection bythis virus, the methods allowing said modulations to be determined beingwell known to the person skilled in the art.

This modulation can be carried out, for example, by an agent capable ofbinding to a protein and thus of inhibiting or of potentiating itsbiological activity, or capable of binding to an envelope protein of theexternal surface of said virus and of blocking the penetration of saidvirus into the host cell or of favoring the action of the immune systemof the infected organism directed against said virus. This modulationcan likewise be carried out by an agent capable of binding to anucleotide sequence of a DNA of said virus and of blocking, for example,the expression of a polypeptide whose biological or structural activityis necessary for the replication or for the proliferation of said virushost cells to host cells in the host animal.

The invention relates to the compounds capable of being selected by aselection method according to the invention.

The invention likewise relates to a pharmaceutical compositioncomprising a compound selected from the following compounds:

a) a nucleotide sequence according to the invention;

b) a polypeptide according to the invention;

c) a vector, a viral particle or a cell transformed according to theinvention;

d) an antibody according to the invention;

e) a compound capable of being selected by a selection method accordingto the invention; possibly in combination with a pharmaceuticallyacceptable vehicle and, if need be, with one or more adjuvants of theappropriate immunity.

The invention also relates to an immunogenic and/or vaccine composition,characterized in that it comprises a compound selected from thefollowing compounds:

a) a nucleotide sequence according to the invention;

b) a polypeptide according to the invention;

c) a vector or a viral particle according to the invention; and

d) a cell according to the invention.

In one embodiment, the vaccine composition according to the invention ischaracterized in that it comprises a mixture of at least two of saidcompounds a), b), c) and d) above and in that one of the two saidcompounds is related to the PWD circovirus of type A and the other isrelated to the PWD circovirus of type B.

In another enbodiment of the invention, the vaccine composition ischaracterized in that it comprises at least one compound a), b), c), ord) above which is related to PWD circovirus of type B. In still anotherembodiment, the vaccine composition is characterized in that itcomprises at least one compound a), b), c), or d) above which is relatedto PWD circovirus of type B ORF′2.

A compound related to the PWD circovirus of type A or of type B isunderstood here as respectively designating a compound obtained from thegenomic sequence of the PWD circovirus of type A or of type B.

The invention is additionally aimed at an immunogenic and/or vaccinecomposition, characterized in that it comprises at least one of thefollowing compounds:

a nucleotide sequence SEQ ID No. 23, SEQ ID No. 25, or one of theirfragments or homologues;

a polypeptide of sequence SEQ ID No. 24, SEQ ID No. 26, or one of theirfragments, or a modification thereof;

a vector or a viral particle comprising a nucleotide sequence SEQ ID No.23, SEQ ID No. 25, or one of their fragments or homologues;

a transformed cell capable of expressing a polypeptide of sequence SEQID No. 24, SEQ ID No. 26, or one of their fragments, or a modificationthereof; or

a mixture of at least two of said compounds.

The invention also comprises an immunogenic and/or vaccine compositionaccording to the invention, characterized in that it comprises saidmixture of at least two of said compounds as a combination product forsimultaneous, separate or protracted use for the prevention or thetreatment of infection by a PWD circovirus, especially of type B.

In a preferred embodiment, the vaccine composition according to theinvention comprises the mixture of the following compounds:

a pcDNA3 plasmid containing a nucleic acid of sequence SEQ ID No. 23;

a pcDNA3 plasmid containing a nucleic acid of sequence SEQ ID No. 25;

a pcDNA3 plasmid containing a nucleic acid coding for the GM-CSFprotein;

a recombinant baculovirus containing a nucleic acid of sequence SEQ IDNo. 23;

a recombinant baculovirus containing a nucleic acid of sequence SEQ IDNo. 25; and

if need be, an adjuvant of the appropriate immunity, especially theadjuvant AIF™.

The invention is likewise directed at a pharmaceutical compositionaccording to the invention, for the prevention or the treatment of aninfection by a PWD circovirus.

The invention is also directed at a pharmaceutical composition accordingto the invention for the prevention or the treatment of an infection bythe PWD circovirus of type B.

The invention likewise concerns the use of a composition according tothe invention, for the preparation of a medicament intended for theprevention or the treatment of infection by a PWD circovirus, preferablyby the PWD circovirus of type B.

Under another aspect, the invention relates to a vector, a viralparticle or a cell according to the invention, for the treatment and/orthe prevention of a disease by gene therapy.

Finally, the invention comprises the use of a vector, of a viralparticle or of a cell according to the invention for the preparation ofa medicament intended for the treatment and/or the prevention of adisease by gene therapy.

The polypeptides of the invention entering into the immunogenic orvaccine compositions according to the invention can be selected bytechniques known to the person skilled in the art such as, for example,depending on the capacity of said polypeptides to stimulate the T cells,which is translated, for example, by their proliferation or thesecretion of interleukins, and which leads to the production ofantibodies directed against said polypeptides.

In pigs, as in mice, in which a weight dose of the vaccine compositioncomparable to the dose used in man is administered, the antibodyreaction is tested by taking of the serum followed by a study of theformation of a complex between the antibodies present in the serum andthe antigen of the vaccine composition, according to the usualtechniques.

The pharmaceutical compositions according to the invention will containan effective quantity of the compounds of the invention, that is to sayin sufficient quantity of said compound(s) allowing the desired effectto be obtained, such as, for example, the modulation of the cellularreplication of PWD circovirus. The person skilled in the art will knowhow to determine this quantity, as a function, for example, of the ageand of the weight of the individual to be treated, of the state ofadvancement of the pathology, of the possible secondary effects and bymeans of a test of evaluation of the effects obtained on a populationrange, these tests being known in these fields of application.

According to the invention, said vaccine combinations will preferably becombined with a pharmaceutically acceptable vehicle and, if need be,with one or more adjuvants of the appropriate immunity.

Today, various types of vaccines are available for protecting animals orman against infectious diseases: attenuated living microorganisms (M.bovis—BCG for tuberculosis), inactivated microorganisms (influenzavirus), a cellular extracts (Bordetella pertussis for whooping cough),recombined proteins (surface antigen of the hepatitis B virus),polysaccharides (pneumococcal). Vaccines prepared from syntheticpeptides or genetically modified microorganisms expressing heterologousantigens are in the course of experimentation. More recently still,recombined plasmid DNAs carrying genes coding for protective antigenshave been proposed as an alternative vaccine strategy. This type ofvaccination is carried out with a particular plasmid originating from aplasmid of E. coli which does not replicate in vivo and which codesuniquely for the vaccinating protein. Animals have been immunized bysimply injecting the naked plasmid DNA into the muscle. This techniqueleads to the expression of the vaccine protein in situ and to an immuneresponse of cellular type (CTL) and of humoral type (antibody). Thisdouble induction of the immune response is one of the principaladvantages of the vaccination technique with naked DNA.

The vaccine compositions comprising nucleotide sequences or vectors intowhich are inserted said sequences are especially described in theinternational application No. WO 90/11092 and likewise in theinternational application No. WO 95/11307.

The constitutive nucleotide sequence of the vaccine compositionaccording to the invention can be injected into the host after havingbeen coupled to compounds which favor the penetration of thispolynucleotide into the interior of the cell or its transport to thecell nucleus. The resultant conjugates can be encapsulated in polymericmicroparticles, as described in the international application No. WO94/27238 (Medisorb Technologies International).

According to another embodiment of the vaccine composition according tothe invention, the nucleotide sequence, preferably a DNA, is complexedwith DEAE-dextran (Pagano et al., 1967) or with nuclear proteins (Kanedaet al., 1989), with lipids (Felgner et al., 1987) or encapsulated inliposomes (Fraley et al., 1980) or else introduced in the form of a gelfacilitating its transfection into the cells (Midoux et al., 1993,Pastore et al., 1994). The polynucleotide or the vector according to theinvention can also be in suspension in a buffer solution or be combinedwith liposomes.

Advantageously, such a vaccine will be prepared according to thetechnique described by Tacson et al. or Huygen et al. in 1996 oralternatively according to the technique described by Davis et al. inthe international application No. WO 95/11307.

Such a vaccine can likewise be prepared in the form of a compositioncontaining a vector according to the invention, placed under the controlof regulation elements allowing its expression in man or animal. It willbe possible, for example, to use, by way of in vivo expression vector ofthe polypeptide antigen of interest, the plasmid pcDNA3 or the plasmidpcDNA1/neo, both marketed by Invitrogen (R&D Systems, Abingdon, UnitedKingdom). It is also possible to use the plasmid V1Jns.tPA, described byShiver et al. in 1995. Such a vaccine will advantageously comprise,apart from the recombinant vector, a saline solution, for example asodium chloride solution.

Pharmaceutically acceptable vehicle is understood as designating acompound or a combination of compounds entering into a pharmaceuticalcomposition or vaccine which does not provoke secondary reactions andwhich allows, for example, the facilitation of the administration of theactive compound, an increase in its duration of life and/or its efficacyin the body, an increase in its solubility in solution or alternativelyan improvement in its conservation. These pharmaceutically acceptablevehicles are well known and will be adapted by the person skilled in theart as a function of the nature and of the mode of administration of thechosen active compound.

As far as the vaccine formulations are concerned, these can compriseadjuvants of the appropriate immunity which are known to the personskilled in the art, such as, for example, aluminum hydroxide, arepresentative of the family of muramyl peptides such as one of thepeptide derivatives of N-acetyl muramyl, a bacterial lysate, oralternatively Freund's incomplete adjuvant.

These compounds can be administered by the systemic route, in particularby the intravenous route, by the intramuscular, intradermal orsubcutaneous route, or by the oral route. In a more preferred manner,the vaccine composition comprising polypeptides according to theinvention will be administered by the intramuscular route, through thefood or by nebulization several times, staggered over time.

Their administration modes, dosages and optimum pharmaceutical forms canbe determined according to the criteria generally taken into account inthe establishment of a treatment adapted to an animal such as, forexample, the age or the weight, the seriousness of its generalcondition, the tolerance to the treatment and the secondary effectsnoted. Preferably, the vaccine of the present invention is administeredin an amount that is protective against piglet weight loss disease.

For example, in the case of a vaccine according to the present inventioncomprising a polypeptide encoded by a nucleotide sequence of the genomeof PCV, or a homolgue or fragment thereof, the polypeptide will beadministered one time or several times, spread out over time, directlyor by means of a transformed cell capable of expressing the polypeptide,in an amount of about 0.1 to 10 μg per kilogram weight of the animal,prefereably about 0.2 to about 5 μg/kg, more preferably about 0.5 toabout 2 μg/kg for a dose.

The present invention likewise relates to the use of nucleotidesequences of PWD circovirus according to the invention for theconstruction of autoreplicative retroviral vectors and the therapeuticapplications of these, especially in the field of human gene therapy invivo.

The feasibility of gene therapy applied to man no longer needs to bedemonstrated and this relates to numerous therapeutic applications likegenetic diseases, infectious diseases and cancers. Numerous documents ofthe prior art describe the means of employing gene therapy, especiallythrough viral vectors. Generally speaking, the vectors are obtained bydeletion of at least some of the viral genes which are replaced by thegenes of therapeutic interest. Such vectors can be propagated in acomplementation line which supplies in trans the deleted viral functionsin order to generate a defective viral vector particle for replicationbut capable of infecting a host cell. To date, the retroviral vectorsare amongst the most widely used and their mode of infection is widelydescribed in the literature accessible to the person skilled in the art.

The principle of gene therapy is to deliver a functional gene, called agene of interest, of which the RNA or the corresponding protein willproduce the desired biochemical effect in the targeted cells or tissues.On the one hand, the insertion of genes allows the prolonged expressionof complex and unstable molecules such as RNAs or proteins which can beextremely difficult or even impossible to obtain or to administerdirectly. On the other hand, the controlled insertion of the desiredgene into the interior of targeted specific cells allows the expressionproduct to be regulated in defined tissues. For this, it is necessary tobe able to insert the desired therapeutic gene into the interior ofchosen cells and thus to have available a method of insertion capable ofspecifically targeting the cells or the tissues chosen.

Among the methods of insertion of genes, such as, for example,microinjection, especially the injection of naked plasmid DNA (Derse, D.et al., 1995, and Zhao, T. M. et al., 1996), electroporation, homologousrecombination, the use of viral particles, such as retroviruses, iswidespread. However, applied in vivo, the gene transfer systems ofrecombinant retroviral type at the same time have a weak infectiouspower (insufficient concentration of viral particles) and a lack ofspecificity with regard to chosen target cells.

The production of cell-specific viral vectors, having a tissue-specifictropism, and whose gene of interest can be translated adequately by thetarget cells, is realizable, for example, by fusing a specific ligand ofthe target host cells to the N-terminal part of a surface protein of theenvelope of PWD circovirus. It is possible to mention, for example, theconstruction of retroviral particles having the CD4 molecule on thesurface of the envelope so as to target the human cells infected by theHIV virus (YOUNG, J. A. T. et al., Sciences 1990, 250, 1421-1423), viralparticles having a peptide hormone fused to an envelope protein tospecifically infect the cells expressing the corresponding receptor(KASAHARA, N. et al., Sciences 1994, 266, 1373-1376) or elsealternatively viral particles having a fused polypeptide capable ofimmobilizing on the receptor of the epidermal growth factor (EGF)(COSSET, F. L. et al., J. of Virology 1995, 69, 10, 6314-6322). Inanother approach, single-chain fragments of antibodies directed againstsurface antigens of the target cells are inserted by fusion with theN-terminal part of the envelope protein (VALSESIA-WITTMAN, S. et al., J.of Virology 1996, 70, 3, 2059-2064; TEARINA CHU, T. H. et al., J. ofVirology 1997, 71, 1, 720-725).

For the purposes of the present invention, a gene of interest in use inthe invention can be obtained from a eukaryotic or prokaryotic organismor from a virus by any conventional technique. It is, preferably,capable of producing an expression product having a therapeutic effectand it can be a product homologous to the cell host or, alternatively,heterologous. In the scope of the present invention, a gene of interestcan code for an (i) intracellular or (ii) membrane product present onthe surface of the host cell or (iii) secreted outside the host cell. Itcan therefore comprise appropriate additional elements such as, forexample, a sequence coding for a secretion signal. These signals areknown to the person skilled in the art.

In accordance with the aims pursued by the present invention, a gene ofinterest can code for a protein corresponding to all or part of a nativeprotein as found in nature. It can likewise be a chimeric protein, forexample arising from the fusion of polypeptides of various origins orfrom a mutant having improved and/or modified biological properties.Such a mutant can be obtained, by conventional biological techniques, bysubstitution, deletion and/or addition of one or more amino acidresidues.

It is very particularly preferred to employ a gene of therapeuticinterest coding for an expression product capable of inhibiting orretarding the establishment and/or the development of a genetic oracquired disease. A vector according to the invention is in particularintended for the prevention or for the treatment of cystic fibrosis, ofhemophilia A or B, of Duchenne's or Becker's myopathy, of cancer, ofAIDS and of other bacteria or infectious diseases due to a pathogenicorganism: virus, bacteria, parasite or prion. The genes of interestutilizable in the present invention are those which code, for example,for the following proteins:

a cytokine and especially an interleukin, an interferon, a tissuenecrosis factor and a growth factor and especially a hematopoieticgrowth factor (G-CSF, GM-CSF),

a factor or cofactor involved in clotting and especially factor VIII,von Willebrand's factor, antithrombin III, protein C, thrombin andhirudin,

an enzyme or an enzyme inhibitor such as the inhibitors of viralproteases,

an expression product of a suicide gene such as thymidine kinase of theHSV virus (herpesvirus) of type 1,

an activator or an inhibitor of ion channels,

a protein of which the absence, the modification or the deregulation ofexpression is responsible for a genetic disease, such as the CFTRprotein, dystrophin or minidystrophin, insulin, ADA (adenosinediaminose), glucocerebrosidase and phenylhydroxylase,

a protein capable of inhibiting the initiation or the progression ofcancers, such as the expression products of tumor suppressor genes, forexample the P53 and Rb genes,

a protein capable of stimulating an immune or an antibody response, and

a protein capable of inhibiting a viral infection or its development,for example the antigenic epitopes of the virus in question or alteredvariants of viral proteins capable of entering into competition with thenative viral proteins.

The invention thus relates to the vectors characterized in that theycomprise a nucleotide sequence of PWD circovirus according to theinvention, and in that they additionally comprise a gene of interest.

The present invention likewise relates to viral particles generated fromsaid vector according to the invention. It additionally relates tomethods for the preparation of viral particles according to theinvention, characterized in that they employ a vector according to theinvention, including viral pseudoparticles (VLP, virus-like particles).

The invention likewise relates to animal cells transfected by a vectoraccording to the invention.

Likewise comprised in the invention are animal cells, especiallymammalian, infected by a viral particle according to the invention.

The present invention likewise relates to a vector, a viral particle ora cell according to the invention, for the treatment and/or theprevention of a genetic disease or of an acquired disease such as canceror an infectious disease. The invention is likewise directed at apharmaceutical composition comprising, by way of therapeutic orprophylactic agent, a vector or a cell according to the invention, incombination with a vehicle acceptable from a pharmaceutical point ofview.

Other characteristics and advantages of the invention appear in theexamples and the figures.

The invention is described in more detail in the following illustrativeexamples. Although the examples may represent only selected embodimentsof the invention, it should be understood that the following examplesare illustrative and not limiting.

EXAMPLES Example 1 Cloning, Sequencing and Characterization of the PWDCircovirus of Type A (PCVA)

1. Experimental Procedures

Experimental reproduction of the infection and its syndrome (cf. FIG.1).

A first test was carried out with pigs from a very well-kept farm, butaffected by piglet weight loss disease (PWD), likewise called fatalpiglet wasting (FPW). Tests carried out with SPF (specificpathogen-free) pigs showed a transfer of contaminant(s) findingexpression in a complex pathology combining hyperthermia, retardation ofgrowth, diarrhea and conjunctivitis. The PDRS (porcine dysgenic andrespiratory syndrome) virus, an infectious disease due to anarteriovirus) was rapidly isolated from breeding pigs and contact pigs.It should have been possible to attribute all the clinical signs to thepresence of the PDRS virus. However, two farm pigs presented signs ofFPW without the PDRS virus being isolated. The histological analyses andblood formulas, however, showed that these pigs were suffering from aninfectious process of viral origin.

In a second test, 8-week SPF pigs were inoculated by the intratrachealroute with organ homogenates of two farm pigs suffering from FPW. Theinoculated pigs exhibited hyperthermia 8 to 9. days post-infection, thentheir growth was retarded. Other SPF pigs, placed in contact, hadsimilar, attenuated signs 30 days after the initial experiment. Noseroconversion with respect to a European or Canadian strain of PDRSvirus was recorded in these animals.

A third test allowed the syndrome to be reproduced from samples takenfrom the pigs of the second test.

Conclusion

The syndrome is reproduced under the experimental conditions. It isdetermined by at least one infectious agent, which is transmittable bydirect contact. The clinical constants are a sometimes high hyperthermia(greater than or equal to 41.5° C.) which develops 8 to 10 days afterinfection. Retardation of the growth can be observed. The other signsare a reversal of the blood formula (reversal of thelymphocyte/polynuclear ratio from 70/30 to 30/70) and frequent lesionson the ganglia, especially those draining the respiratory apparatus(ganglionic hypertrophy, loss of structure with necrosis andinfiltration by mononucleated or plurinucleated giant cells).

2. Laboratory Studies

Various cell supports including primary pig kidney cells or cell lines,pig testicle cells, monkey kidney cells, pig lymphocytes, pig alveolarmacrophages and circulating blood monocytes were used to demonstrate thepossible presence of a virus. No cytopathic effect was demonstrated inthese cells. On the other hand, the use of a serum of a pig sick afterexperimental infection allowed an intracellular antigen to be revealedin the monocytes, the macrophages and approximately 10% of pig kidney(PK) cells infected with organ homogenates. This indirect revealing wascarried out kinetically at different culture times. It is evident fromthis that the antigen initially appears in the nucleus of the infectedcells before spreading into the cytoplasm. The successive passages incell culture did not allow the signal to be amplified.

Under electron microscopy on organ homogenates, spherical particleslabeled specifically by the serum of sick pigs, infected under theexperimental conditions, were visualized. The size of these particles isestimated at 20 nm.

After two passages of these organ homogenates over pig lymphocytes andthen three passages over pig kidney or testicle cells, a cytopathiceffect developed and was amplified. An adenovirus was visualized in theelectron microscope, which, under the experimental conditions, did notreproduce FPW (only a hyperthermia peak was noted 24 to 48 hours afterinfection, and then nothing more).

It has been possible to demonstrate DNA bands in certain samples of pigsinfected under the experimental conditions and having exhibited signs ofthe disease (results not shown). A certain connection exists between thesamples giving a positive result in cell culture and those having a DNAband.

Conclusion

At least two types of virus were demonstrated in the organ homogenatesfrom pigs suffering from FPW. One is an adenovirus, but by itself aloneit does not reproduce the disease. The other type of virus is acircovirus and is associated with FPW. This circovirus, of which twotypes have been isolated and sequenced, designated below PWD circovirustype A (or PCVA) and PWD circovirus of type B (or PCVB) have mutationswith respect to the known sequences of circovirus which arenonpathogenic for the pig.

3. Cloning and Sequencing of the DNA of the PWD Circovirus of Type A

Extraction of the replicative form (RF) DNA, cleavage by the KpnI enzymeand amplification by a pair of primers flanking the KpnI restrictionsite. Sequencing of the two strands at least twice by the Sanger method.

The nucleic sequence of the strand of (+) polarity of the genome of thePWD circovirus of type A (or PCVA), strain FPW, is represented by thesequence SEQ ID No. 1 in the list of sequences, the nucleic sequence ofthe strand of (−) polarity of the genome of the PWD circovirus of type A(or PCVA) being represented by the nucleic sequence 3′→5′ of FIG. 3 orby the sequence SEQ ID No. 5 (represented according to the orientation5′→3′) in the list of sequences.

The amino acid sequences SEQ ID No. 10, SEQ ID No. 12 and SEQ ID No. 14of the list of sequences respectively represent the sequences ofproteins encoded by the nucleic sequences of the 3 open reading framesSEQ ID No. 9 (ORF1), corresponding to the REP protein, SEQ ID No. 11(ORF2) and SEQ ID No. 13 (ORF3), determined from the sequence SEQ ID No.1 of the strand of (+) polarity or of the nucleic sequence SEQ ID No. 5of the strand of (−) polarity of the genome of the PWD circovirus oftype A.

4. Comparison of the Nucleotide Sequences and Amino Acids of the PWDCircovirus of Type A (or Associated With PWD) Which are Obtained Withthe Corresponding Sequences of MEEHAN and MANKERTZ Circoviruses ofPorcine Cell Lines

Use of the DNA sequence analysis software, DNASIS.

Sequences of Oligonucleotides Used as Primers or Probes in the Detectionand/or Identification Procedures

1. Specific detection of the PWD circovirus of type A: SEQ ID No. 46primer PCV 5: 5′ GTG TGC TCG ACA TTG GTG TG 3′; SEQ ID No. 47 primer PCV10: 5′ TGG AAT GTT AAC GAG CTG AG 3′; 2. Specific detection of thecircovirus of the cell lines: SEQ ID No. 46 primer PCF 5: 5′ GTG TGC TCGACA TTG GTG TG 3′; SEQ ID No. 52 primer MEE 1: 5′ TGG AAT GTT AAC TACCTC AA 3′; 3. Differential detection: the pairs of primers    used arethose described, for example, in the    paragraphs 1 and 2 above; 4.Detection of the monomeric circular replicative forms RF: SEQ ID No. 46primer PCV 5: 5′ GTG TGC TCG ACA TTG GTG TG 3′; SEQ ID No. 48 primer PCV6: 5′ CTC GCA GCC ATC TTG GAA TG 3′; 5. Detection of the vectorscarrying the dimers in tandem:       Nar dimer: SEQ ID No. 49 primer KS620: 5′ CGC GCG TAA TAC GAC TCA CT 3′; SEQ ID No. 46 primer PCV 5: 5′GTG TGC TCG ACA TTG GTG TG 3′;       Kpn dimer: SEQ ID No. 49 primer KS620: 5′ CGC GCG TAA TAC GAC TCA CT 3′; SEQ ID No. 48 primer PCV 6: 5′CTC GCA GCC ATC TTG GAA TG 3′;

6. Differential Detection:

The pairs of primers used are those described, for example, inparagraphs 4 and 5 above.

The procedures using the pairs or primers described in paragraphs 4 and5 are of particular interest for differentially detecting the circularmonomeric forms of specific replicative forms of the virion or of theDNA in replication and the dimeric forms found in the so-calledin-tandem molecular constructs.

The in-tandem constructs of the viral genome (dimers) such as theconstructs used for the preparation of the pBS KS +tandem PCV KpnIvector, deposited at the CNCM under the number I-1891, Jul. 3, 1997 (E.coli transformed by said vector) are very interesting for their use inmethods of production in sufficient quantity of an inoculum formed ofDNA, intended for the virus production, this in the absence of asatisfactory virus production protocol in a cell system. These saidmethods of production using these in-tandem constructs of the viralgenome will allow the virulence factors to be studied by mutation and byway of consequence will be able to be used for the production of acollection of viruses carrying the mutations indicated in theconstruction of vectors which will have the appropriate tropism andvirulence. These vectors with autoreplicative structure have the soughtgene transfer properties, especially for their applications in genetherapy, and in vaccinology.

Western-blot Analysis of Recombinant Proteins of the PWD Circovirus ofType A

The results were obtained using a specific antiserum of the PWDcircovirus produced during test 1 (cf. FIG. 1).

Type of products analyzed.

The analyses were carried out on cell extracts of Sf9 cells obtainedafter infection by the recombinant baculovirus PCV ORF 1.

The culture of Sf9 cells was carried out in a 25 cm² Petri dishaccording to the standard culture methods for these cells. Aftercentrifugation, the cell pellets are taken up with 300 μl of PBS buffer(phosphate saline buffer).

Electrophoresis (PAGE-SDS)

The electrophoresis is carried out on the cell extracts of Sf9 cellsobtained previously on 5 samples (cf. Table 1 below) under the followingconditions:

% polyacrylamide gel: 8%; conditions: denaturing

Voltage: 80 V; duration: 135 mn.

TABLE 1 Nature of the samples subjected to electrophoresis Well No. 1 23 4 5 Sample PM Raoul Raoul Raoul Raoul applied Rainbow 24 h 48 h 72 h96 h μl of sample 10 15 15 15 15 μ of  0  5  5  5  5 Laemmli 4X Legendsto Table 1: Laemmli 4X: loading buffer PM Rainbow: molecular-weightmarkers (35, 52, 77, 107, 160 and 250 kD) Raoul 24 h, 48 h, 72 h and 96h: expression products of the ORF1 of the PWD circovirus of type A.

Western Blot

After electrophoresis, the bands obtained in the different wells aretransferred to nitrocellulose membrane for 1 h at 100 v in a TGM buffer(tris-glycine-methanol).

The Western blot is carried out under the following conditions:

1) Saturation with a solution containing 5% of skimmed milk; 0.05% ofTween 20 in a TBS 1×buffer (tris buffer saline) for 30 min.

2) 1st antibody:

10 ml of PWD anticircovirus antibody of type A are added diluted to1/100, then the reaction mixture is incubated for one night at 4° C.Three washes of 10 min in TBS 1× are carried out.

3) 2nd antibody:

10 ml of pig rabbit P164 antibody anti-imm unoglobulins, coupled toperoxidase (Dakopath) are added diluted to 1/100, then the reactionmedium is incubated for 3 hours at 37° C. Three washes of 10 min in TBS1× are carried out.

4) Visualization

The substrate 4-chloro-1-naphthol in the presence of oxygenated water isused for visualization.

Results

The results are shown in FIG. 7.

Kinetics of Appearance of Antibodies Specific for the REP RecombinantProtein of the PWD Circovirus of Type A Expressed in Baculovirus AfterInfection of Pigs by the PWD Circovirus of Type A (Test 4, cf. FIG. 1)

After infection of the pigs, a sample of serum of each of the infectedpigs is taken at different periods expressed in the table by the date oftaking (carried out here in the same year) and is then analyzed byWestern blot.

The visualization of the specific antibodies is carried out in themanner described previously.

The results obtained are shown by Table 2 below.

TABLE 2 Kinetics of appearance of specific antibodies Sample Pigs 10/616/06 23/06 01/07 08/07 15/07 21/07 A3 1 Neg. Control 2 Neg. B2 Infec. 1Neg. Neg. Neg. + + ++ +++ RP+ 2 Neg. Neg. Neg. Neg. Neg. Neg. Neg. 3Neg. Neg. Neg. Neg. + + + 4 Neg. Neg. Neg. Neg. Neg. Neg. ++ Legends toTable 2: A3 control: uninfected control animals; B2 Infec. RP+: animalsinfected with pig kidney (PK) cells containing the circovirus; Neg.:negative; +, ++, +++: intensity scale of the positive reaction; 10/06,16/06, 23/06, 01/07, 08/07, 15/07, 21/07: dates expressed in day/monthon which the different withdrawals of serum were carried out.

Example 2 Cloning, Sequencing and Characterization of the Type B PWDCircovirus (PCVB)

The techniques used for cloning, sequencing and characterization of thetype B PWD circovirus (PCVB) are those used in Example 1 above for thetype A PWD circovirus (PCVA).

The nucleic sequence of the strand of (+) polarity of the genome of thePWD circovirus of type B (or PCVB) is represented by the sequence SEQ IDNo. 15 in the sequence listing, the nucleic sequence of the strand of(−) polarity of the genome of the PWD circovirus of type B (or PCVB)being represented by the nucleic sequence 3′→5′ of FIG. 8 or by thesequence SEQ ID No. 19 (represented according to the orientation 5′→3′)in the sequence listing.

The amino acid sequences SEQ ID No. 24, SEQ ID No. 26 and SEQ ID No. 28of the sequence listing respectively represent the sequences of theproteins encoded by the nucleic sequences of the 3 open reading framesSEQ ID No. 23 (ORF′1), corresponding to the REP protein, SEQ ID No. 25(ORF′2) and SEQ ID No. 27 (ORF′3), determined from the sequence SEQ IDNo. 15 of the strand of (+) polarity or from the nucleic sequence SEQ IDNo. 19 of the strand of (−)polarity of the genome of the PWD circovirusof type B.

Example 3 Comparative Analysis of Nucleotide Sequences (ORF1, ORF2 andGenomic) and Amino Acid Sequences Encoded by the ORF1 and the ORF2 ofthe PWD Circoviruses of Type A (PCVA) and of Type B (PCVB)

The results expressed in % of homology are shown in Tables 3 and 4below.

TABLE 3 Compared analysis of the amino acid sequences % homology ORF1ORF2 PCVA/PCVB 80.4 56.2

TABLE 4 Compared analysis of the nucleotide sequences % homology GenomicORF1 ORF2 The remainder PCVA/PCVB 70.4 80.4 60.1 66.1

Example 4 Observation of the Disease and Reproduction of the DiseaseUnder Experimental Conditions

a) Test No. 1: Observation of the Disease

The objective is to take breeding animals at the start of disease and toplace them under experimental conditions to follow the progression ofthe pathology and describe all the clinical signs thereof. This firsttest was carried out on 3 breeding pigs aged 10 weeks of which 2 werealready ill (suffering from wasting), and on 3 other pigs aged 13 weeks,not having signs of disease. The clinical observation was spread over aperiod of 37 days. Two pigs of 10 weeks wasted rapidly (pigs 1 and 2,FIG. 9) and had to be painlessly killed 5 and 6 days after theirarrival. A single pig exhibited hyperthermia over 5 days and diarrhea.Two other pigs exhibited dyspnea and cough, of which one additionallyhad hyperthermia, greater than 41° C., for the two first days of itsstay. Another pig had retarded growth in the second week (pig 6, FIG.9), without any other clinical sign being recorded. On the lesionallevel, 5 pigs out of 6 exhibited macroscopic lesions of gray pneumonia,the sixth exhibited cicatricial lesions on the lung.

b) Test No. 2: Reproduction of the Disease From Inocula Prepared in FarmPigs.

The two sick pigs in test 1 served to prepare inocula which were testedin test 2 on specific-pathogen-free (SPF) pigs. The SPF pigs were aged 9weeks at the time of inoculation. The clinical and lesional results areshown in Table 5.

TABLE 5 Summary of the measurements carried out during experimentalreproduction of PWD. (The values of the control animals are reported inbrackets, the underlined values indicate a difference between infectedanimals and control animals) Test Measurement 2 3 4 5 6 7 Status of thepigs SPF SPF SPF SPF Conventional Conventional CNEVA field CNEVA CNEVAAge 9 weeks 6 weeks 5 weeks 5 weeks 5 weeks 6-7 weeks Number 4 6 12 8 88 Inoculation route Intratracheal Intratracheal Intratracheal +Intratracheal + Intratracheal + Intratracheal + route routeintramuscular route intramuscular route intramuscular routeintramuscular route Inoculum titer per ND* ND* 10^(4.53) TCID₅₀ per ml:10^(4.53) TCID₅₀ per ml: 10^(4.53) TCID₅₀ per ml: 10^(4.53) TCID₅₀ perml: pig 1 ml IM + 5 ml IT 1 ml IM + 5 ml IT 1 ml IM + 5 ml IT 1 ml IM +5 ml IT Start of hyper- 10 days 9-13 days 12-13 days 9-14 days 8-12 days12 days thermia post-infection post-infection post-infectionpost-infection post-infection post-infection % of pigs in 100% 83% 92%100% 75% 88% hyperthermia** Number of days of  7 4.5 3.3 5.8 7.5 11.6hyperthermia per pig** Maximum 40.4 to 40.6 to 40.2 to 40.3 to 40.6 to40.2 to temperatures Hyperthermia**** 41.7° C. 42.3° C. 41.6° C. 40.8°C. 42° C. 41.9° C. % per week W1  3.5 (3.5)  17 (36)  7 (5)  37 (17)  16(17)  20 (28) W2   42 (3.5)  7 (13)  13 (1)  21 (3)  52 (10)  37 (28) W3  35 (3.5)  33 (10)  28 (7)  62 (2)  34 (12)  79 (17) W4   21 (3.5)  28(7)  5 (0)  6 (3)  25 (22)  55 (3) DMG: W1  928 (1053) 417 (357) 564(620) 650 (589) 401 (407) 509 (512) W2  678 (1028) 428 (617) 503 (718)612 (584) 294 (514) 410 (310) W3  661 (1000) 771 (642) 381 (657) 520(851) 375 (586) 435 (440) W4  786 (1100) 550 (657) 764 (778) 641 (696)473 (610) 451 (681) Contact pigs Yes to 100% Yes to 75% Not tested Nottested Not tested Not tested transmission % of pulmonary 25 75  0 25 2512 lesions % of ganglionic 17 33 67 25 50 12 lesions *ND: notdetermined, **hyperthermia when the temperature is greater than 40° C.,***range of maximum temperatures recorded at the individual level,****the percentage corresponds to the number of temperature recordingsgreater than 40° C. divided by the total number of temperaturerecordings in the week on all of the pigs.

In this test, there was no wasting, at the very most a retardation ofthe growth in the second, third or fourth week after infection. Thesedata illustrate that certain breeding conditions probably favor theexpression of the disease.

c) Tests No. 3 to No. 7: Reproduction of the Experimental Tests

The increase in the number of the experimental tests on pigs had themastering and better characterization of the experimental model as anobjective. All of the results are presented in Table 5.

Under the experimental conditions, PWD is thus characterized by a longincubation, of 8 to 14 days, true hyperthermia over 2 to 8 days, adecrease in food consumption and a retardation of the increase in weighton the second, third or fourth week post-infection. The lesional tableassociated with this clinical expression includes, in the main,ganglionic hypertrophy and lesions of pneumonia.

Conclusion

The perfection of this experimental model allows the direct etiologicalrole of the PWD circovirus in the disease to be indisputablydemonstrated. In addition, this model is an indispensable tool for theunderstanding of pathogenic mechanisms and the study of future vaccinecandidates.

Example 5 Demonstration of the Vaccine Composition Protective EfficacyProduced From Nucleic Fragments of PWD circovirus Sequence

1) Animals Used for the Study

Piglets having the PWD disease, reproduced under experimental conditionsdescribed in paragraph c) of Example 4, were used in a protocol forevaluating the vaccine composition efficacy, comprising nucleicfragments of PWD circovirus sequence.

2) Tested Vaccine Composition and Vaccination Protocol

a) Components Used for the Study

The plasmids were obtained from the pcDNA3 plasmid of INVITROGENE

pcDNA30RF− plasmids

These plasmids are plasmids which do not carry a PWD circovirus nucleicacid insert and are used as a negative control plasmid.

pcDNA3ORF1+ plasmid and pcDNA3ORF2+ plasmid

The pcDNA3ORF1+and pcDNA3ORF2+ plasmids are plasmids which carry anucleic acid insert of the sequence of the PWD circovirus of TYPE B,respectively an insert comprising the nucleic acid fragment SEQ ID No.23 (ORF′1) coding for the Rep protein of sequence SEQ ID No. 24 and aninsert comprising the nucleic acid fragment SEQ ID No. 25 (ORF′2) codingfor the protein of sequence SEQ ID No. 26, probably corresponding to thecapsid protein, these nucleic constructs comprising the ATG initiationcodon of the coding sequence of the corresponding protein.

GMCSF+ plasmid

GM-CSF (granulocyte/macrophage colony stimulating factor) is a cytokinewhich occurs in the development, the maturation and the activation ofmacrophages, granulocytes and dendritic cells which present an antigen.The beneficial contribution of the GM-CSF in vaccination is consideredto be a cellular activation with, especially, the recruitment and thedifferentiation of cells which present an antigen.

This pcDNA3-GMCSF+ plasmid carries a nucleic acid insert coding for thegranulocyte/macrophage colony stimulation factor, the GM-CSF protein.

The gene coding for this GM-CSF protein was cloned and sequenced byInumaru et al. (Immunol. Cell Biol., 1995, 73 (5), 474-476). ThepcDNA3-GMCSF+ plasmid was obtained by Dr. B. Charley of INRA ofJouy-en-Josas (78, France).

Recombinant baculoviruses

The so-called ORF− baculoviruses are viruses not carrying any insertcomprising a nucleic acid fragment capable of expressing a PWDcircovirus protein.

The so-called ORF1+(BAC ORF1+) or ORF2+(BAC ORF2+) baculoviruses arerecombinant baculoviruses respectively carrying an insert comprising anucleic acid fragment SEQ ID No. 23 (ORF′1) and an insert comprising thenucleic acid fragment SEQ ID No. 25 (ORF′2).

Adjuvant

The adjuvant supplied by the Seppic Company, a subsidiary of AIRLIQUIDE, is the adjuvant corresponding to the reference AIF SEPPIC.

b) Vaccination Protocol

Weaned piglets aged 3 weeks are divided into four batches A, B, C and Deach comprising 8 piglets.

Batches A, B and C, aged 3 weeks, each receive a first injection(injection M1) of 1 ml containing 200 micrograms of plasmids (naked DNA)in PBS, pH: 7.2, by the intramuscular route for each of the plasmidsmentioned below for each batch, then, at the age of 5 weeks, a secondinjection (injection M2) comprising these same plasmids. A thirdinjection is carried out simultaneously on the other side of the neck.This third injection comprises 1 ml of a suspension containing 5.10⁶cells infected by recombinant baculoviruses and 1 ml of AIF SEPPICadjuvant.

Batch A (F1) (Control Batch):

first injection

pcDNA3ORF1− plasmid, pcDNA3ORF2− plasmid and GMCSF+ plasmid.

second and third injection (simultaneous)

pcDNA3ORF1− plasmid, pcDNA3ORF2− plasmid and GMCSF+ plasmid;

Cells transformed by baculoviruses not containing any nucleic acidinsert coding for a PWD circovirus protein;

AIF SEPPIC adjuvant.

Batch B (F2) (Control Batch):

first injection

pcDNA3ORF1− plasmid, pcDNA3ORF2− plasmid and GMCSF+ plasmid;

second and third injection (simultaneous)

pcDNA3ORF1− plasmid, pcDNA3ORF2− plasmid and GMCSF+ plasmid;

Cells transformed by baculoviruses not containing any nucleic acidinsert coding for a PWD circovirus protein;

AIF SEPPIC adjuvant.

Batch C (F3):

first injection

pcDNA3ORF1+ plasmid, pcDNA3ORF2+ plasmid and GMCSF+ plasmid;

second and third injection (simultaneous)

pcDNA3ORF1+ plasmid, pcDNA3ORF2+ plasmid and GMCSF+ plasmid;

Cells transformed by BAC ORF1 +and BAC ORF2+recombinant baculovirusescapable of respectively expressing the Rep protein of sequence SEQ IDNo. 24 and the protein of sequence SEQ ID No. 26 of the PWD circovirusof TYPE B.

Batch D (F4) (Control Batch): No Injection

The batches of piglets B, C and D are infected (tested) at the age of 6weeks although batch A is not subjected to the test.

3) Observation of the Batches

counting of coughing/sneezing: 15 minutes/batch/day;

consistency of fecal matter: every day;

regular recordings: weekly taking of blood, weighing;

weighing of food refuse: 3 times per week;

calculation of the daily mean gain in weight (dmg);

The daily mean gains were calculated for each of the batches over aperiod of 28 days following testing (cf. FIG. 10), an intermediatecalculation of the dmg was likewise carried out for each of the batchesover the first and second periods of 14 days. The results obtained arereported below in Table 6.

TABLE 6 Daily mean gains F1 F2 F3 F4  d0-d14 411 g 450 g 511 g 461 gd14-d28 623 g 362 g 601 g 443 g  d0-d28 554 g 406 g 556 g 452 g

Measurement of Hyperthermia

The measurement of hyperthermia, of greater than 41° C. (cf. FIG. 11)and greater than 40.2° C., was carried out for each of the batches overa total period of 28 days following testing. The results obtained,corresponding to the ratio expressed as a percentage between the numberof recordings of heat of greater than 41° C. (or greater than 40.2° C.)and the total number of recordings of heat carried out on all of thepigs per one-week period are reported below in Tables 7 and 8,respectively for the hyperthermia measurements of greater than 41° C.and greater than 40.2° C.

TABLE 7 Hyperthermia > 41° C. F1 F2 F3 F4 W1 4.1 0. 0. 0. W2 10.7 16. 0.8.9 W3 4.7 27. 0. 45. W4 0. 0. 0. 7.5

TABLE 8 Hyperthermia > 40.2 F1 F2 F3 F4 W1 29.1 10.41 29.1 20.8 W2 28.539.2 10.7 37.5 W3 14.3 68.7 25.0 81.2 W4 3.3 17.5 20.0 55

4) Conclusion

The recordings carried out clearly show that the animals which receivedthe three injections of a vaccine composition comprising nucleic acidfragments of PWD circovirus according to the invention and/or capable ofexpressing recombinant proteins of PWD circovirus, in particular of typeB, did not exhibit hyperthermia (cf. FIG. 10). These animalsadditionally did not experience a decline in their growth, the dmgsbeing comparable to those of uninfected control animals (cf. FIG. 9).They did not exhibit any particular clinical sign.

These results demonstrate the efficacious protection of the pigletsagainst infection with a PWD circovirus of the invention, the primaryagent responsible for PWD or FPW, provided by a vaccine compositionprepared from a nucleic acid fragment of the nucleic sequence of PWDcircovirus according to the invention, in particular of type B, and/orfrom recombinant proteins encoded by these nucleic acid fragments.

These results in particular show that the proteins encoded by the ORF1and ORF2 of PWD circovirus according to the invention are immunogenicproteins inducing an efficacious protective response for the preventionof infection by a PWD circovirus.

Example 6 Serological Diagnosis of PWD Circovirus by ImmunodeterminationUsing Recombinant Proteins or Synthetic Peptides of PWD Circovirus

A—Serological Diagnosis With Recombinant Proteins

The identification and the sequencing of porcine PWD circovirus allowrecombinant proteins of PWD circovirus to be produced by the techniquesof genetic recombination well known to the person skilled in the art.

By these techniques, recombinant proteins encoded, in particular, by theORF′2 of the PWD circovirus, type B, were expressed by transformed Sf9insect cells and then isolated.

These recombinant proteins encoded by the ORF′2 are extracted, afterculture of the transformed Sf9 cells, by thermal cell lysis by means of3 cycles of freezing/thawing to −70° C./+37° C. Healthy Sf9 cells ornontransformed control Sf9 cells are also lyzed.

These two antigenic fractions originating from nontransformed controlSf9 cells and Sf9 cells expressing the ORF′2 are precipitated at 4° C.by a 60% plus or minus 5% saturated ammonium sulfate solution.Determination of total proteins is carried out with the aid of theBiorad kit. 500 ng of control Sf9 proteins and of semipurified Sf9proteins expressing the ORF′2, in solution in 0.05 M bicarbonate bufferpH 9.6, are passively adsorbed at the bottom of 3 different cupules of aNunc Maxisorp microplate by incubation for one night at +4° C.

The reactivity of pig sera with respect to each of these antigenicfractions is evaluated by an indirect ELISA reaction of which theexperimental protocol is detailed below:

Saturation step: 200 μl/cupule of PBS1×/3% semi-skimmed milk, 1 h 30incubation at 37° C.

Washing: 200 μl/cupule of PBS1×/Tween 20: 0.05%, 3 rapid washes.

Serum incubation step: 100 μl/cupule of serum diluted to 1/100 inPBS1×/semi-skimmed milk, 1%/Tween 20: 0.05%, 1 h incubation at 37° C.

Washing: 200 μl/cupule of PBS1×/Tween 20: 0.05%, 2 rapid washes followedby 2 washes of 5 min.

Conjugate incubation step: 50 lI/cupule of rabbit anti-pig conjugatediluted to 1/1000 in PBS1×/semi-skimmed milk, 1%/Tween 20: 0.05%, 1 hincubation at 37° C.

Washing: 200 μl/cupule of PBS1×/Tween 20: 0.05%, 2 rapid washes followedby 2 washes of 5 min.

Visualization step: 100 μl/cupule of OPD substrate/citrate buffer/H₂O₂,15 min incubation at 37° C.

Stopping of reaction: 50 μl/cupule of 1 N H₂SO₄.

Reading in a spectrophotometer at 490 nm.

Results

The results obtained are shown below in Table 9.

TABLE 9 Reactivity Reactivity of Pig Serum of Pig Serum not inoculatedwith inoculated with Antigens Circovirus Circovirus Purified Sf9 control0.076 0.088 Sf9 expressing purified 0.071 1.035 ORF′2

The results are expressed in optical density measured in aspectrophotometer at 490 nm during analysis by ELISA of the reactivityof pig sera which are or are not inoculated with the type B PWDcircovirus according to the protocol indicated above.

B—Serological Diagnosis by Synthetic Peptide

The epitopic mapping of the proteins encoded, for example, by thenucleic sequences ORF1 and ORF2 of the two types of PWD circovirus(types A and B) additionally allowed immunogenic circoviral epitopes tobe identified on the proteins encoded by the nucleic sequences ORF′1 andORF′2 as well as the specific epitopes of the protein encoded by thenucleic sequence ORF′2 of the type B PWD circovirus. Four specificepitopes of the type B PWD circovirus and one epitope common to the twotypes of PWD circovirus situated on the protein encoded by the nucleicsequence ORF′2 were synthesized in peptide form. The equivalent peptidesin the circovirus of type A were likewise synthesized. All thesepeptides were evaluated as diagnostic antigens within the context ofcarrying out a serological test.

Results

The results obtained are shown in Table 10 below.

TABLE 10 Results of the evaluation as a diagnostic antigen of syntheticpeptides encoded by the nucleic sequences ORF2 and ORF′2 of PWDcircovirus of type A and B. Infected pig serum reactivity Circovirus BType SPF Conventional 1 Conventional 2 Epitopic Peptide PWD circovirusPosition AA sequence D0/D54 D0/D42 D0/D42 specificity SEQ ID NO: 29 121B 71-85 VDMMRFNINDFLPPG +/−, +++ +/−, +++ −, +++ Circovirus B SEQ ID NO:55 177 B 70-84 NVNELRFNIGQFLPP +/−, + +/−, +/− +/−, − SEQ ID NO: 30 131B 115-129 QGDRGVGSSAVILDD +/−, +/− ++, ++ +/−, + Circovirus B SEQ ID NO:56 188 A 114-127 TSNQRGVGSTVVIL +/−, − −, +/− +/−, +/− SEQ ID NO: 31 133B 119-134 GVGSSAVILDDNVFTK −, ++ ++, +++ +/−, ++ SEQ ID NO: 57 189 A118-132 RGVGSTVVILDANFV +/−, − −, +/− +/−, +/− SEQ ID NO: 58 146 B171-185 FTIDYFQPNNKRNQL −, +/− −, ++ −, ++ Circovirus SEQ ID NO: 59 202A 170-184 DQTIDWFQPNNKRNQ +++, +/−, ++ +, ++ A & B +++ SEQ ID NO: 32 152B 195-209 VDHVGLGTAFENSIY −, ++ +++, +++ +/−, + Circovirus B SEQ ID NO:60 208 A 194-208 NVEHTGLGYALQNAT −, − −, − −, − +/−, +, ++, +++.Increasing intensities of the reactivities observed in Spot peptides ona nitrocellulose membrane. The porcine sera tested are from animalsexperimentally infected with the circovirus of type B within the animalhouses of the CNEVA. Samples are taken from the animals beforeinoculation on d0 and 42 days or 54 days after inoculation, on d42, d54.

Example 7 Characterization of the Specific Epitopes of the PWDCircovirus of Type B

The proteins encoded by the ORF2 of the porcine circoviruses of type Aand B were chosen for this study. For each of the ORF2s (types A and B),56 peptides of 15 amino acids which overlap every 4 amino acids weresynthesized, thus covering the whole of the protein (cf. Table 11below).

TABLE 11 Sequence of amino acids of the 56 peptides of 15 amino acidssynthesized from the nucleic sequence ORF′2 (type B) and ORF2 (type A)of PWD circovirus with their corresponding spot number (cf. FIG. 12)Type B ORF′2 Type A ORF2 Spot No. Sequence Spot No. Sequence SEQ IDNO:61 107 HRPRSHLGQILRRRP SEQ ID NO:84 163 TRPRSHLGNILRRRP SEQ ID NO:62108 SHLGQILRRRPWLVH SEQ ID NO:85 164 SHLGNILRRRPYLVH SEQ ID NO:63 109QILRRRPWLVHPRHR SEQ ID NO:86 165 NILRRRPYLVHPAFR SEQ ID NO:64 110RRPWLVHPRHRYRWR SEQ ID NO:87 166 RRPYLVHPAFRNRYR SEQ ID NO:65 111LVHPRHRYRWRRKNG SEQ ID NO:88 167 LVHPAFRNRYRWRRK SEQ ID NO:66 112RHRYRWRRKNGIFNT SEQ ID NO:89 168 AFRNRYRWRRKTGIF SEQ ID NO:67 113RWRRKNGIFNTRLSR SEQ ID NO:90 169 RYRWRRKTGIFNSRL SEQ ID N0:68 114KNGIFNTRLSRTFGY SEQ ID NO:91 170 RRKTGIFNSRLSREF SEQ ID NO:69 115FNTRLSRTFGYTVKR SEQ ID NO:92 171 GIFNSRLSREFVLTI SEQ ID NO:70 116LSRTFGYTVKRTTVR SEQ ID NO:93 172 SRLSREFVLTIRGGH SEQ ID NO:71 117FGYTVKRTTVRTPSW SEQ ID NO:94 173 REFVLTIRGGHSQPS SEQ ID NO:72 118VKRTTVRTPSWAVDM SEQ ID NO:95 174 LTIRGGHSOPSWNVN SEQ ID NO:73 119TVRTPSWAVDMMRFN SEQ ID NO:96 175 GGHSQPSWNVNELRF SEQ ID NO:74 120PSWAVDMMRFNINDF SEQ ID NO:97 176 QPSWNVNELRFNIGO SEQ ID NO:29 121VDMMRFNINDFLPPG SEQ ID NO:98 177 NVNELRFNIGQFLPP SEQ ID NO:75 122RFNINDFLPPGGGSN SEQ ID NO:99 178 LRFNIGQFLPPSGGT SEQ ID NO:76 123NDFLPPGGGSNPRSV SEQ ID NO:100 179 IGQFLPPSGGTNPLP SEQ ID NO:77 124PPGGGSNPRSVPFEY SEQ ID NO:101 180 LPPSGGTNPLPLPFQ SEQ ID NO:78 125GSNPRSVPFEYYRIR SEQ ID NO:102 181 GGTNPLPLPFQYYRI SEQ ID NO:79 126RSVPFEYYRIRKVKV SEQ ID NO:103 182 PLPLPFQYYRIRKAK SEQ ID NO:80 127FEYYRIRKVKVEFWP SEQ ID NO:104 183 PFQYYRIRKAKYEFY SEQ ID NO:81 128RIRKVKVEFWPCSPI SEQ ID NO:105 184 YRIRKAKYEFYPRDP SEQ ID NO:82 129VKVEFWPCSPITQGD SEQ ID NO:106 185 KAKYEFYPRDPITSN SEQ ID NO:83 130FWPCSPITQGDRGVG SEQ TD NO:107 186 EFYPRDPITSNQRGV SEQ ID NO:30 131SPITQGDRGVGSSAV SEQ ID NO:108 187 RDPITSNQRGVGSTV SEQ ID NO:31 132QGDRGVGSSAVILDD SEQ ID NO:109 188 TSNQRGVGSTVVILD SEQ ID NO:110 133GVGSSAVILDDNFVT SEQ ID NO:136 189 RGVGSTVVILDANFV SEQ ID NO:111 134SAVILDDNFVTKATA SEQ ID NO:137 190 STVVILDANFVTPST SEQ ID NO:112 135LDDNFVTKATALTYD SEQ ID NO:138 191 ILDANFVTPSTNLAY SEQ ID NO:113 136FVTKATALTYDPYVN SEQ ID NO:139 192 NFVTPSTNLAYDPYI SEQ ID NO:114 137ATALTYDPYVNYSSR SEQ ID NO:140 193 PSTNLAYDPYINYSS SEQ ID NO:115 138TYDPYVNYSSRIITIT SEQ ID NO:141 194 LAYDPYINYSSRHTI SEQ ID NO:116 139YVNYSSRHTITQPFS SEQ ID NO:142 195 PYINYSSRHTIRQPF SEQ ID NO:117 140SSRHTITQPFSYHSR SEQ ID NO:143 196 YSSRIITIRQPFTYHS SEQ ID NO:118 141TITQPFSYHSRYFTP SEQ ID NO:144 197 HTIRQPFTYHSRYFT SEQ ID NO:119 142PFSYHSRYFTPKPVL SEQ ID NO:145 198 QPFTYHSRYFTPKPE SEQ ID NO:120 143HSRYFTPKPVLDFTI SEQ ID NO:146 199 YHSRYFTPKPELDQT SEQ ID NO:121 144FTPKPVLDFTIDYYFQ SEQ ID NO:147 200 YFTPKPELDQTIDWF SEQ ID NO:122 145PVLDFTIDYFQPNNK SEQ ID NO:148 201 KPELDQTIDWFQPNN SEQ ID NO:123 146FTIDYFQPNNKRNQL SEQ ID NO:149 202 DQTIDWFQPNNKRNQ SEQ ID NO:124 147YFQPNNKRNQLWLRL SEQ ID NO:150 203 DWFQPNNKRNQLWLR SEQ ID NO:125 148NNKRNQLWLRLQTAG SEQ ID NO:151 204 PNNKRNQLWLHLNTR SEQ ID NO:126 149NQLWLRLQTAGNVDR SEQ ID NO:152 205 RNQLWLHLNTHTNVE SEQ ID NO:127 150LRLQTAGNVDHVGLG SEQ ID NO:153 206 WLHLNTHTNVEHTGL SEQ ID NO:128 151TAGNVDHVGLGTAFE SEQ JD NO:154 207 NTHTNVEHTGLGYAL SEQ ID NO:32 152VDRVGLGTAFENSIY SEQ ID NO:155 208 NVEHTGLGYALQNAT SEQ ID NO:129 153GLGTAFENSIYDQEY SEQ ID NO:156 209 TGLGYALQNATTAQN SEQ ID NO:130 154AFENSIYDQEYNIRV SEQ ID NO:157 210 YALQNATTAQNYVVR SEQ ID NO:131 155SIYDQEYNIRVTMYV SEQ ID NO:158 211 NATTAQNYVVRLTIY SEQ ID NO:132 156QEYNIRVTMYVQFRE SEQ ID NO:159 212 AQNYVVRLTIYVQFR SEQ ID NO:133 157IRVTMYVQFREFNFK SEQ ID NO:160 213 VVRLTIYVQFREFIL SEQ ID NO:134 158MYVQFREFNFKDPPL SEQ ID NO:161 214 TIYVQFREFILKDPL SEQ ID NO:135 159VQFREFNFKDPPLNP SEQ ID NO:162 215 YVQFREFILKDPLNE

These peptides were synthesized according to the “spot” method whichconsists in simultaneous synthesis of a large number of peptides on acellulose solid support, each site of synthesis of a peptideconstituting a spot (Synt:em, NIMES). This method involves orientationof the peptides on the plate, these being fixed covalently by thecarboxy-terminal end. A spot represents approximately 50 nmol ofpeptide.

The reference of the spots and corresponding peptide sequences is givenin Table 11.

These membranes were used for immunoreactivity tests with respect toserum of SPF pigs which were or were not infected experimentally withthe type B PWD circoviral strain as well as with respect to sera ofinfected pigs from conventional farms (conventional farms 1 or 2). Thisstudy allowed specific immunoreactive peptides of the circovirus of typeB corresponding to the spots No. 121, No. 132, No. 133 and No. 152(respectively of amino acid sequences SEQ ID No. 29, SEQ ID No. 30, SEQID No. 31 and SEQ ID No. 32) to be demonstrated. An illustration isshown in FIG. 12 where the membranes are visualized with an infected pigserum coming from a conventional farm. Nonspecific immunoreactivepeptides of type [lacuna] were likewise demonstrated, among which weshall keep the peptide No. 146 SEQ ID No. 123 which is stronglyimmunogenic.

A comparison between the peptide sequences of circoviruses of type A andB (FIG. 13) indicates a divergence ranging from 20 to 60% for thespecific immunoreactive peptides of the type B, and a weaker divergence(13%) between the nonspecific peptides.

Example 8 Protection of Swine From Post-weaning Multisystemic WastingSyndrome (PMWS) Conferred by Procine Circovirus Type B (PCV-B) ORF′2Protein

The ORF′1-encoded protein (REP) and ORF′2-encoded putative capsidprotein of PCV-B were expressed, either in insect cells by recombinantbaculovirus vectors, or in mammalian cell lines by transfection withplasmidic expression vectors. These two circovirus-derived proteins weredetectable in both expression system. As evaluated by weight gains,hyperthermia and absence of lesions following challenge, the pigs wereprotected against a virulent circovirus challenge after one first DNAimmunization with plasmids directing ORF′2 protein and GM-CSF expressionand a second injection, 15 days later, with the same plasmid preparationplus the ORF′2 recombinant protein. A lower level of protection wasobserved when the pigs were vaccinated with ORF′1 protein, as opposed topigs vaccinated with ORF′2 protein.

A. Development of an Experimental Model of PMWS in Swine:

Eight 3 week-old SPF pigs were inoculated intratracheally (5 ml) andintramuscularly (1 ml).

B. Production and Control of PCV-B Plasmids:

PCV-B ORF′1 and ORF′2 genes , isolated from PCV-B challenge strain, havebeen cloned into vector plasmid pcDNA3.1.

All constructs have been validated through a partial sequencing of thePCV-B genes in the final plasmids and expression control byimmunoperoxidase on PK15 cells respectively transfected with eachplasmid , using swine polyclonal antibodies. Plasmid encoding GM-CSF hasbeen co-administred.

C. Construction of Recombinant Baculoviruses:

ORF′1 and ORF′2 proteins were expressed under polyhedrin promotercontrol. Recombinant proteins were detected by western-blot using swinepolyclonal antibodies.

D. Vaccination and Challenge:

Four groups of 7 pigs were vaccinated intramuscularly at day 0 (Do), twoweeks later, they received the same plasmid preparation plus therecombinant baculovirus.

E. Monitoring:

All groups of pigs were housed in isolated experimental units with airfiltration and low air pressure. Clinical observations and rectaltemperatures were recorded every day. The pigs were weighed weekly.

F. Conclusions

Expression of PCV-B ORF′2 or PCV-B ORF′1 in swine resulted in asignificantly enhanced level of protection as evaluated by weightevolution and body temperature evolution following challenge with PCV-Bcircovirus. These results are summarized in FIGS. 14 and 15.

The invention described herein may be embodied in other specific formswithout departing from the spirit or essential characteristics thereof.The specific embodiments previously described are therefore to beconsidered as illustrative of, and not limiting, the scope of theinvention. Additionally, the disclosure of all publications and patentapplications cited above and below, including International PatentApplication No. PCT/FR98/02634, filed Dec. 4, 1998, and published asInternational Publication No. WO 99/29871 on Jun. 17, 1999, areexpressly incorporated herein by reference in their entireties to thesame extent as if each were incorporated by reference individually.

Bibliographic References

Allan, G. M. et al., 1995, Vet. Microbiol., 44: 49-64.

Barany, F., 1911, PNAS. USA, 88: 189-193.

Boulton, L. H. et al., 1997, J. Gen. Virol., 78 (Pt 6), 1265-1270.

Buckholz, R. G., 1993, Yeast systems for the expression of heterologousgene products. Curr. Op. Biotechnology 4: 538-542.

Burg, J. L. et al., 1996, Mol. and Cell. Probes, 10: 257-271.

Chu, B. C. F. et al., 1986, NAR, 14: 5591-5603.

Chu, P. W. G. et al., 1993, Virus Research, 27: 161-171.

Clark, E. G., 1997, American Association of Swine Practitioners,499-501.

Daft, B. et al., 1996, American Association of Veterinary LaboratoryDiagnosticians, 32.

Derse, D. et al., 1995, J. Virol., 69(3): 1907-1912.

Duck, P. et al., 1990, Biotechniques, 9: 142-147.

Dulac, G. C. et al., 1989, Can. J. Vet. Res., 53: 431-433.

Edwards, C. P., and Aruffo, A., 1993, Current applications of COS cellbased transient expression systems. Curr. Op. Biotechnology 4: 558-563.

Edwards, S. et al., 1994, Vet. Rec., 134: 680-681.

Erlich, H. A., 1989, In PCR Technology. Principles and Applications forDNA Amplification. New York: Stockton Press.

Feigner, et al., 1987, Proc. Natl. Acad. Sci., 84: 7413.

Fontes, E. P. B. et al., 1994, J. Biol. Chem., Vol. 269, No. 11:8459-8465.

Fraley et al., 1980, J. Biol. Chem., 255: 10431.

Guateli, J. C. et al., 1990, PNAS. USA, 87: 1874-1878.

Hackland, A. F. et al., 1994, Arch. Virol., 139: 1-22.

Hanson, S. F. et al., 1995, Virology, 211: 1-9.

Harding, J. C., 1997, American Association of Swine Practitioners, 503.

Harding, R. M. et al., 1993, Journal of General Virology, 74: 323-328.

Harding, J. C. and Clark, E. G., 1997, Swine Health and Production, Vol.5, No. 5: 201-203.

Heyraud-Nitschke, F. et al., 1995, Nucleic Acids Research, Vol. 23, No.6.

Horner, G. W., 1991, Surveillance 18(5): 23.

Houben-Weyl, 1974, in Methode der Organischen Chemie, E. Wunsch Ed.,Volume 15-I and 15-II, Thieme, Stuttgart.

Huygen, K. et al., 1996, Nature Medicine, 2(8): 893-898.

Innis, M. A. et al., 1990, in PCR Protocols. A guide to Methods andApplications, San Diego, Academic Press.

Kaneda, et al., 1989, Science, 243: 375.

Kievitis, T. et al., 1991, J. Virol. Methods, 35: 273-286.

Kohler, G. et al., 1975, Nature, 256(5517): 495-497.

Kwoh, D. Y. et al., 1989, PNAS. USA, 86: 1173-1177.

Ladany, S. et al., 1989, J. Clin. Microbiol. 27: 2778-2783.

Lazarowitz, S. G. et al., 1989, The EMBO Journal, Vol. 8 No. 4:1023-1032.

Luckow, V. A., 1993, Baculovirus systems for the expression of humangene products. Curr. Op. Biotechnology 4: 564-572.

Mankertz, A. et al., 1997, J. Virol., 71: 2562-2566.

Matthews, J. A. et al., 1988, Anal. Biochem., 169: 1-25.

McNeilly, F. et al., 1996, Vet. Immunol. Immunopathol., 49: 295-306.

Meehan, B. M. et al., 1997, J. Gen. Virol. 78: 221-227.

Merrifield, R. D., 1966, J. Am. Chem. Soc., 88(21): 5051-5052.

Midoux, 1993, Nucleic Acids Research, 21: 871-878.

Miele, E. A. et al., 1983, J. Mol. Biol., 171: 281-295.

Murphy, F. A. et al., 1995, Sixth Report of the International Committeeon Taxonomy of Viruses. Springer-Verlag Wien New York.

Nayar, G. P. et al., 1997, Can. Vet. J. 38(6): 385-386.

Olins, P. O., and Lee, S. C., 1993, Recent advances in heterologous geneexpression in E.coli. Curr. Op. Biotechnology 4: 520-525.

Pagano et al., 1967, J. Virol., 1: 891.

Rolfs, A. et al., 1991, In PCR Topics. Usage of Polymerase Chainreaction in Genetic and Infectious Disease. Berlin: Springer-Verlag.

Sambrook, J. et al., 1989, In Molecular cloning: A Laboratory Manual.Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press.

Sanchez-Pescador, R., 1988, J. Clin. Microbiol., 26(10): 1934-1938.

Segev D., 1992, in “Non-radioactive Labeling and Detection ofBiomolecules”. Kessler C. Springer Verlag, Berlin, New-York: 197-205.

Shiver, J. W., 1995, in Vaccines 1995, eds Chanock, R. M. Brown, F.Ginsberg, H. S. & Norrby, E., pp. 95-98, Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y.

Tascon, R. E. et al., 1996, Nature Medicine, 2(8): 888-892.

Tischer, I. et al., 1982, Nature, 295: 64-66.

Tischer, I. et al., 1986, Arch. Virol., 91: 271-276.

Tischer, I. et al., 1988, Zentralbl Bakteriol Mikrobiol Hyg [A] 270:280-287.

Tischer, I. et al., 1995, Arch. Virol., 140: 737-743.

Urdea, M. S., 1988, Nucleic Acids Research, II: 4937-4957.

Walker, G. T. et al., 1992, NAR 20: 1691-1696.

Walker, G. T. et al., 1992, PNAS. USA, 89: 392-396.

White, B. A. et al., 1997, Methods in Molecular Biology, 67, HumanaPress, Towota.

Zhao, T. M. et al., 1996, Proc. Natl. Acad. Sci., USA 93(13): 6653-6648.

SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 170 <210> SEQ ID NO 1 <211>LENGTH: 1759 <212> TYPE: DNA <213> ORGANISM: Type A PWD circovirus <220>FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(78) <221> NAME/KEY:CDS <222> LOCATION: (82)..(99) <221> NAME/KEY: CDS <222> LOCATION:(106)..(156) <221> NAME/KEY: CDS <222> LOCATION: (160)..(195) <221>NAME/KEY: CDS <222> LOCATION: (199)..(231) <221> NAME/KEY: CDS <222>LOCATION: (235)..(246) <221> NAME/KEY: CDS <222> LOCATION: (250)..(315)<221> NAME/KEY: CDS <222> LOCATION: (319)..(330) <221> NAME/KEY: CDS<222> LOCATION: (334)..(489) <221> NAME/KEY: CDS <222> LOCATION:(493)..(525) <221> NAME/KEY: CDS <222> LOCATION: (529)..(591) <221>NAME/KEY: CDS <222> LOCATION: (595)..(600) <221> NAME/KEY: CDS <222>LOCATION: (604)..(606) <221> NAME/KEY: CDS <222> LOCATION: (610)..(627)<221> NAME/KEY: CDS <222> LOCATION: (634)..(636) <221> NAME/KEY: CDS<222> LOCATION: (640)..(681) <221> NAME/KEY: CDS <222> LOCATION:(685)..(708) <221> NAME/KEY: CDS <222> LOCATION: (712)..(726) <221>NAME/KEY: CDS <222> LOCATION: (730)..(753) <221> NAME/KEY: CDS <222>LOCATION: (757)..(933) <221> NAME/KEY: CDS <222> LOCATION: (937)..(969)<221> NAME/KEY: CDS <222> LOCATION: (973)..(1047) <221> NAME/KEY: CDS<222> LOCATION: (1051)..(1056) <221> NAME/KEY: CDS <222> LOCATION:(1060)..(1071) <221> NAME/KEY: CDS <222> LOCATION: (1075)..(1236) <221>NAME/KEY: CDS <222> LOCATION: (1240)..(1257) <221> NAME/KEY: CDS <222>LOCATION: (1261)..(1293) <221> NAME/KEY: CDS <222> LOCATION:(1297)..(1350) <221> NAME/KEY: CDS <222> LOCATION: (1354)..(1380) <221>NAME/KEY: CDS <222> LOCATION: (1384)..(1386) <221> NAME/KEY: CDS <222>LOCATION: (1390)..(1416) <221> NAME/KEY: CDS <222> LOCATION:(1420)..(1425) <221> NAME/KEY: CDS <222> LOCATION: (1429)..(1497) <221>NAME/KEY: CDS <222> LOCATION: (1501)..(1512) <221> NAME/KEY: CDS <222>LOCATION: (1516)..(1551) <221> NAME/KEY: CDS <222> LOCATION:(1555)..(1566) <221> NAME/KEY: CDS <222> LOCATION: (1570)..(1581) <221>NAME/KEY: CDS <222> LOCATION: (1585)..(1620) <221> NAME/KEY: CDS <222>LOCATION: (1624)..(1752) <221> NAME/KEY: CDS <222> LOCATION:(1756)..(1758) <400> SEQUENCE: 1 acc agc gca ctt cgg cag cgg cag cac ctcggc agc gtc agt gaa aat 48 Thr Ser Ala Leu Arg Gln Arg Gln His Leu GlySer Val Ser Glu Asn 1 5 10 15 gcc aag caa gaa aag cgg ccc gca acc ccataa gag gtg ggt gtt cac 96 Ala Lys Gln Glu Lys Arg Pro Ala Thr Pro GluVal Gly Val His 20 25 30 cct taataa tcc ttc cga gga gga gaa aaa caa aatacg gga gct tcc 144 Pro Ser Phe Arg Gly Gly Glu Lys Gln Asn Thr Gly AlaSer 35 40 45 aat ctc cct ttt tga tta ttt tgt ttg tgg cga gga agg ttt ggaaga 192 Asn Leu Pro Phe Leu Phe Cys Leu Trp Arg Gly Arg Phe Gly Arg 5055 60 ggg tag aac tcc tca cct cca ggg gtt tgc gaa ttt tgc taa gaa gca240 Gly Asn Ser Ser Pro Pro Gly Val Cys Glu Phe Cys Glu Ala 65 70 gacttt taa caa ggt gaa gtg gta ttt tgg tgc ccg ctg cca cat cga 288 Asp PheGln Gly Glu Val Val Phe Trp Cys Pro Leu Pro His Arg 75 80 85 gaa agc gaaagg aac cga cca gca gaa taa aga ata ctg cag taa aga 336 Glu Ser Glu ArgAsn Arg Pro Ala Glu Arg Ile Leu Gln Arg 90 95 100 agg cca cat act tatcga gtg tgg agc tcc gcg gaa cca ggg gaa gcg 384 Arg Pro His Thr Tyr ArgVal Trp Ser Ser Ala Glu Pro Gly Glu Ala 105 110 115 cag cga cct gtc tactgc tgt gag tac cct ttt gga gac ggg gtc ttt 432 Gln Arg Pro Val Tyr CysCys Glu Tyr Pro Phe Gly Asp Gly Val Phe 120 125 130 135 ggt gac tgt agccga gca gtt tcc tgt aac gta tgt gag aaa ttt ccg 480 Gly Asp Cys Ser ArgAla Val Ser Cys Asn Val Cys Glu Lys Phe Pro 140 145 150 cgg gct ggc tgaact ttt gaa agt gag cgg gaa gat gca gaa gcg tga 528 Arg Ala Gly Thr PheGlu Ser Glu Arg Glu Asp Ala Glu Ala 155 160 165 ttg gaa gac agc tgt acacgt cat agt ggg ccc gcc cgg ttg tgg gaa 576 Leu Glu Asp Ser Cys Thr ArgHis Ser Gly Pro Ala Arg Leu Trp Glu 170 175 180 gag cca gtg ggc ccg taattt tgc tga gcc tag gga cac cta ctg gaa 624 Glu Pro Val Gly Pro Phe CysAla Gly His Leu Leu Glu 185 190 gcc tagtag aaa taa gtg gtg gga tgg atatca tgg aga aga agt tgt 672 Ala Lys Val Val Gly Trp Ile Ser Trp Arg ArgSer Cys 195 200 205 tgt ttt gga tga ttt tta tgg ctg gtt acc ttg gga tgatct act gag 720 Cys Phe Gly Phe Leu Trp Leu Val Thr Leu Gly Ser Thr Glu210 215 220 act gtg tga ccg gta tcc att gac tgt aga gac taa agg ggg tactgt 768 Thr Val Pro Val Ser Ile Asp Cys Arg Asp Arg Gly Tyr Cys 225 230235 tcc ttt ttt ggc ccg cag tat ttt gat tac cag caa tca ggc ccc cca 816Ser Phe Phe Gly Pro Gln Tyr Phe Asp Tyr Gln Gln Ser Gly Pro Pro 240 245250 gga atg gta ctc ctc aac tgc tgt ccc agc tgt aga agc tct cta tcg 864Gly Met Val Leu Leu Asn Cys Cys Pro Ser Cys Arg Ser Ser Leu Ser 255 260265 gag gat tac tac ttt gca att ttg gaa gac tgc tgg aga aca atc cac 912Glu Asp Tyr Tyr Phe Ala Ile Leu Glu Asp Cys Trp Arg Thr Ile His 270 275280 gga ggt acc cga agg ccg att tga agc agt gga ccc acc ctg tgc cct 960Gly Gly Thr Arg Arg Pro Ile Ser Ser Gly Pro Thr Leu Cys Pro 285 290 295ttt ccc ata taa aat aaa tta ctg agt ctt ttt tgt tat cac atc gta 1008 PhePro Ile Asn Lys Leu Leu Ser Leu Phe Cys Tyr His Ile Val 300 305 310 atggtt ttt att ttt att cat tta gag ggt ctt tca gga taa att ctc 1056 Met ValPhe Ile Phe Ile His Leu Glu Gly Leu Ser Gly Ile Leu 315 320 325 tga attgta cat aaa tag tca acc tta cca cat aat ttt ggg ctg tgg 1104 Ile Val HisLys Ser Thr Leu Pro His Asn Phe Gly Leu Trp 330 335 340 ttg cat ttt ggagcg cat agc cca ggc ctg tgt gct cga cat tgg tgt 1152 Leu His Phe Gly AlaHis Ser Pro Gly Leu Cys Ala Arg His Trp Cys 345 350 355 ggg tat tta aatgga gcc aca gct ggt ttc ttt tat tat ttg gct gga 1200 Gly Tyr Leu Asn GlyAla Thr Ala Gly Phe Phe Tyr Tyr Leu Ala Gly 360 365 370 acc aat caa ttgttt ggt cta gct ctg gtt tgg ggg tga agt acc tgg 1248 Thr Asn Gln Leu PheGly Leu Ala Leu Val Trp Gly Ser Thr Trp 375 380 385 agt ggt agg taa agggct gcc tta tgg tgt ggc ggg agg agt agt taa 1296 Ser Gly Arg Arg Ala AlaLeu Trp Cys Gly Gly Arg Ser Ser 390 395 400 tat agg ggt cat agg cca agttgg tgg agg ggg tta caa agt tgg cat 1344 Tyr Arg Gly His Arg Pro Ser TrpTrp Arg Gly Leu Gln Ser Trp His 405 410 415 cca aga taa caa cag tgg acccaa cac ctc ttt gat tag agg tga tgg 1392 Pro Arg Gln Gln Trp Thr Gln HisLeu Phe Asp Arg Trp 420 425 430 ggt ctc tgg ggt aaa att cat att tag cctttc taa tac ggt agt att 1440 Gly Leu Trp Gly Lys Ile His Ile Pro Phe TyrGly Ser Ile 435 440 445 gga aag gta ggg gta ggg ggt tgg tgc cgc ctg aggggg gga gga act 1488 Gly Lys Val Gly Val Gly Gly Trp Cys Arg Leu Arg GlyGly Gly Thr 450 455 460 ggc cga tgt tga atc tca gct cgt taa cat tcc aagatg gct gcg agt 1536 Gly Arg Cys Ile Ser Ala Arg His Ser Lys Met Ala AlaSer 465 470 475 gtc ctc ctc tta tgg tga gta caa att ctc tag aaa ggc gggaat tga 1584 Val Leu Leu Leu Trp Val Gln Ile Leu Lys Gly Gly Asn 480 485aga tac ccg tct ttc ggc gcc atc tgt aac ggt ttc tga agg cgg ggt 1632 ArgTyr Pro Ser Phe Gly Ala Ile Cys Asn Gly Phe Arg Arg Gly 490 495 500 gtacca aat atg gtc ttc tcc gga gga tgt ttc caa gat ggc tgc ggg 1680 Val ProAsn Met Val Phe Ser Gly Gly Cys Phe Gln Asp Gly Cys Gly 505 510 515 520ggc ggg tcc gtc ttc tgc ggt aac gcc tcc ttg gcc acg tca tcc tat 1728 GlyGly Ser Val Phe Cys Gly Asn Ala Ser Leu Ala Thr Ser Ser Tyr 525 530 535aaa agt gaa aga agt gcg ctg ctg tag tat t 1759 Lys Ser Glu Arg Ser AlaLeu Leu Tyr 540 545 <210> SEQ ID NO 2 <211> LENGTH: 545 <212> TYPE: PRT<213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 2 Thr Ser Ala LeuArg Gln Arg Gln His Leu Gly Ser Val Ser Glu Asn 1 5 10 15 Ala Lys GlnGlu Lys Arg Pro Ala Thr Pro Glu Val Gly Val His Pro 20 25 30 Ser Phe ArgGly Gly Glu Lys Gln Asn Thr Gly Ala Ser Asn Leu Pro 35 40 45 Phe Leu PheCys Leu Trp Arg Gly Arg Phe Gly Arg Gly Asn Ser Ser 50 55 60 Pro Pro GlyVal Cys Glu Phe Cys Glu Ala Asp Phe Gln Gly Glu Val 65 70 75 80 Val PheTrp Cys Pro Leu Pro His Arg Glu Ser Glu Arg Asn Arg Pro 85 90 95 Ala GluArg Ile Leu Gln Arg Arg Pro His Thr Tyr Arg Val Trp Ser 100 105 110 SerAla Glu Pro Gly Glu Ala Gln Arg Pro Val Tyr Cys Cys Glu Tyr 115 120 125Pro Phe Gly Asp Gly Val Phe Gly Asp Cys Ser Arg Ala Val Ser Cys 130 135140 Asn Val Cys Glu Lys Phe Pro Arg Ala Gly Thr Phe Glu Ser Glu Arg 145150 155 160 Glu Asp Ala Glu Ala Leu Glu Asp Ser Cys Thr Arg His Ser GlyPro 165 170 175 Ala Arg Leu Trp Glu Glu Pro Val Gly Pro Phe Cys Ala GlyHis Leu 180 185 190 Leu Glu Ala Lys Val Val Gly Trp Ile Ser Trp Arg ArgSer Cys Cys 195 200 205 Phe Gly Phe Leu Trp Leu Val Thr Leu Gly Ser ThrGlu Thr Val Pro 210 215 220 Val Ser Ile Asp Cys Arg Asp Arg Gly Tyr CysSer Phe Phe Gly Pro 225 230 235 240 Gln Tyr Phe Asp Tyr Gln Gln Ser GlyPro Pro Gly Met Val Leu Leu 245 250 255 Asn Cys Cys Pro Ser Cys Arg SerSer Leu Ser Glu Asp Tyr Tyr Phe 260 265 270 Ala Ile Leu Glu Asp Cys TrpArg Thr Ile His Gly Gly Thr Arg Arg 275 280 285 Pro Ile Ser Ser Gly ProThr Leu Cys Pro Phe Pro Ile Asn Lys Leu 290 295 300 Leu Ser Leu Phe CysTyr His Ile Val Met Val Phe Ile Phe Ile His 305 310 315 320 Leu Glu GlyLeu Ser Gly Ile Leu Ile Val His Lys Ser Thr Leu Pro 325 330 335 His AsnPhe Gly Leu Trp Leu His Phe Gly Ala His Ser Pro Gly Leu 340 345 350 CysAla Arg His Trp Cys Gly Tyr Leu Asn Gly Ala Thr Ala Gly Phe 355 360 365Phe Tyr Tyr Leu Ala Gly Thr Asn Gln Leu Phe Gly Leu Ala Leu Val 370 375380 Trp Gly Ser Thr Trp Ser Gly Arg Arg Ala Ala Leu Trp Cys Gly Gly 385390 395 400 Arg Ser Ser Tyr Arg Gly His Arg Pro Ser Trp Trp Arg Gly LeuGln 405 410 415 Ser Trp His Pro Arg Gln Gln Trp Thr Gln His Leu Phe AspArg Trp 420 425 430 Gly Leu Trp Gly Lys Ile His Ile Pro Phe Tyr Gly SerIle Gly Lys 435 440 445 Val Gly Val Gly Gly Trp Cys Arg Leu Arg Gly GlyGly Thr Gly Arg 450 455 460 Cys Ile Ser Ala Arg His Ser Lys Met Ala AlaSer Val Leu Leu Leu 465 470 475 480 Trp Val Gln Ile Leu Lys Gly Gly AsnArg Tyr Pro Ser Phe Gly Ala 485 490 495 Ile Cys Asn Gly Phe Arg Arg GlyVal Pro Asn Met Val Phe Ser Gly 500 505 510 Gly Cys Phe Gln Asp Gly CysGly Gly Gly Ser Val Phe Cys Gly Asn 515 520 525 Ala Ser Leu Ala Thr SerSer Tyr Lys Ser Glu Arg Ser Ala Leu Leu 530 535 540 Tyr 545 <210> SEQ IDNO 3 <211> LENGTH: 577 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 3 Pro Ala His Phe Gly Ser Gly Ser Thr Ser AlaAla Ser Val Lys Met 1 5 10 15 Pro Ser Lys Lys Ser Gly Pro Gln Pro HisLys Arg Trp Val Phe Thr 20 25 30 Leu Asn Asn Pro Ser Glu Glu Glu Lys AsnLys Ile Arg Glu Leu Pro 35 40 45 Ile Ser Leu Phe Asp Tyr Phe Val Cys GlyGlu Glu Gly Leu Glu Glu 50 55 60 Gly Arg Thr Pro His Leu Gln Gly Phe AlaAsn Phe Ala Lys Lys Gln 65 70 75 80 Thr Phe Asn Lys Val Lys Trp Tyr PheGly Ala Arg Cys His Ile Glu 85 90 95 Lys Ala Lys Gly Thr Asp Gln Gln AsnLys Glu Tyr Cys Ser Lys Glu 100 105 110 Gly His Ile Leu Ile Glu Cys GlyAla Pro Arg Asn Gln Gly Lys Arg 115 120 125 Ser Asp Leu Ser Thr Ala ValSer Thr Leu Leu Glu Thr Gly Ser Leu 130 135 140 Val Thr Val Ala Glu GlnPhe Pro Val Thr Tyr Val Arg Asn Phe Arg 145 150 155 160 Gly Leu Ala GluLeu Leu Lys Val Ser Gly Lys Met Gln Lys Arg Asp 165 170 175 Trp Lys ThrAla Val His Val Ile Val Gly Pro Pro Gly Cys Gly Lys 180 185 190 Ser GlnTrp Ala Arg Asn Phe Ala Glu Pro Arg Asp Thr Tyr Trp Lys 195 200 205 ProSer Arg Asn Lys Trp Trp Asp Gly Tyr His Gly Glu Glu Val Val 210 215 220Val Leu Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp Asp Leu Leu Arg 225 230235 240 Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu Thr Lys Gly Gly Thr Val245 250 255 Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn Gln Ala ProGln 260 265 270 Glu Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Glu Ala LeuTyr Arg 275 280 285 Arg Ile Thr Thr Leu Gln Phe Trp Lys Thr Ala Gly GluGln Ser Thr 290 295 300 Glu Val Pro Glu Gly Arg Phe Glu Ala Val Asp ProPro Cys Ala Leu 305 310 315 320 Phe Pro Tyr Lys Ile Asn Tyr Val Phe PheVal Ile Thr Ser Trp Phe 325 330 335 Leu Phe Leu Phe Ile Arg Val Phe GlnAsp Lys Phe Ser Glu Leu Tyr 340 345 350 Ile Asn Ser Gln Pro Tyr His IleIle Leu Gly Cys Gly Cys Ile Leu 355 360 365 Glu Arg Ile Ala Gln Ala CysVal Leu Asp Ile Gly Val Gly Ile Met 370 375 380 Glu Pro Gln Leu Val SerPhe Ile Ile Trp Leu Glu Pro Ile Asn Cys 385 390 395 400 Leu Val Leu TrpPhe Gly Gly Glu Val Pro Gly Val Val Gly Lys Gly 405 410 415 Leu Pro TyrGly Val Ala Gly Gly Val Val Asn Ile Gly Val Ile Gly 420 425 430 Gln ValGly Gly Gly Gly Tyr Lys Val Gly Ile Gln Asp Asn Asn Ser 435 440 445 GlyPro Asn Thr Ser Leu Ile Arg Gly Asp Gly Val Ser Gly Val Lys 450 455 460Phe Ile Phe Ser Leu Ser Asn Thr Val Val Leu Glu Arg Gly Val Gly 465 470475 480 Ala Ala Gly Gly Glu Glu Leu Ala Asp Val Glu Ser Gln Leu Val Asn485 490 495 Ile Pro Arg Trp Leu Arg Val Ser Ser Ser Tyr Gly Glu Tyr LysPhe 500 505 510 Ser Arg Lys Ala Gly Ile Glu Asp Thr Arg Leu Ser Ala ProSer Val 515 520 525 Thr Val Ser Glu Gly Gly Val Tyr Gln Ile Trp Ser SerPro Glu Asp 530 535 540 Val Ser Lys Met Ala Ala Gly Ala Gly Pro Ser SerAla Val Thr Pro 545 550 555 560 Pro Trp Pro Arg His Pro Ile Lys Val LysGlu Val Arg Cys Cys Ser 565 570 575 Ile <210> SEQ ID NO 4 <211> LENGTH:553 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 4 Gln Arg Thr Ser Ala Ala Ala Ala Pro Arg Gln Arg Gln Lys CysGln 1 5 10 15 Ala Arg Lys Ala Ala Arg Asn Pro Ile Arg Gly Gly Cys SerPro Leu 20 25 30 Leu Pro Arg Arg Arg Lys Thr Lys Tyr Gly Ser Phe Gln SerPro Phe 35 40 45 Leu Ile Ile Leu Phe Val Ala Arg Lys Val Trp Lys Arg ValGlu Leu 50 55 60 Leu Thr Ser Arg Gly Leu Arg Ile Leu Leu Arg Ser Arg LeuLeu Thr 65 70 75 80 Arg Ser Gly Ile Leu Val Pro Ala Ala Thr Ser Arg LysArg Lys Glu 85 90 95 Pro Thr Ser Arg Ile Lys Asn Thr Ala Val Lys Lys AlaThr Tyr Leu 100 105 110 Ser Ser Val Glu Leu Arg Gly Thr Arg Gly Ser AlaAla Thr Cys Leu 115 120 125 Leu Leu Val Pro Phe Trp Arg Arg Gly Leu TrpLeu Pro Ser Ser Phe 130 135 140 Leu Arg Met Glu Ile Ser Ala Gly Trp LeuAsn Phe Lys Ala Gly Arg 145 150 155 160 Cys Arg Ser Val Ile Gly Arg GlnLeu Tyr Thr Ser Trp Ala Arg Pro 165 170 175 Val Val Gly Arg Ala Ser GlyPro Val Ile Leu Leu Ser Leu Gly Thr 180 185 190 Pro Thr Gly Ser Leu ValGlu Ile Ser Gly Gly Met Asp Ile Met Glu 195 200 205 Lys Lys Leu Leu PheTrp Met Ile Phe Met Ala Gly Tyr Leu Gly Met 210 215 220 Ile Tyr Asp CysVal Thr Gly Ile His Leu Arg Leu Lys Gly Val Leu 225 230 235 240 Phe LeuPhe Trp Pro Ala Val Phe Leu Pro Ala Ile Arg Pro Pro Arg 245 250 255 AsnGly Thr Pro Gln Leu Leu Ser Gln Leu Lys Leu Ser Ile Gly Gly 260 265 270Leu Leu Leu Cys Asn Phe Gly Arg Leu Leu Glu Asn Asn Pro Arg Arg 275 280285 Tyr Pro Lys Ala Asp Leu Lys Gln Trp Thr His Pro Val Pro Phe Ser 290295 300 His Ile Lys Ile Thr Glu Ser Phe Leu Leu Ser His Arg Asn Gly Phe305 310 315 320 Tyr Phe Tyr Ser Phe Arg Gly Ser Phe Arg Ile Asn Ser LeuAsn Cys 325 330 335 Thr Ile Val Asn Leu Thr Thr Phe Trp Ala Val Val AlaPhe Trp Ser 340 345 350 Ala Pro Arg Pro Val Cys Ser Thr Leu Val Trp ValPhe Lys Trp Ser 355 360 365 His Ser Trp Phe Leu Leu Leu Phe Gly Trp AsnGln Ser Ile Val Trp 370 375 380 Ser Ser Ser Gly Leu Gly Val Lys Tyr LeuGlu Trp Val Lys Gly Cys 385 390 395 400 Leu Met Val Trp Arg Glu Glu LeuIle Gly Ser Ala Lys Leu Val Glu 405 410 415 Gly Val Thr Lys Leu Ala SerLys Ile Thr Thr Val Asp Pro Thr Pro 420 425 430 Leu Leu Glu Val Met GlySer Leu Gly Asn Ser Tyr Leu Ala Phe Leu 435 440 445 Ile Arg Tyr Trp LysGly Arg Gly Arg Gly Leu Val Pro Pro Glu Gly 450 455 460 Gly Arg Asn TrpPro Met Leu Asn Leu Ser Ser Leu Thr Phe Gln Asp 465 470 475 480 Gly CysGlu Cys Pro Pro Leu Met Val Ser Thr Asn Ser Leu Glu Arg 485 490 495 ArgGlu Leu Lys Ile Pro Val Phe Arg Arg His Leu Arg Phe Leu Lys 500 505 510Ala Gly Cys Thr Lys Tyr Gly Leu Leu Arg Arg Met Phe Pro Arg Trp 515 520525 Leu Arg Gly Arg Val Arg Leu Leu Arg Arg Leu Leu Gly His Val Ile 530535 540 Leu Lys Lys Lys Cys Ala Ala Val Val 545 550 <210> SEQ ID NO 5<211> LENGTH: 1759 <212> TYPE: DNA <213> ORGANISM: Type A PWD circovirus<400> SEQUENCE: 5 aatactacag cagcgcactt ctttcacttt tataggatga cgtggccaaggaggcgttac 60 cgcagaagac ggacccgccc ccgcagccat cttggaaacg tcctccggagaagaccatat 120 ttggtacacc ccgccttcag aaaccgttac agatggcgcc gaaagacgggtatcttcaat 180 tcccgccttt ctagagaatt tgtactcacc ataagaggag gacactcgcagccatcttgg 240 aatgttaacg agctgagatt caacatcggc cagttcctcc ccccctcaggcggcaccaac 300 cccctacccc tacctttcca atactaccgt attagaaagg ctaaatatgaattttacccc 360 agagacccca tcacctctaa tcaaagaggt gttgggtcca ctgttgttatcttggatgcc 420 aactttgtaa ccccctccac caacttggcc tatgacccct atattaactactcctcccgc 480 cacaccataa ggcagccctt tacctaccac tccaggtact tcacccccaaaccagagcta 540 gaccaaacaa ttgattggtt ccagccaaat aataaaagaa accagctgtggctccattta 600 aatacccaca ccaatgtcga gcacacaggc ctgggctatg cgctccaaaatgcaaccaca 660 gcccaaaatt atgtggtaag gttgactatt tatgtacaat tcagagaatttatcctgaaa 720 gaccctctaa atgaataaaa ataaaaacca ttacgatgtg ataacaaaaaagactcagta 780 atttatttta tatgggaaaa gggcacaggg tgggtccact gcttcaaatcggccttcggg 840 tacctccgtg gattgttctc cagcagtctt ccaaaattgc aaagtagtaatcctccgata 900 gagagcttct acagctggga cagcagttga ggagtaccat tcctggggggcctgattgct 960 ggtaatcaaa atactgcggg ccaaaaaagg aacagtaccc cctttagtctctacagtcaa 1020 tggataccgg tcacacagtc tcagtagatc atcccaaggt aaccagccataaaaatcatc 1080 caaaacaaca acttcttctc catgatatcc atcccaccac ttatttctactaggcttcca 1140 gtaggtgtcc ctaggctcag caaaattacg ggcccactgg ctcttcccacaaccgggcgg 1200 gcccactatg acgtgtacag ctgtcttcca atcacgctgc tgcatcttcccgctcacttt 1260 caaaagttca gccagcccgc ggaaatttct cacatacgtt acaggaaactgctcggctac 1320 agtcaccaaa gaccccgtct ccaaaagggt actcacagca gtagacaggtcgctgcgctt 1380 cccctggttc cgcggagctc cacactcgat aagtatgtgg ccttctttactgcagtattc 1440 tttattctgc tggtcggttc ctttcgcttt ctcgatgtgg cagcgggcaccaaaatacca 1500 cttcaccttg ttaaaagtct gcttcttagc aaaattcgca aacccctggaggtgaggagt 1560 tctaccctct tccaaacctt cctcgccaca aacaaaataa tcaaaaagggagattggaag 1620 ctcccgtatt ttgtttttct cctcctcgga aggattatta agggtgaacacccacctctt 1680 atggggttgc gggccgcttt tcttgcttgg cattttcact gacgctgccgaggtgctgcc 1740 gctgccgaag tgcgctggt 1759 <210> SEQ ID NO 6 <211>LENGTH: 567 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 6 Gly Ala Cys Lys Pro Leu Pro Leu Val Glu Ala Ala Asp Thr PheIle 1 5 10 15 Gly Leu Leu Phe Leu Pro Gly Cys Gly Trp Leu Leu His ThrAsn Val 20 25 30 Arg Leu Leu Gly Glu Ser Ser Ser Phe Phe Leu Ile Arg SerSer Gly 35 40 45 Ile Glu Arg Lys Ser Lys Thr Gln Pro Ser Ser Pro Lys SerSer Pro 50 55 60 Leu Val Gly Arg Trp Pro Asn Ala Phe Lys Ala Leu Phe CysVal Lys 65 70 75 80 Leu Leu Thr Phe His Tyr Lys Pro Ala Arg Gln Trp MetSer Phe Ala 85 90 95 Phe Pro Val Ser Trp Cys Phe Leu Ser Tyr Gln Leu LeuSer Pro Trp 100 105 110 Met Ser Ile Ser His Pro Ala Gly Arg Phe Trp ProPhe Arg Leu Ser 115 120 125 Arg Asp Val Ala Thr Leu Val Arg Lys Ser ValPro Asp Lys Thr Val 130 135 140 Thr Ala Ser Cys Asn Gly Thr Val Tyr ThrLeu Phe Lys Arg Pro Ser 145 150 155 160 Ala Ser Ser Lys Phe Thr Leu ProPhe Ile Cys Cys Arg Ser Gln Phe 165 170 175 Val Ala Thr Cys Thr Met ThrPro Gly Gly Pro Gln Pro Phe Leu Trp 180 185 190 His Ala Arg Leu Lys AlaSer Gly Leu Ser Val Gln Phe Gly Leu Leu 195 200 205 Phe Leu His His SerPro Tyr Pro Ser Ser Thr Thr Thr Lys Ser Ser 210 215 220 Lys Pro Gln AsnGly Gln Ser Ser Arg Ser Leu Ser His Ser Arg Tyr 225 230 235 240 Gly AsnVal Thr Ser Val Leu Pro Pro Val Thr Gly Lys Lys Ala Arg 245 250 255 LeuIle Lys Ile Val Leu Leu Ala Gly Trp Ser His Tyr Glu Glu Val 260 265 270Ala Thr Gly Ala Thr Ser Ala Arg Arg Leu Ile Val Val Lys Cys Asn 275 280285 Gln Phe Val Ala Pro Ser Cys Asp Val Ser Thr Gly Ser Pro Arg Asn 290295 300 Ser Ala Thr Ser Gly Gly Gln Ala Arg Lys Gly Tyr Leu Ile Phe Gln305 310 315 320 Thr Lys Lys Thr Ile Val Asp Tyr His Asn Lys Asn Lys AsnMet Leu 325 330 335 Thr Lys Ser Leu Asn Glu Ser Asn Tyr Met Phe Leu GlyTrp Met Ile 340 345 350 Lys Pro Gln Pro Gln Met Lys Ser Arg Met Ala TrpAla Gln Thr Ser 355 360 365 Ser Met Pro Thr Pro Ile Ile Ser Gly Cys SerThr Glu Lys Ile Ile 370 375 380 Gln Ser Ser Gly Ile Leu Gln Lys Thr SerGln Asn Pro Pro Ser Thr 385 390 395 400 Gly Pro Thr Thr Pro Leu Pro SerGly Pro Thr Ala Pro Pro Thr Thr 405 410 415 Leu Ile Pro Thr Met Pro TrpThr Pro Pro Pro Pro Leu Thr Pro Met 420 425 430 Trp Ser Leu Leu Leu ProGly Leu Val Glu Lys Ile Leu Pro Ser Pro 435 440 445 Thr Glu Pro Thr PheAsn Met Asn Leu Arg Glu Leu Val Thr Thr Asn 450 455 460 Ser Leu Tyr ProTyr Pro Thr Pro Ala Ala Gln Pro Pro Ser Ser Ser 465 470 475 480 Ala SerThr Ser Asp Ser Thr Leu Met Gly Leu His Ser Arg Thr Asp 485 490 495 GluGlu Pro Ser Tyr Leu Asn Glu Leu Phe Ala Pro Ile Ser Ser Val 500 505 510Arg Arg Glu Ala Gly Asp Thr Val Thr Glu Ser Pro Pro Thr Tyr Trp 515 520525 Ile His Asp Glu Gly Ser Ser Thr Glu Leu Ile Ala Ala Pro Ala Pro 530535 540 Gly Asp Glu Ala Thr Val Gly Gly Gln Gly Arg Gly Ile Phe Thr Phe545 550 555 560 Ser Thr Arg Gln Gln Leu Ile 565 <210> SEQ ID NO 7 <211>LENGTH: 580 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 7 Trp Arg Val Glu Ala Ala Ala Ala Gly Arg Cys Arg His Phe HisTrp 1 5 10 15 Ala Leu Phe Ala Ala Arg Leu Gly Met Leu Pro Pro His GluGly Lys 20 25 30 Ile Ile Arg Gly Leu Leu Leu Phe Val Phe Tyr Pro Leu LysTrp Asp 35 40 45 Gly Lys Lys Ile Ile Lys Asn Thr Ala Leu Phe Thr Gln PheLeu Thr 50 55 60 Ser Ser Arg Val Glu Leu Pro Lys Arg Ile Lys Ser Leu LeuLeu Ser 65 70 75 80 Lys Val Leu His Leu Pro Ile Lys Thr Gly Ala Ala ValAsp Leu Phe 85 90 95 Arg Phe Ser Gly Val Leu Leu Ile Phe Phe Val Ala ThrPhe Phe Ala 100 105 110 Val Tyr Lys Asp Leu Thr Ser Ser Arg Pro Val LeuPro Leu Ala Ala 115 120 125 Val Gln Arg Ser Ser His Thr Gly Lys Gln LeuArg Pro Arg Gln His 130 135 140 Ser Tyr Gly Leu Leu Lys Arg Tyr Arg IleHis Ser Ile Glu Ala Pro 145 150 155 160 Gln Ser Phe Lys Gln Phe His AlaPro Leu His Leu Leu Thr Ile Pro 165 170 175 Leu Cys Ser Tyr Val Asp TyrHis Ala Arg Gly Thr Thr Pro Leu Ala 180 185 190 Leu Pro Gly Thr Ile LysSer Leu Arg Pro Val Gly Val Pro Leu Arg 195 200 205 Thr Ser Ile Leu ProPro Ile Ser Ile Met Ser Phe Phe Asn Asn Asn 210 215 220 Gln Ile Ile LysIle Ala Pro Arg Pro Ile Ile Gln Ser Gln Thr Val 225 230 235 240 Pro IleTrp Gln Ser Tyr Leu Ser Phe Pro Thr Ser Asn Arg Lys Gln 245 250 255 GlyAla Thr Asn Gln Asn Gly Ala Ile Leu Gly Gly Leu Phe Pro Val 260 265 270Gly Ser Ser Asp Trp Ser Tyr Phe Ser Glu Ile Pro Pro Asn Ser Ser 275 280285 Gln Leu Lys Pro Leu Ser Ser Ser Phe Leu Gly Arg Leu Tyr Gly Phe 290295 300 Ala Ser Lys Phe Cys His Val Trp Gly Thr Gly Lys Glu Trp Ile Phe305 310 315 320 Tyr Ile Val Ser Asp Lys Lys Asn Asp Cys Arg Leu Pro LysLys Glu 325 330 335 Asn Leu Pro Asp Lys Leu Ile Phe Glu Arg Phe Gln ValTyr Ile Thr 340 345 350 Leu Arg Val Val Tyr Asn Gln Ala Thr Thr Ala AsnGln Leu Ala Tyr 355 360 365 Gly Leu Gly Thr His Glu Val Asn Thr His ThrAsn Leu His Leu Trp 370 375 380 Leu Gln Asn Arg Lys Asn Asn Pro Gln PheTrp Asp Ile Thr Gln Asp 385 390 395 400 Leu Glu Pro Lys Pro Thr Phe TyrArg Ser His Tyr Thr Phe Pro Gln 405 410 415 Arg Ile Thr His Arg Ser SerTyr Asn Ile His Pro Asp Tyr Ala Leu 420 425 430 Asn Thr Ser Pro Thr ValPhe Asn Ala Asp Leu Ile Val Val Thr Ser 435 440 445 Gly Val Gly Arg GlnAsn Ser Thr Ile Pro Asp Arg Pro Tyr Phe Glu 450 455 460 Tyr Lys Ala LysArg Ile Arg Tyr Tyr Gln Phe Pro Leu Pro Leu Pro 465 470 475 480 Asn ThrGly Gly Ser Pro Pro Leu Phe Gln Gly Ile Asn Phe Arg Leu 485 490 495 GluAsn Val Asn Trp Ser Pro Gln Ser His Gly Gly Arg Ile Thr Leu 500 505 510Val Phe Glu Arg Ser Leu Arg Ser Asn Phe Ile Gly Thr Lys Arg Arg 515 520525 Trp Arg Tyr Arg Asn Arg Phe Ala Pro His Val Leu Tyr Pro Arg Arg 530535 540 Arg Leu Ile Asn Gly Leu His Ser Arg Pro Arg Thr Arg Arg Arg Arg545 550 555 560 Tyr Arg Arg Arg Pro Trp Thr Met Arg Tyr Phe His Phe PheHis Ala 565 570 575 Ala Thr Thr Asn 580 <210> SEQ ID NO 8 <211> LENGTH:557 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 8 Leu Ala Ser Arg Cys Arg Cys Cys Arg Pro Leu Thr Leu Ser PheAla 1 5 10 15 Leu Cys Ser Phe Arg Gly Ala Val Gly Tyr Ser Thr Pro ThrGly Tyr 20 25 30 Asp Lys Arg Pro Pro Ser Phe Cys Phe Val Pro Ala Glu LeuArg Gly 35 40 45 Lys Gln Asn Asn Gln Lys His Arg Pro Leu Asn Pro Leu ProTyr Phe 50 55 60 Glu Glu Gly Gly Pro Thr Gln Ser Asn Gln Ser Ala Ser LysCys Pro 65 70 75 80 Ser Thr Thr Asn Gly His Gly Ser Gly Cys Arg Ser LeuSer Leu Phe 85 90 95 Arg Gly Ala Ser Tyr Leu Ile Ser Cys Tyr Leu Leu GlyCys Val Arg 100 105 110 Thr His Leu Glu Ala Ser Gly Pro Ser Ala Cys ArgGly Thr Gln Gln 115 120 125 Ser Tyr Gly Lys Pro Ser Pro Thr Lys Pro SerGln Leu Arg Ala Thr 130 135 140 Glu Gln Leu Thr His Ser Phe Asn Gly ArgAla Pro Gln Val Lys Ser 145 150 155 160 Leu Ser Arg Ser Ser Ala Ala AlaHis Asn Ser Ser Leu Gln Val Arg 165 170 175 Leu Pro Gly Ala Arg Asn HisSer Ser Gly Thr Pro Gly Tyr Asn Gln 180 185 190 Gln Ala Pro Cys Arg SerSer Ala Tyr Phe Tyr Thr Thr Pro His Ile 195 200 205 Asp His Leu Leu LeuGln Gln Lys Pro His Asn Lys His Ser Thr Val 210 215 220 Lys Pro His AspVal Ser Val Thr His Gly Thr Asp Met Ser Gln Leu 225 230 235 240 Ser LeuPro Tyr Gln Glu Lys Lys Pro Gly Cys Tyr Lys Ser Trp Cys 245 250 255 AspPro Gly Gly Pro Ile Thr Ser Arg Leu Gln Gln Gly Leu Gln Leu 260 265 270Leu Glu Arg Asp Ser Ser Lys Ala Ile Lys Ser Ser Gln Gln Leu Val 275 280285 Ile Trp Pro Pro Val Arg Leu Gly Ile Gln Leu Leu Pro Gly Val Arg 290295 300 His Gly Lys Gly Met Tyr Phe Leu Asn Ser Leu Arg Lys Gln Met Thr305 310 315 320 Ile Thr Lys Ile Lys Ile Lys Ser Pro Arg Glu Pro Tyr IleArg Gln 325 330 335 Ile Thr Cys Leu Tyr Asp Val Lys Gly Cys Leu Lys ProSer His Asn 340 345 350 Cys Lys Pro Ala Cys Leu Gly Pro Arg His Ala ArgCys Gln His Pro 355 360 365 Tyr Lys Phe Pro Ala Val Val Pro Lys Lys LysAla Pro Val Leu Asn 370 375 380 Asn Pro Arg Ala Arg Thr Gln Pro His LeuVal Gln Leu Pro Leu Tyr 385 390 395 400 Leu Ala Ala Lys His His Pro ProLeu Leu Leu Tyr Leu Pro Leu Gly 405 410 415 Leu Gln His Leu Pro Asn CysLeu Gln Cys Gly Leu Tyr Cys Cys His 420 425 430 Val Trp Cys Arg Lys SerLeu His His Pro Arg Gln Pro Leu Ile Ile 435 440 445 Gly Lys Tyr Pro LeuIle Pro Phe Thr Pro Thr Pro Pro Gln His Arg 450 455 460 Arg Leu Pro ProPro Val Pro Arg His Gln Ile Glu Ala Arg Cys Glu 465 470 475 480 Leu IleAla Ala Leu Thr Arg Arg Lys His His Thr Cys Ile Arg Phe 485 490 495 ProPro Phe Gln Leu Tyr Gly Asp Lys Pro Ala Met Gln Leu Pro Lys 500 505 510Gln Leu Arg Pro Thr Gly Phe Ile Thr Lys Glu Pro Pro His Lys Trp 515 520525 Ser Pro Gln Pro Pro Pro Asp Thr Lys Gln Pro Leu Ala Glu Lys Ala 530535 540 Val Asp Asp Leu Leu Ser Leu Leu Ala Ser Ser Tyr Tyr 545 550 555<210> SEQ ID NO 9 <211> LENGTH: 939 <212> TYPE: DNA <213> ORGANISM: TypeA PWD circovirus <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION:(1)..(936) <400> SEQUENCE: 9 atg cca agc aag aaa agc ggc ccg caa ccc cataag agg tgg gtg ttc 48 Met Pro Ser Lys Lys Ser Gly Pro Gln Pro His LysArg Trp Val Phe 1 5 10 15 acc ctt aat aat cct tcc gag gag gag aaa aacaaa ata cgg gag ctt 96 Thr Leu Asn Asn Pro Ser Glu Glu Glu Lys Asn LysIle Arg Glu Leu 20 25 30 cca atc tcc ctt ttt gat tat ttt gtt tgt ggc gaggaa ggt ttg gaa 144 Pro Ile Ser Leu Phe Asp Tyr Phe Val Cys Gly Glu GluGly Leu Glu 35 40 45 gag ggt aga act cct cac ctc cag ggg ttt gcg aat tttgct aag aag 192 Glu Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe AlaLys Lys 50 55 60 cag act ttt aac aag gtg aag tgg tat ttt ggt gcc cgc tgccac atc 240 Gln Thr Phe Asn Lys Val Lys Trp Tyr Phe Gly Ala Arg Cys HisIle 65 70 75 80 gag aaa gcg aaa gga acc gac cag cag aat aaa gaa tac tgcagt aaa 288 Glu Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Glu Tyr Cys SerLys 85 90 95 gaa ggc cac ata ctt atc gag tgt gga gct ccg cgg aac cag gggaag 336 Glu Gly His Ile Leu Ile Glu Cys Gly Ala Pro Arg Asn Gln Gly Lys100 105 110 cgc agc gac ctg tct act gct gtg agt acc ctt ttg gag acg gggtct 384 Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Glu Thr Gly Ser115 120 125 ttg gtg act gta gcc gag cag ttt cct gta acg tat gtg aga aatttc 432 Leu Val Thr Val Ala Glu Gln Phe Pro Val Thr Tyr Val Arg Asn Phe130 135 140 cgc ggg ctg gct gaa ctt ttg aaa gtg agc ggg aag atg cag cagcgt 480 Arg Gly Leu Ala Glu Leu Leu Lys Val Ser Gly Lys Met Gln Gln Arg145 150 155 160 gat tgg aag aca gct gta cac gtc ata gtg ggc ccg ccc ggttgt ggg 528 Asp Trp Lys Thr Ala Val His Val Ile Val Gly Pro Pro Gly CysGly 165 170 175 aag agc cag tgg gcc cgt aat ttt gct gag cct agg gac acctac tgg 576 Lys Ser Gln Trp Ala Arg Asn Phe Ala Glu Pro Arg Asp Thr TyrTrp 180 185 190 aag cct agt aga aat aag tgg tgg gat gga tat cat gga gaagaa gtt 624 Lys Pro Ser Arg Asn Lys Trp Trp Asp Gly Tyr His Gly Glu GluVal 195 200 205 gtt gtt ttg gat gat ttt tat ggc tgg tta cct tgg gat gatcta ctg 672 Val Val Leu Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp Asp LeuLeu 210 215 220 aga ctg tgt gac cgg tat cca ttg act gta gag act aaa gggggt act 720 Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu Thr Lys Gly GlyThr 225 230 235 240 gtt cct ttt ttg gcc cgc agt att ttg att acc agc aatcag gcc ccc 768 Val Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn GlnAla Pro 245 250 255 cag gaa tgg tac tcc tca act gct gtc cca gct gta gaagct ctc tat 816 Gln Glu Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Glu AlaLeu Tyr 260 265 270 cgg agg att act act ttg caa ttt tgg aag act gct ggagaa caa tcc 864 Arg Arg Ile Thr Thr Leu Gln Phe Trp Lys Thr Ala Gly GluGln Ser 275 280 285 acg gag gta ccc gaa ggc cga ttt gaa gca gtg gac ccaccc tgt gcc 912 Thr Glu Val Pro Glu Gly Arg Phe Glu Ala Val Asp Pro ProCys Ala 290 295 300 ctt ttc cca tat aaa ata aat tac tga 939 Leu Phe ProTyr Lys Ile Asn Tyr 305 310 <210> SEQ ID NO 10 <211> LENGTH: 312 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 10 MetPro Ser Lys Lys Ser Gly Pro Gln Pro His Lys Arg Trp Val Phe 1 5 10 15Thr Leu Asn Asn Pro Ser Glu Glu Glu Lys Asn Lys Ile Arg Glu Leu 20 25 30Pro Ile Ser Leu Phe Asp Tyr Phe Val Cys Gly Glu Glu Gly Leu Glu 35 40 45Glu Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe Ala Lys Lys 50 55 60Gln Thr Phe Asn Lys Val Lys Trp Tyr Phe Gly Ala Arg Cys His Ile 65 70 7580 Glu Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Glu Tyr Cys Ser Lys 85 9095 Glu Gly His Ile Leu Ile Glu Cys Gly Ala Pro Arg Asn Gln Gly Lys 100105 110 Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Glu Thr Gly Ser115 120 125 Leu Val Thr Val Ala Glu Gln Phe Pro Val Thr Tyr Val Arg AsnPhe 130 135 140 Arg Gly Leu Ala Glu Leu Leu Lys Val Ser Gly Lys Met GlnGln Arg 145 150 155 160 Asp Trp Lys Thr Ala Val His Val Ile Val Gly ProPro Gly Cys Gly 165 170 175 Lys Ser Gln Trp Ala Arg Asn Phe Ala Glu ProArg Asp Thr Tyr Trp 180 185 190 Lys Pro Ser Arg Asn Lys Trp Trp Asp GlyTyr His Gly Glu Glu Val 195 200 205 Val Val Leu Asp Asp Phe Tyr Gly TrpLeu Pro Trp Asp Asp Leu Leu 210 215 220 Arg Leu Cys Asp Arg Tyr Pro LeuThr Val Glu Thr Lys Gly Gly Thr 225 230 235 240 Val Pro Phe Leu Ala ArgSer Ile Leu Ile Thr Ser Asn Gln Ala Pro 245 250 255 Gln Glu Trp Tyr SerSer Thr Ala Val Pro Ala Val Glu Ala Leu Tyr 260 265 270 Arg Arg Ile ThrThr Leu Gln Phe Trp Lys Thr Ala Gly Glu Gln Ser 275 280 285 Thr Glu ValPro Glu Gly Arg Phe Glu Ala Val Asp Pro Pro Cys Ala 290 295 300 Leu PhePro Tyr Lys Ile Asn Tyr 305 310 <210> SEQ ID NO 11 <211> LENGTH: 702<212> TYPE: DNA <213> ORGANISM: Type A PWD circovirus <220> FEATURE:<221> NAME/KEY: CDS <222> LOCATION: (1)..(699) <400> SEQUENCE: 11 atgacg tgg cca agg agg cgt tac cgc aga aga cgg acc cgc ccc cgc 48 Met ThrTrp Pro Arg Arg Arg Tyr Arg Arg Arg Arg Thr Arg Pro Arg 1 5 10 15 agccat ctt gga aac atc ctc cgg aga aga cca tat ttg gta cac ccc 96 Ser HisLeu Gly Asn Ile Leu Arg Arg Arg Pro Tyr Leu Val His Pro 20 25 30 gcc ttcaga aac cgt tac aga tgg cgc cga aag acg ggt atc ttc aat 144 Ala Phe ArgAsn Arg Tyr Arg Trp Arg Arg Lys Thr Gly Ile Phe Asn 35 40 45 tcc cgc ctttct aga gaa ttt gta ctc acc ata aga gga gga cac tcg 192 Ser Arg Leu SerArg Glu Phe Val Leu Thr Ile Arg Gly Gly His Ser 50 55 60 cag cca tct tggaat gtt aac gag ctg aga ttc aac atc ggc cag ttc 240 Gln Pro Ser Trp AsnVal Asn Glu Leu Arg Phe Asn Ile Gly Gln Phe 65 70 75 80 ctc ccc ccc tcaggc ggc acc aac ccc cta ccc cta cct ttc caa tac 288 Leu Pro Pro Ser GlyGly Thr Asn Pro Leu Pro Leu Pro Phe Gln Tyr 85 90 95 tac cgt att aga aaggct aaa tat gaa ttt tac ccc aga gac ccc atc 336 Tyr Arg Ile Arg Lys AlaLys Tyr Glu Phe Tyr Pro Arg Asp Pro Ile 100 105 110 acc tct aat caa agaggt gtt ggg tcc act gtt gtt atc ttg gat gcc 384 Thr Ser Asn Gln Arg GlyVal Gly Ser Thr Val Val Ile Leu Asp Ala 115 120 125 aac ttt gta acc ccctcc acc aac ttg gcc tat gac ccc tat att aac 432 Asn Phe Val Thr Pro SerThr Asn Leu Ala Tyr Asp Pro Tyr Ile Asn 130 135 140 tac tcc tcc cgc cacacc ata agg cag ccc ttt acc tac cac tcc agg 480 Tyr Ser Ser Arg His ThrIle Arg Gln Pro Phe Thr Tyr His Ser Arg 145 150 155 160 tac ttc acc cccaaa cca gag cta gac caa aca att gat tgg ttc cag 528 Tyr Phe Thr Pro LysPro Glu Leu Asp Gln Thr Ile Asp Trp Phe Gln 165 170 175 cca aat aat aaaaga aac cag ctg tgg ctc cat tta aat acc cac acc 576 Pro Asn Asn Lys ArgAsn Gln Leu Trp Leu His Leu Asn Thr His Thr 180 185 190 aat gtc gag cacaca ggc ctg ggc tat gcg ctc caa aat gca acc aca 624 Asn Val Glu His ThrGly Leu Gly Tyr Ala Leu Gln Asn Ala Thr Thr 195 200 205 gcc caa aat tatgtg gta agg ttg act att tat gta caa ttc aga gaa 672 Ala Gln Asn Tyr ValVal Arg Leu Thr Ile Tyr Val Gln Phe Arg Glu 210 215 220 ttt atc ctg aaagac cct cta aat gaa taa 702 Phe Ile Leu Lys Asp Pro Leu Asn Glu 225 230<210> SEQ ID NO 12 <211> LENGTH: 233 <212> TYPE: PRT <213> ORGANISM:Type A PWD circovirus <400> SEQUENCE: 12 Met Thr Trp Pro Arg Arg Arg TyrArg Arg Arg Arg Thr Arg Pro Arg 1 5 10 15 Ser His Leu Gly Asn Ile LeuArg Arg Arg Pro Tyr Leu Val His Pro 20 25 30 Ala Phe Arg Asn Arg Tyr ArgTrp Arg Arg Lys Thr Gly Ile Phe Asn 35 40 45 Ser Arg Leu Ser Arg Glu PheVal Leu Thr Ile Arg Gly Gly His Ser 50 55 60 Gln Pro Ser Trp Asn Val AsnGlu Leu Arg Phe Asn Ile Gly Gln Phe 65 70 75 80 Leu Pro Pro Ser Gly GlyThr Asn Pro Leu Pro Leu Pro Phe Gln Tyr 85 90 95 Tyr Arg Ile Arg Lys AlaLys Tyr Glu Phe Tyr Pro Arg Asp Pro Ile 100 105 110 Thr Ser Asn Gln ArgGly Val Gly Ser Thr Val Val Ile Leu Asp Ala 115 120 125 Asn Phe Val ThrPro Ser Thr Asn Leu Ala Tyr Asp Pro Tyr Ile Asn 130 135 140 Tyr Ser SerArg His Thr Ile Arg Gln Pro Phe Thr Tyr His Ser Arg 145 150 155 160 TyrPhe Thr Pro Lys Pro Glu Leu Asp Gln Thr Ile Asp Trp Phe Gln 165 170 175Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu His Leu Asn Thr His Thr 180 185190 Asn Val Glu His Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Thr Thr 195200 205 Ala Gln Asn Tyr Val Val Arg Leu Thr Ile Tyr Val Gln Phe Arg Glu210 215 220 Phe Ile Leu Lys Asp Pro Leu Asn Glu 225 230 <210> SEQ ID NO13 <211> LENGTH: 621 <212> TYPE: DNA <213> ORGANISM: Type A PWDcircovirus <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(618)<400> SEQUENCE: 13 atg ata tcc atc cca cca ctt att tct act agg ctt ccagta ggt gtc 48 Met Ile Ser Ile Pro Pro Leu Ile Ser Thr Arg Leu Pro ValGly Val 1 5 10 15 cct agg ctc agc aaa att acg ggc cca ctg gct ctt cccaca acc ggg 96 Pro Arg Leu Ser Lys Ile Thr Gly Pro Leu Ala Leu Pro ThrThr Gly 20 25 30 cgg gcc cac tat gac gtg tac agc tgt ctt cca atc acg ctgctg cat 144 Arg Ala His Tyr Asp Val Tyr Ser Cys Leu Pro Ile Thr Leu LeuHis 35 40 45 ctt ccc gct cac ttt caa aag ttc agc cag ccc gcg gaa att tctcac 192 Leu Pro Ala His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser His50 55 60 ata cgt tac agg aaa ctg ctc ggc tac agt cac caa aga ccc cgt ctc240 Ile Arg Tyr Arg Lys Leu Leu Gly Tyr Ser His Gln Arg Pro Arg Leu 6570 75 80 caa aag ggt act cac agc agt aga cag gtc gct gcg ctt ccc ctg gtt288 Gln Lys Gly Thr His Ser Ser Arg Gln Val Ala Ala Leu Pro Leu Val 8590 95 ccg cgg agc tcc aca ctc gat aag tat gtg gcc ttc ttt act gca gta336 Pro Arg Ser Ser Thr Leu Asp Lys Tyr Val Ala Phe Phe Thr Ala Val 100105 110 ttc ttt att ctg ctg gtc ggt tcc ttt cgc ttt ctc gat gtg gca gcg384 Phe Phe Ile Leu Leu Val Gly Ser Phe Arg Phe Leu Asp Val Ala Ala 115120 125 ggc acc aaa ata cca ctt cac ctt gtt aaa agt ctg ctt ctt agc aaa432 Gly Thr Lys Ile Pro Leu His Leu Val Lys Ser Leu Leu Leu Ser Lys 130135 140 att cgc aaa ccc ctg gag gtg agg agt tct acc ctc ttc caa acc ttc480 Ile Arg Lys Pro Leu Glu Val Arg Ser Ser Thr Leu Phe Gln Thr Phe 145150 155 160 ctc gcc aca aac aaa ata atc aaa aag gga gat tgg aag ctc ccgtat 528 Leu Ala Thr Asn Lys Ile Ile Lys Lys Gly Asp Trp Lys Leu Pro Tyr165 170 175 ttt gtt ttt ctc ctc ctc gga agg att att aag ggt gaa cac ccacct 576 Phe Val Phe Leu Leu Leu Gly Arg Ile Ile Lys Gly Glu His Pro Pro180 185 190 ctt atg ggg ttg cgg gcc gct ttt ctt gct tgg cat ttt cac tga621 Leu Met Gly Leu Arg Ala Ala Phe Leu Ala Trp His Phe His 195 200 205<210> SEQ ID NO 14 <211> LENGTH: 206 <212> TYPE: PRT <213> ORGANISM:Type A PWD circovirus <400> SEQUENCE: 14 Met Ile Ser Ile Pro Pro Leu IleSer Thr Arg Leu Pro Val Gly Val 1 5 10 15 Pro Arg Leu Ser Lys Ile ThrGly Pro Leu Ala Leu Pro Thr Thr Gly 20 25 30 Arg Ala His Tyr Asp Val TyrSer Cys Leu Pro Ile Thr Leu Leu His 35 40 45 Leu Pro Ala His Phe Gln LysPhe Ser Gln Pro Ala Glu Ile Ser His 50 55 60 Ile Arg Tyr Arg Lys Leu LeuGly Tyr Ser His Gln Arg Pro Arg Leu 65 70 75 80 Gln Lys Gly Thr His SerSer Arg Gln Val Ala Ala Leu Pro Leu Val 85 90 95 Pro Arg Ser Ser Thr LeuAsp Lys Tyr Val Ala Phe Phe Thr Ala Val 100 105 110 Phe Phe Ile Leu LeuVal Gly Ser Phe Arg Phe Leu Asp Val Ala Ala 115 120 125 Gly Thr Lys IlePro Leu His Leu Val Lys Ser Leu Leu Leu Ser Lys 130 135 140 Ile Arg LysPro Leu Glu Val Arg Ser Ser Thr Leu Phe Gln Thr Phe 145 150 155 160 LeuAla Thr Asn Lys Ile Ile Lys Lys Gly Asp Trp Lys Leu Pro Tyr 165 170 175Phe Val Phe Leu Leu Leu Gly Arg Ile Ile Lys Gly Glu His Pro Pro 180 185190 Leu Met Gly Leu Arg Ala Ala Phe Leu Ala Trp His Phe His 195 200 205<210> SEQ ID NO 15 <211> LENGTH: 1767 <212> TYPE: DNA <213> ORGANISM:Type B PWD circovirus <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION:(1)..(111) <221> NAME/KEY: CDS <222> LOCATION: (115)..(243) <221>NAME/KEY: CDS <222> LOCATION: (247)..(267) <221> NAME/KEY: CDS <222>LOCATION: (271)..(360) <221> NAME/KEY: CDS <222> LOCATION: (364)..(417)<221> NAME/KEY: CDS <222> LOCATION: (421)..(447) <221> NAME/KEY: CDS<222> LOCATION: (451)..(471) <221> NAME/KEY: CDS <222> LOCATION:(475)..(510) <221> NAME/KEY: CDS <222> LOCATION: (514)..(516) <221>NAME/KEY: CDS <222> LOCATION: (520)..(729) <221> NAME/KEY: CDS <222>LOCATION: (733)..(753) <221> NAME/KEY: CDS <222> LOCATION: (757)..(759)<221> NAME/KEY: CDS <222> LOCATION: (763)..(804) <221> NAME/KEY: CDS<222> LOCATION: (808)..(861) <221> NAME/KEY: CDS <222> LOCATION:(865)..(984) <221> NAME/KEY: CDS <222> LOCATION: (988)..(1173) <221>NAME/KEY: CDS <222> LOCATION: (1177)..(1233) <221> NAME/KEY: CDS <222>LOCATION: (1237)..(1359) <221> NAME/KEY: CDS <222> LOCATION:(1363)..(1476) <221> NAME/KEY: CDS <222> LOCATION: (1480)..(1737) <221>NAME/KEY: CDS <222> LOCATION: (1741)..(1767) <400> SEQUENCE: 15 acc agcgca ctt cgg cag cgg cag cac ctc ggc agc acc tca gca gca 48 Thr Ser AlaLeu Arg Gln Arg Gln His Leu Gly Ser Thr Ser Ala Ala 1 5 10 15 aca tgccca gca aga aga atg gaa gaa gcg gac ccc aac ccc ata aaa 96 Thr Cys ProAla Arg Arg Met Glu Glu Ala Asp Pro Asn Pro Ile Lys 20 25 30 ggt ggg tgttca ctc tga ata atc ctt ccg aag acg agc gca aga aaa 144 Gly Gly Cys SerLeu Ile Ile Leu Pro Lys Thr Ser Ala Arg Lys 35 40 45 tac ggg atc ttc caatat ccc tat ttg att att tta ttg ttg gcg agg 192 Tyr Gly Ile Phe Gln TyrPro Tyr Leu Ile Ile Leu Leu Leu Ala Arg 50 55 60 agg gta atg agg aag gacgaa cac ctc acc tcc agg ggt tcg cta att 240 Arg Val Met Arg Lys Asp GluHis Leu Thr Ser Arg Gly Ser Leu Ile 65 70 75 ttg tga aga agc aga ctt ttaata aag tga agt ggt att tgg gtg ccc 288 Leu Arg Ser Arg Leu Leu Ile LysSer Gly Ile Trp Val Pro 80 85 90 gct gcc aca tcg aga aag cga aag gaa cagatc agc aga ata aag aat 336 Ala Ala Thr Ser Arg Lys Arg Lys Glu Gln IleSer Arg Ile Lys Asn 95 100 105 act gca gta aag aag gca act tac tga tggagt gtg gag ctc cta gat 384 Thr Ala Val Lys Lys Ala Thr Tyr Trp Ser ValGlu Leu Leu Asp 110 115 120 ctc agg gac aac gga gtg acc tgt cta ctg ctgtga gta cct tgt tgg 432 Leu Arg Asp Asn Gly Val Thr Cys Leu Leu Leu ValPro Cys Trp 125 130 135 aga gcg gga gtc tgg tga ccg ttg cag agc agc accctg taa cgt ttg 480 Arg Ala Gly Val Trp Pro Leu Gln Ser Ser Thr Leu ArgLeu 140 145 150 tca gaa att tcc gcg ggc tgg ctg aac ttt tga aag tga gcggga aaa 528 Ser Glu Ile Ser Ala Gly Trp Leu Asn Phe Lys Ala Gly Lys 155160 165 tgc aga agc gtg att gga aga cta atg tac acg tca ttg tgg ggc cac576 Cys Arg Ser Val Ile Gly Arg Leu Met Tyr Thr Ser Leu Trp Gly His 170175 180 ctg ggt gtg gta aaa gca aat ggg ctg cta att ttg cag acc cgg aaa624 Leu Gly Val Val Lys Ala Asn Gly Leu Leu Ile Leu Gln Thr Arg Lys 185190 195 cca cat act gga aac cac cta gaa aca agt ggt ggg atg gtt acc atg672 Pro His Thr Gly Asn His Leu Glu Thr Ser Gly Gly Met Val Thr Met 200205 210 215 gtg aag aag tgg ttg tta ttg atg act ttt atg gct ggc tgc cctggg 720 Val Lys Lys Trp Leu Leu Leu Met Thr Phe Met Ala Gly Cys Pro Gly220 225 230 atg atc tac tga gac tgt gtg atc gat atc cat tga ctg tag agacta 768 Met Ile Tyr Asp Cys Val Ile Asp Ile His Leu Arg Leu 235 240 aaggtg gaa ctg tac ctt ttt tgg ccc gca gta ttc tga tta cca gca 816 Lys ValGlu Leu Tyr Leu Phe Trp Pro Ala Val Phe Leu Pro Ala 245 250 255 atc agaccc cgt tgg aat ggt act cct caa ctg ctg tcc cag ctg tag 864 Ile Arg ProArg Trp Asn Gly Thr Pro Gln Leu Leu Ser Gln Leu 260 265 270 aag ctc tttatc gga gga tta ctt cct tgg tat ttt gga aga atg cta 912 Lys Leu Phe IleGly Gly Leu Leu Pro Trp Tyr Phe Gly Arg Met Leu 275 280 285 290 cag aacaat cca cgg agg aag ggg gcc agt tcg tca ccc ttt ccc ccc 960 Gln Asn AsnPro Arg Arg Lys Gly Ala Ser Ser Ser Pro Phe Pro Pro 295 300 305 cat gccctg aat ttc cat atg aaa taa att act gag tct ttt tta tca 1008 His Ala LeuAsn Phe His Met Lys Ile Thr Glu Ser Phe Leu Ser 310 315 320 ctt cgt aatggt ttt tat tat tca tta agg gtt aag tgg ggg gtc ttt 1056 Leu Arg Asn GlyPhe Tyr Tyr Ser Leu Arg Val Lys Trp Gly Val Phe 325 330 335 aaa att aaattc tct gaa ttg tac ata cat ggt tac acg gat att gta 1104 Lys Ile Lys PheSer Glu Leu Tyr Ile His Gly Tyr Thr Asp Ile Val 340 345 350 ttc ctg gtcgta tat act gtt ttc gaa cgc agt gcc gag gcc tac gtg 1152 Phe Leu Val ValTyr Thr Val Phe Glu Arg Ser Ala Glu Ala Tyr Val 355 360 365 gtc tac atttcc agc agt ttg tag tct cag cca cag ctg gtt tct ttt 1200 Val Tyr Ile SerSer Ser Leu Ser Gln Pro Gln Leu Val Ser Phe 370 375 380 gtt gtt tgg ttggaa gta atc aat agt gaa atc tag gac agg ttt ggg 1248 Val Val Trp Leu GluVal Ile Asn Ser Glu Ile Asp Arg Phe Gly 385 390 395 ggt aaa gta ccg ggagtg gta gga gaa ggg ctg ggt tat ggt atg gcg 1296 Gly Lys Val Pro Gly ValVal Gly Glu Gly Leu Gly Tyr Gly Met Ala 400 405 410 415 gga gga gta gtttac ata ggg gtc ata ggt gag ggc tgt ggc ctt tgt 1344 Gly Gly Val Val TyrIle Gly Val Ile Gly Glu Gly Cys Gly Leu Cys 420 425 430 tac aaa gtt atcatc taa aat aac agc act gga gcc cac tcc cct gtc 1392 Tyr Lys Val Ile IleAsn Asn Ser Thr Gly Ala His Ser Pro Val 435 440 445 acc ctg ggt gat cgggga gca ggg cca gaa ttc aac ctt aac ctt tct 1440 Thr Leu Gly Asp Arg GlyAla Gly Pro Glu Phe Asn Leu Asn Leu Ser 450 455 460 tat tct gta gta ttcaaa ggg cac aga gcg ggg gtt tga ccc ccc tcc 1488 Tyr Ser Val Val Phe LysGly His Arg Ala Gly Val Pro Pro Ser 465 470 475 tgg ggg aag aaa gtc attaat att gaa tct cat cat gtc cac cgc cca 1536 Trp Gly Lys Lys Val Ile AsnIle Glu Ser His His Val His Arg Pro 480 485 490 gga ggg cgt tct gac tgtggt tcg ctt gac agt ata tcc gaa ggt gcg 1584 Gly Gly Arg Ser Asp Cys GlySer Leu Asp Ser Ile Ser Glu Gly Ala 495 500 505 gga gag gcg ggt gtt gaagat gcc att ttt cct tct cca gcg gta acg 1632 Gly Glu Ala Gly Val Glu AspAla Ile Phe Pro Ser Pro Ala Val Thr 510 515 520 525 gtg gcg ggg gtg gacgag cca ggg gcg gcg gcg gag gat ctg gcc aag 1680 Val Ala Gly Val Asp GluPro Gly Ala Ala Ala Glu Asp Leu Ala Lys 530 535 540 atg gct gcg ggg gcggtg tct tct tct tcg gta acg cct cct tgg ata 1728 Met Ala Ala Gly Ala ValSer Ser Ser Ser Val Thr Pro Pro Trp Ile 545 550 555 cgt cat atc tga aaacga aag aag tgc gct gta agt att 1767 Arg His Ile Lys Arg Lys Lys Cys AlaVal Ser Ile 560 565 <210> SEQ ID NO 16 <211> LENGTH: 569 <212> TYPE: PRT<213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 16 Thr Ser Ala LeuArg Gln Arg Gln His Leu Gly Ser Thr Ser Ala Ala 1 5 10 15 Thr Cys ProAla Arg Arg Met Glu Glu Ala Asp Pro Asn Pro Ile Lys 20 25 30 Gly Gly CysSer Leu Ile Ile Leu Pro Lys Thr Ser Ala Arg Lys Tyr 35 40 45 Gly Ile PheGln Tyr Pro Tyr Leu Ile Ile Leu Leu Leu Ala Arg Arg 50 55 60 Val Met ArgLys Asp Glu His Leu Thr Ser Arg Gly Ser Leu Ile Leu 65 70 75 80 Arg SerArg Leu Leu Ile Lys Ser Gly Ile Trp Val Pro Ala Ala Thr 85 90 95 Ser ArgLys Arg Lys Glu Gln Ile Ser Arg Ile Lys Asn Thr Ala Val 100 105 110 LysLys Ala Thr Tyr Trp Ser Val Glu Leu Leu Asp Leu Arg Asp Asn 115 120 125Gly Val Thr Cys Leu Leu Leu Val Pro Cys Trp Arg Ala Gly Val Trp 130 135140 Pro Leu Gln Ser Ser Thr Leu Arg Leu Ser Glu Ile Ser Ala Gly Trp 145150 155 160 Leu Asn Phe Lys Ala Gly Lys Cys Arg Ser Val Ile Gly Arg LeuMet 165 170 175 Tyr Thr Ser Leu Trp Gly His Leu Gly Val Val Lys Ala AsnGly Leu 180 185 190 Leu Ile Leu Gln Thr Arg Lys Pro His Thr Gly Asn HisLeu Glu Thr 195 200 205 Ser Gly Gly Met Val Thr Met Val Lys Lys Trp LeuLeu Leu Met Thr 210 215 220 Phe Met Ala Gly Cys Pro Gly Met Ile Tyr AspCys Val Ile Asp Ile 225 230 235 240 His Leu Arg Leu Lys Val Glu Leu TyrLeu Phe Trp Pro Ala Val Phe 245 250 255 Leu Pro Ala Ile Arg Pro Arg TrpAsn Gly Thr Pro Gln Leu Leu Ser 260 265 270 Gln Leu Lys Leu Phe Ile GlyGly Leu Leu Pro Trp Tyr Phe Gly Arg 275 280 285 Met Leu Gln Asn Asn ProArg Arg Lys Gly Ala Ser Ser Ser Pro Phe 290 295 300 Pro Pro His Ala LeuAsn Phe His Met Lys Ile Thr Glu Ser Phe Leu 305 310 315 320 Ser Leu ArgAsn Gly Phe Tyr Tyr Ser Leu Arg Val Lys Trp Gly Val 325 330 335 Phe LysIle Lys Phe Ser Glu Leu Tyr Ile His Gly Tyr Thr Asp Ile 340 345 350 ValPhe Leu Val Val Tyr Thr Val Phe Glu Arg Ser Ala Glu Ala Tyr 355 360 365Val Val Tyr Ile Ser Ser Ser Leu Ser Gln Pro Gln Leu Val Ser Phe 370 375380 Val Val Trp Leu Glu Val Ile Asn Ser Glu Ile Asp Arg Phe Gly Gly 385390 395 400 Lys Val Pro Gly Val Val Gly Glu Gly Leu Gly Tyr Gly Met AlaGly 405 410 415 Gly Val Val Tyr Ile Gly Val Ile Gly Glu Gly Cys Gly LeuCys Tyr 420 425 430 Lys Val Ile Ile Asn Asn Ser Thr Gly Ala His Ser ProVal Thr Leu 435 440 445 Gly Asp Arg Gly Ala Gly Pro Glu Phe Asn Leu AsnLeu Ser Tyr Ser 450 455 460 Val Val Phe Lys Gly His Arg Ala Gly Val ProPro Ser Trp Gly Lys 465 470 475 480 Lys Val Ile Asn Ile Glu Ser His HisVal His Arg Pro Gly Gly Arg 485 490 495 Ser Asp Cys Gly Ser Leu Asp SerIle Ser Glu Gly Ala Gly Glu Ala 500 505 510 Gly Val Glu Asp Ala Ile PhePro Ser Pro Ala Val Thr Val Ala Gly 515 520 525 Val Asp Glu Pro Gly AlaAla Ala Glu Asp Leu Ala Lys Met Ala Ala 530 535 540 Gly Ala Val Ser SerSer Ser Val Thr Pro Pro Trp Ile Arg His Ile 545 550 555 560 Lys Arg LysLys Cys Ala Val Ser Ile 565 <210> SEQ ID NO 17 <211> LENGTH: 542 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 17 ProAla His Phe Gly Ser Gly Ser Thr Ser Ala Ala Pro Gln Gln Gln 1 5 10 15His Ala Gln Gln Glu Glu Trp Lys Lys Arg Thr Pro Thr Pro Lys Val 20 25 30Gly Val His Ser Glu Ser Phe Arg Arg Arg Ala Gln Glu Asn Thr Gly 35 40 45Ser Ser Asn Ile Pro Ile Leu Phe Tyr Cys Trp Arg Gly Gly Gly Arg 50 55 60Thr Asn Thr Ser Pro Pro Gly Val Arg Phe Cys Glu Glu Ala Asp Phe 65 70 7580 Ser Glu Val Val Phe Gly Cys Pro Leu Pro His Arg Glu Ser Glu Arg 85 9095 Asn Arg Ser Ala Glu Arg Ile Leu Gln Arg Arg Gln Leu Thr Asp Gly 100105 110 Val Trp Ser Ser Ile Ser Gly Thr Thr Glu Pro Val Tyr Cys Cys Glu115 120 125 Tyr Leu Val Gly Glu Arg Glu Ser Gly Asp Arg Cys Arg Ala AlaPro 130 135 140 Cys Asn Val Cys Gln Lys Phe Pro Arg Ala Gly Thr Phe GluSer Glu 145 150 155 160 Arg Glu Asn Ala Glu Ala Cys Thr Arg His Cys GlyAla Thr Trp Val 165 170 175 Trp Lys Gln Met Gly Cys Phe Cys Arg Pro GlyAsn His Ile Leu Glu 180 185 190 Thr Thr Lys Gln Val Val Gly Trp Leu ProTrp Arg Ser Gly Cys Tyr 195 200 205 Leu Leu Trp Leu Ala Ala Leu Gly SerThr Glu Thr Val Ser Ile Ser 210 215 220 Ile Asp Cys Arg Asp Arg Trp AsnCys Thr Phe Phe Gly Pro Gln Tyr 225 230 235 240 Ser Asp Tyr Gln Gln SerAsp Pro Val Gly Met Val Leu Leu Asn Cys 245 250 255 Cys Pro Ser Cys ArgSer Ser Leu Ser Glu Asp Tyr Phe Leu Gly Ile 260 265 270 Leu Glu Glu CysTyr Arg Thr Ile His Gly Gly Arg Gly Pro Val Arg 275 280 285 His Pro PhePro Pro Met Pro Asn Lys Leu Leu Ser Leu Phe Tyr His 290 295 300 Phe ValMet Val Phe Ile Ile His Gly Leu Ser Gly Gly Ser Leu Lys 305 310 315 320Leu Asn Ser Leu Asn Cys Thr Tyr Met Val Thr Arg Ile Leu Tyr Ser 325 330335 Trp Ser Tyr Ile Leu Phe Ser Asn Ala Val Pro Arg Pro Thr Trp Ser 340345 350 Thr Phe Pro Ala Val Cys Ser Leu Ser His Ser Trp Phe Leu Leu Leu355 360 365 Phe Gly Trp Lys Ser Ile Val Lys Ser Arg Thr Gly Leu Gly ValLys 370 375 380 Tyr Arg Glu Trp Glu Lys Gly Trp Val Met Val Trp Arg GluGlu Val 385 390 395 400 Arg Ala Val Ala Phe Val Thr Lys Leu Ser Ser LysIle Thr Ala Leu 405 410 415 Glu Pro Thr Pro Leu Ser Pro Trp Val Ile GlyGlu Gln Gly Gln Asn 420 425 430 Ser Thr Leu Thr Phe Leu Ile Leu Tyr SerLys Gly Thr Glu Arg Gly 435 440 445 Phe Asp Pro Pro Pro Gly Gly Arg LysSer Leu Ile Leu Asn Leu Ile 450 455 460 Met Ser Thr Ala Gln Glu Gly ValLeu Thr Val Val Arg Leu Thr Val 465 470 475 480 Tyr Pro Lys Val Arg GluArg Arg Val Leu Lys Met Pro Phe Phe Leu 485 490 495 Leu Gln Arg Arg TrpArg Gly Trp Thr Ser Gln Gly Arg Arg Arg Arg 500 505 510 Ile Trp Pro ArgTrp Leu Arg Gly Arg Cys Leu Leu Leu Arg Arg Leu 515 520 525 Leu Gly TyrVal Ile Ser Glu Asn Glu Arg Ser Ala Leu Val 530 535 540 <210> SEQ ID NO18 <211> LENGTH: 566 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 18 Gln Arg Thr Ser Ala Ala Ala Ala Pro ArgGln His Leu Ser Ser Asn 1 5 10 15 Met Pro Ser Lys Lys Asn Gly Arg SerGly Pro Gln Pro His Lys Arg 20 25 30 Trp Val Phe Thr Leu Asn Asn Pro SerGlu Asp Glu Arg Lys Lys Ile 35 40 45 Arg Asp Leu Pro Ile Ser Leu Phe AspTyr Phe Ile Val Gly Glu Glu 50 55 60 Gly Asn Glu Glu Gly Arg Thr Pro HisLeu Gln Gly Phe Ala Asn Phe 65 70 75 80 Val Lys Lys Gln Thr Phe Asn LysVal Lys Trp Tyr Leu Gly Ala Arg 85 90 95 Cys His Ile Glu Lys Ala Lys GlyThr Asp Gln Gln Asn Lys Glu Tyr 100 105 110 Cys Ser Lys Glu Gly Asn LeuLeu Met Glu Cys Gly Ala Pro Arg Ser 115 120 125 Gln Gly Gln Arg Ser AspLeu Ser Thr Ala Val Ser Thr Leu Leu Glu 130 135 140 Ser Gly Ser Leu ValThr Val Ala Glu Gln His Pro Val Thr Phe Val 145 150 155 160 Arg Asn PheArg Gly Leu Ala Glu Leu Leu Lys Val Ser Gly Lys Met 165 170 175 Gln LysArg Asp Trp Lys Thr Asn Val His Val Ile Val Gly Pro Pro 180 185 190 GlyCys Gly Lys Ser Lys Trp Ala Ala Asn Phe Ala Asp Pro Glu Thr 195 200 205Thr Tyr Trp Lys Pro Pro Arg Asn Lys Trp Trp Asp Gly Tyr His Gly 210 215220 Glu Glu Val Val Val Ile Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp 225230 235 240 Asp Leu Leu Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu ThrLys 245 250 255 Gly Gly Thr Val Pro Phe Leu Ala Arg Ser Ile Leu Ile ThrSer Asn 260 265 270 Gln Thr Pro Leu Glu Trp Tyr Ser Ser Thr Ala Val ProAla Val Glu 275 280 285 Ala Leu Tyr Arg Arg Ile Thr Ser Leu Val Phe TrpLys Asn Ala Thr 290 295 300 Glu Gln Ser Thr Glu Glu Gly Gly Gln Phe ValThr Leu Ser Pro Pro 305 310 315 320 Cys Pro Glu Phe Pro Tyr Glu Ile AsnTyr Val Phe Phe Ile Thr Ser 325 330 335 Trp Phe Leu Leu Phe Ile Lys GlyVal Gly Gly Leu Ile Val His Thr 340 345 350 Trp Leu His Gly Tyr Cys IlePro Gly Arg Ile Tyr Cys Phe Arg Thr 355 360 365 Gln Cys Arg Gly Leu ArgGly Leu His Phe Gln Gln Phe Val Val Ser 370 375 380 Ala Thr Ala Gly PhePhe Cys Cys Leu Val Gly Ser Asn Gln Asn Leu 385 390 395 400 Gly Gln ValTrp Gly Ser Thr Gly Ser Gly Arg Arg Arg Ala Gly Leu 405 410 415 Trp TyrGly Gly Arg Ser Ser Leu His Arg Gly His Arg Gly Leu Trp 420 425 430 ProLeu Leu Gln Ser Tyr His Leu Lys Gln His Trp Ser Pro Leu Pro 435 440 445Cys His Pro Gly Ser Gly Ser Arg Ala Arg Ile Gln Pro Pro Phe Leu 450 455460 Phe Cys Ser Ile Gln Arg Ala Gln Ser Gly Gly Leu Thr Pro Leu Leu 465470 475 480 Gly Glu Glu Ser His Ile Ser Ser Cys Pro Pro Pro Arg Arg AlaPhe 485 490 495 Leu Trp Phe Ala Gln Tyr Ile Arg Arg Cys Gly Arg Gly GlyCys Arg 500 505 510 Cys His Phe Ser Phe Ser Ser Gly Asn Gly Gly Gly GlyGly Arg Ala 515 520 525 Arg Gly Gly Gly Gly Gly Ser Gly Gln Asp Gly CysGly Gly Gly Val 530 535 540 Phe Phe Phe Gly Asn Ala Ser Leu Asp Thr SerTyr Leu Lys Thr Lys 545 550 555 560 Glu Val Arg Cys Lys Tyr 565 <210>SEQ ID NO 19 <211> LENGTH: 1767 <212> TYPE: DNA <213> ORGANISM: Type BPWD circovirus <400> SEQUENCE: 19 aatacttaca gcgcacttct ttcgttttcagatatgacgt atccaaggag gcgttaccga 60 agaagaagac accgcccccg cagccatcttggccagatcc tccgccgccg cccctggctc 120 gtccaccccc gccaccgtta ccgctggagaaggaaaaatg gcatcttcaa cacccgcctc 180 tcccgcacct tcggatatac tgtcaagcgaaccacagtca gaacgccctc ctgggcggtg 240 gacatgatga gattcaatat taatgactttcttcccccag gaggggggtc aaacccccgc 300 tctgtgccct ttgaatacta cagaataagaaaggttaagg ttgaattctg gccctgctcc 360 ccgatcaccc agggtgacag gggagtgggctccagtgctg ttattttaga tgataacttt 420 gtaacaaagg ccacagccct cacctatgacccctatgtaa actactcctc ccgccatacc 480 ataacccagc ccttctccta ccactcccggtactttaccc ccaaacctgt cctagatttc 540 actattgatt acttccaacc aaacaacaaaagaaaccagc tgtggctgag actacaaact 600 gctggaaatg tagaccacgt aggcctcggcactgcgttcg aaaacagtat atacgaccag 660 gaatacaata tccgtgtaac catgtatgtacaattcagag aatttaattt taaagacccc 720 ccacttaacc cttaatgaat aataaaaaccattacgaagt gataaaaaag actcagtaat 780 ttatttcata tggaaattca gggcatgggggggaaagggt gacgaactgg cccccttcct 840 ccgtggattg ttctgtagca ttcttccaaaataccaagga agtaatcctc cgataaagag 900 cttctacagc tgggacagca gttgaggagtaccattccaa cggggtctga ttgctggtaa 960 tcagaatact gcgggccaaa aaaggtacagttccaccttt agtctctaca gtcaatggat 1020 atcgatcaca cagtctcagt agatcatcccagggcagcca gccataaaag tcatcaataa 1080 caaccacttc ttcaccatgg taaccatcccaccacttgtt tctaggtggt ttccagtatg 1140 tggtttccgg gtctgcaaaa ttagcagcccatttgctttt accacaccca ggtggcccca 1200 caatgacgtg tacattagtc ttccaatcacgcttctgcat tttcccgctc actttcaaaa 1260 gttcagccag cccgcggaaa tttctgacaaacgttacagg gtgctgctct gcaacggtca 1320 ccagactccc gctctccaac aaggtactcacagcagtaga caggtcactc cgttgtccct 1380 gagatctagg agctccacac tccatcagtaagttgccttc tttactgcag tattctttat 1440 tctgctgatc tgttcctttc gctttctcgatgtggcagcg ggcacccaaa taccacttca 1500 ctttattaaa agtctgcttc ttcacaaaattagcgaaccc ctggaggtga ggtgttcgtc 1560 cttcctcatt accctcctcg ccaacaataaaataatcaaa tagggatatt ggaagatccc 1620 gtattttctt gcgctcgtct tcggaaggattattcagagt gaacacccac cttttatggg 1680 gttggggtcc gcttcttcca ttcttcttgctgggcatgtt gctgctgagg tgctgccgag 1740 gtgctgccgc tgccgaagtg cgctggt 1767<210> SEQ ID NO 20 <211> LENGTH: 567 <212> TYPE: PRT <213> ORGANISM:Type B PWD circovirus <400> SEQUENCE: 20 Gly Ala Cys Lys Pro Leu Pro LeuVal Glu Ala Ala Gly Cys Cys Cys 1 5 10 15 Ala Trp Cys Ser Ser His PhePhe Arg Val Gly Val Gly Tyr Phe Thr 20 25 30 Pro Thr Glu Ser Tyr Asp LysArg Leu Arg Ala Cys Ser Phe Val Pro 35 40 45 Asp Glu Leu Ile Gly Ile GlnAsn Asn Gln Gln Arg Pro Pro Tyr His 50 55 60 Pro Leu Val Phe Val Glu GlyGly Pro Thr Arg Asn Gln Ser Ser Ala 65 70 75 80 Ser Lys Tyr Leu Ser ThrThr Asn Pro His Gly Ser Gly Cys Arg Ser 85 90 95 Leu Ser Leu Phe Leu AspAla Ser Tyr Leu Ile Ser Cys Tyr Leu Leu 100 105 110 Cys Ser Val Ser ProThr His Leu Glu Ile Glu Pro Val Val Ser His 115 120 125 Gly Thr Gln GlnSer Tyr Arg Thr Pro Ser Arg Ser Asp Pro Ser Arg 130 135 140 Gln Leu AlaAla Gly Gln Leu Thr Gln Phe Asn Gly Arg Ala Pro Gln 145 150 155 160 ValLys Ser Leu Ser Arg Ser Phe Ala Ser Ala His Asn Ser Ser His 165 170 175Val Arg Gln Pro Ala Val Gln Thr His Tyr Phe Cys Ile Pro Gln Asn 180 185190 Gln Leu Gly Pro Phe Trp Met Ser Ser Val Val Phe Cys Thr Thr Pro 195200 205 His Asn Gly His His Leu Leu Pro Gln Gln His Ser Lys His Ser Ala210 215 220 Ala Arg Pro His Asp Val Ser Val Thr His Asp Ile Asp Met SerGln 225 230 235 240 Leu Ser Leu His Phe Gln Val Lys Lys Pro Gly Cys TyrGlu Ser Trp 245 250 255 Cys Asp Ser Gly Thr Pro Ile Thr Ser Arg Leu GlnGln Gly Leu Gln 260 265 270 Leu Leu Glu Lys Asp Ser Ser Lys Arg Pro IleLys Ser Ser His Leu 275 280 285 Val Ile Trp Pro Pro Leu Pro Gly Thr ArgGly Lys Gly Gly Met Gly 290 295 300 Gln Ile Glu Met His Phe Leu Asn SerLeu Arg Lys Lys Thr Ile Thr 305 310 315 320 Lys Ile Ile Pro Asn Leu ProPro Asp Lys Phe Asn Phe Glu Arg Phe 325 330 335 Gln Val Tyr Met Thr ValArg Ile Asn Tyr Glu Gln Asp Tyr Ile Ser 340 345 350 Asn Glu Phe Ala ThrGly Leu Gly Val His Asp Val Asn Gly Ala Thr 355 360 365 Gln Leu Arg LeuTrp Leu Gln Asn Arg Lys Asn Asn Pro Gln Phe Tyr 370 375 380 Asp Ile ThrPhe Asp Leu Val Pro Lys Pro Thr Phe Tyr Arg Ser His 385 390 395 400 TyrSer Phe Pro Gln Thr Ile Thr His Arg Ser Ser Tyr Asn Val Tyr 405 410 415Pro Asp Tyr Thr Leu Ala Thr Ala Lys Thr Val Pro Asn Asp Asp Leu 420 425430 Ile Val Ala Ser Ser Gly Val Gly Arg Asp Gly Gln Thr Ile Pro Ser 435440 445 Cys Pro Trp Phe Glu Val Lys Val Lys Arg Ile Arg Tyr Tyr Glu Phe450 455 460 Pro Val Ser Arg Pro Asn Ser Gly Gly Gly Pro Pro Leu Phe AspAsn 465 470 475 480 Ile Asn Phe Arg Met Met Asp Val Ala Trp Ser Pro ThrArg Val Thr 485 490 495 Thr Arg Lys Val Thr Tyr Gly Phe Thr Arg Ser LeuArg Thr Asn Phe 500 505 510 Ile Gly Asn Lys Arg Arg Trp Arg Tyr Arg HisArg Pro His Val Leu 515 520 525 Trp Pro Arg Arg Arg Leu Ile Gln Gly LeuHis Ser Arg Pro Arg His 530 535 540 Arg Arg Arg Arg Tyr Arg Arg Arg ProTyr Thr Met Asp Ser Phe Ser 545 550 555 560 Leu Leu Ala Ser Tyr Thr Asn565 <210> SEQ ID NO 21 <211> LENGTH: 566 <212> TYPE: PRT <213> ORGANISM:Type B PWD circovirus <400> SEQUENCE: 21 Trp Arg Val Glu Ala Ala Ala AlaGly Arg Cys Cys Arg Leu Leu Leu 1 5 10 15 Met Gly Leu Leu Phe Phe ProLeu Leu Pro Gly Trp Gly Trp Leu Leu 20 25 30 His Thr Asn Val Arg Phe LeuGly Glu Ser Ser Ser Arg Leu Phe Ile 35 40 45 Arg Ser Arg Gly Ile Asp ArgAsn Ser Lys Ile Thr Pro Ser Ser Pro 50 55 60 Leu Ser Ser Pro Arg Val GlyArg Trp Pro Asn Ala Leu Lys Thr Phe 65 70 75 80 Phe Cys Val Lys Leu LeuThr Phe His Tyr Lys Pro Ala Arg Gln Trp 85 90 95 Met Ser Phe Ala Phe ProVal Ser Cys Phe Leu Ser Tyr Gln Leu Leu 100 105 110 Ser Pro Leu Lys SerIle Ser His Pro Ala Gly Leu Asp Pro Cys Arg 115 120 125 Leu Ser Arg AspVal Ala Thr Leu Val Lys Asn Ser Leu Pro Leu Arg 130 135 140 Thr Val ThrAla Ser Cys Cys Gly Thr Val Asn Thr Leu Phe Lys Arg 145 150 155 160 ProSer Ala Ser Ser Lys Phe Thr Leu Pro Phe Ile Cys Phe Arg Ser 165 170 175Gln Phe Val Leu Thr Cys Thr Met Thr Pro Gly Gly Pro His Pro Leu 180 185190 Leu Leu His Ala Ala Leu Lys Ala Ser Gly Ser Val Val Tyr Gln Phe 195200 205 Gly Gly Leu Phe Leu His His Ser Pro Trp Pro Ser Ser Thr Thr Thr210 215 220 Ile Ser Ser Lys Pro Gln Ser Gly Gln Ser Ser Arg Ser Leu SerHis 225 230 235 240 Ser Arg Tyr Gly Asn Val Thr Ser Val Leu Pro Pro ValThr Gly Lys 245 250 255 Lys Ala Arg Leu Ile Arg Ile Val Leu Leu Val GlyAsn Ser His Tyr 260 265 270 Glu Glu Val Ala Thr Gly Ala Thr Ser Ala ArgArg Leu Ile Val Glu 275 280 285 Lys Thr Asn Gln Phe Phe Ala Val Ser CysAsp Val Ser Ser Pro Pro 290 295 300 Trp Asn Thr Val Arg Glu Gly Gly HisGly Ser Asn Gly Tyr Ser Ile 305 310 315 320 Phe Gln Thr Lys Lys Ile ValGlu Tyr His Asn Lys Asn Asn Met Leu 325 330 335 Pro Thr Pro Pro Arg PheIle Arg Gln Ile Thr Cys Val His Asn Cys 340 345 350 Pro Tyr Gln Ile GlyPro Arg Ile Tyr Gln Lys Arg Val Cys His Arg 355 360 365 Pro Arg Arg ProArg Cys Lys Trp Cys Asn Thr Thr Glu Ala Val Ala 370 375 380 Pro Lys LysGln Gln Lys Thr Pro Leu Leu Tyr His Phe Arg Pro Cys 385 390 395 400 ThrGln Pro Tyr Leu Val Pro Leu Pro Leu Leu Leu Ala Pro Asn His 405 410 415Tyr Pro Pro Leu Leu Leu Lys Cys Leu Pro Leu His Pro Ser His Gly 420 425430 Lys Asn Cys Leu Arg Phe Tyr Cys Cys Gln Leu Gly Ser Gly Gln Gly 435440 445 Pro His Asp Pro Leu Leu Ala Leu Ile Gly Gly Lys Lys Asn Gln Leu450 455 460 Ile Leu Ala Cys Leu Pro Pro Lys Val Gly Arg Arg Pro Ser SerLeu 465 470 475 480 Tyr Gln Ile Glu Asp His Gly Gly Gly Leu Leu Ala AsnGln Ser His 485 490 495 Asn Ala Gln Cys Tyr Ile Arg Leu His Pro Leu ProPro His Gln Leu 500 505 510 His Trp Lys Glu Lys Glu Leu Pro Leu Pro ProPro Pro Pro Arg Ala 515 520 525 Leu Pro Pro Pro Pro Pro Asp Pro Trp SerPro Gln Pro Pro Pro Thr 530 535 540 Lys Lys Lys Pro Leu Ala Glu Lys SerVal Asp Tyr Arg Phe Val Phe 545 550 555 560 Ser Thr Arg Gln Leu Tyr 565<210> SEQ ID NO 22 <211> LENGTH: 569 <212> TYPE: PRT <213> ORGANISM:Type B PWD circovirus <400> SEQUENCE: 22 Leu Ala Ser Arg Cys Arg Cys CysArg Pro Leu Val Glu Ala Ala Val 1 5 10 15 His Gly Ala Leu Leu Ile SerSer Ala Ser Gly Leu Gly Met Phe Pro 20 25 30 Pro His Glu Ser Gln Ile IleArg Gly Phe Val Leu Ala Leu Phe Tyr 35 40 45 Pro Ile Lys Trp Tyr Gly LysIle Ile Lys Asn Asn Ala Leu Leu Thr 50 55 60 Ile Leu Phe Ser Ser Cys ArgVal Glu Leu Pro Glu Ser Ile Lys His 65 70 75 80 Leu Leu Leu Ser Lys IlePhe His Leu Pro Ile Gln Thr Gly Ala Ala 85 90 95 Val Asp Leu Phe Arg PheSer Cys Ile Leu Leu Ile Phe Phe Val Ala 100 105 110 Thr Phe Phe Ala ValGln His Leu Thr Ser Ser Arg Ser Arg Leu Ser 115 120 125 Leu Pro Thr ValGln Arg Ser Ser His Thr Gly Gln Gln Leu Ala Pro 130 135 140 Thr Gln HisGly Asn Cys Leu Leu Val Arg Tyr Arg Lys Asp Ser Ile 145 150 155 160 GluAla Pro Gln Ser Phe Lys Gln Phe His Ala Pro Phe His Leu Leu 165 170 175Thr Ile Pro Leu Ser Ile Tyr Val Asp Asn His Pro Trp Arg Pro Thr 180 185190 Thr Phe Ala Phe Pro Ser Ser Ile Lys Cys Val Arg Phe Gly Cys Val 195200 205 Pro Phe Trp Arg Ser Val Leu Pro Pro Ile Thr Val Met Thr Phe Phe210 215 220 His Asn Asn Asn Ile Val Lys Ile Ala Pro Gln Gly Pro Ile IleGln 225 230 235 240 Ser Gln Thr Ser Ser Ile Trp Gln Ser Tyr Leu Ser PheThr Ser Ser 245 250 255 Tyr Arg Lys Gln Gly Ala Thr Asn Gln Asn Gly AlaIle Leu Gly Arg 260 265 270 Gln Phe Pro Val Gly Ser Ser Asp Trp Ser TyrPhe Ser Lys Ile Pro 275 280 285 Pro Asn Ser Gly Gln Tyr Lys Pro Leu IleSer Cys Phe Leu Gly Arg 290 295 300 Leu Phe Pro Ala Leu Glu Asp Gly LysGly Gly Trp Ala Arg Phe Lys 305 310 315 320 Trp Ile Phe Trp Ile Val SerAsp Lys Lys Asp Ser Arg Leu Pro Lys 325 330 335 Glu Asn Leu Thr Leu HisPro Thr Lys Leu Ile Leu Asn Glu Ser Asn 340 345 350 Tyr Met Cys Pro ValSer Ile Thr Asn Arg Thr Thr Tyr Val Thr Lys 355 360 365 Ser Arg Leu AlaSer Ala Thr Thr Met Glu Leu Leu Lys Tyr Asp Gly 370 375 380 Cys Ser ThrGlu Lys Thr Thr Gln Asn Ser Thr Ile Leu Leu Ser Ile 385 390 395 400 SerLeu Asn Pro Pro Leu Thr Gly Pro Thr Thr Pro Ser Pro Ser Pro 405 410 415Pro Ile Ala Pro Pro Thr Thr Met Pro Thr Met Pro Ser Pro Gln Pro 420 425430 Arg Gln Leu Thr Ile Met Phe Leu Leu Val Pro Ala Trp Glu Gly Thr 435440 445 Val Arg Pro Ser Arg Pro Ala Pro Gly Ser Asn Leu Arg Leu Arg Glu450 455 460 Glu Thr Thr Asn Leu Pro Cys Leu Ala Pro Thr Gln Gly Gly GluGln 465 470 475 480 Pro Phe Phe Thr Met Leu Ile Ser Asp Thr Trp Arg GlyPro Pro Arg 485 490 495 Glu Ser Gln Pro Glu Ser Ser Leu Ile Asp Ser ProAla Pro Ser Ala 500 505 510 Pro Thr Ser Ser Ala Met Lys Gly Glu Gly AlaThr Val Thr Ala Pro 515 520 525 Thr Ser Ser Gly Pro Ala Ala Ala Ser SerArg Ala Leu Ile Ala Ala 530 535 540 Pro Ala Thr Asp Glu Glu Glu Thr ValGly Gly Gln Ile Arg Ile Gln 545 550 555 560 Phe Arg Phe Phe His Ala ThrLeu Ile 565 <210> SEQ ID NO 23 <211> LENGTH: 945 <212> TYPE: DNA <213>ORGANISM: Type B PWD circovirus <220> FEATURE: <221> NAME/KEY: CDS <222>LOCATION: (1)..(942) <400> SEQUENCE: 23 atg ccc agc aag aag aat gga agaagc gga ccc caa ccc cat aaa agg 48 Met Pro Ser Lys Lys Asn Gly Arg SerGly Pro Gln Pro His Lys Arg 1 5 10 15 tgg gtg ttc act ctg aat aat ccttcc gaa gac gag cgc aag aaa ata 96 Trp Val Phe Thr Leu Asn Asn Pro SerGlu Asp Glu Arg Lys Lys Ile 20 25 30 cgg gat ctt cca ata tcc cta ttt gattat ttt att gtt ggc gag gag 144 Arg Asp Leu Pro Ile Ser Leu Phe Asp TyrPhe Ile Val Gly Glu Glu 35 40 45 ggt aat gag gaa gga cga aca cct cac ctccag ggg ttc gct aat ttt 192 Gly Asn Glu Glu Gly Arg Thr Pro His Leu GlnGly Phe Ala Asn Phe 50 55 60 gtg aag aag cag act ttt aat aaa gtg aag tggtat ttg ggt gcc cgc 240 Val Lys Lys Gln Thr Phe Asn Lys Val Lys Trp TyrLeu Gly Ala Arg 65 70 75 80 tgc cac atc gag aaa gcg aaa gga aca gat cagcag aat aaa gaa tac 288 Cys His Ile Glu Lys Ala Lys Gly Thr Asp Gln GlnAsn Lys Glu Tyr 85 90 95 tgc agt aaa gaa ggc aac tta ctg atg gag tgt ggagct cct aga tct 336 Cys Ser Lys Glu Gly Asn Leu Leu Met Glu Cys Gly AlaPro Arg Ser 100 105 110 cag gga caa cgg agt gac ctg tct act gct gtg agtacc ttg ttg gag 384 Gln Gly Gln Arg Ser Asp Leu Ser Thr Ala Val Ser ThrLeu Leu Glu 115 120 125 agc ggg agt ctg gtg acc gtt gca gag cag cac cctgta acg ttt gtc 432 Ser Gly Ser Leu Val Thr Val Ala Glu Gln His Pro ValThr Phe Val 130 135 140 aga aat ttc cgc ggg ctg gct gaa ctt ttg aaa gtgagc ggg aaa atg 480 Arg Asn Phe Arg Gly Leu Ala Glu Leu Leu Lys Val SerGly Lys Met 145 150 155 160 cag aag cgt gat tgg aag act aat gta cac gtcatt gtg ggg cca cct 528 Gln Lys Arg Asp Trp Lys Thr Asn Val His Val IleVal Gly Pro Pro 165 170 175 ggg tgt ggt aaa agc aaa tgg gct gct aat tttgca gac ccg gaa acc 576 Gly Cys Gly Lys Ser Lys Trp Ala Ala Asn Phe AlaAsp Pro Glu Thr 180 185 190 aca tac tgg aaa cca cct aga aac aag tgg tgggat ggt tac cat ggt 624 Thr Tyr Trp Lys Pro Pro Arg Asn Lys Trp Trp AspGly Tyr His Gly 195 200 205 gaa gaa gtg gtt gtt att gat gac ttt tat ggctgg ctg ccc tgg gat 672 Glu Glu Val Val Val Ile Asp Asp Phe Tyr Gly TrpLeu Pro Trp Asp 210 215 220 gat cta ctg aga ctg tgt gat cga tat cca ttgact gta gag act aaa 720 Asp Leu Leu Arg Leu Cys Asp Arg Tyr Pro Leu ThrVal Glu Thr Lys 225 230 235 240 ggt gga act gta cct ttt ttg gcc cgc agtatt ctg att acc agc aat 768 Gly Gly Thr Val Pro Phe Leu Ala Arg Ser IleLeu Ile Thr Ser Asn 245 250 255 cag acc ccg ttg gaa tgg tac tcc tca actgct gtc cca gct gta gaa 816 Gln Thr Pro Leu Glu Trp Tyr Ser Ser Thr AlaVal Pro Ala Val Glu 260 265 270 gct ctt tat cgg agg att act tcc ttg gtattt tgg aag aat gct aca 864 Ala Leu Tyr Arg Arg Ile Thr Ser Leu Val PheTrp Lys Asn Ala Thr 275 280 285 gaa caa tcc acg gag gaa ggg ggc cag ttcgtc acc ctt tcc ccc cca 912 Glu Gln Ser Thr Glu Glu Gly Gly Gln Phe ValThr Leu Ser Pro Pro 290 295 300 tgc cct gaa ttt cca tat gaa ata aat tactga 945 Cys Pro Glu Phe Pro Tyr Glu Ile Asn Tyr 305 310 <210> SEQ ID NO24 <211> LENGTH: 314 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 24 Met Pro Ser Lys Lys Asn Gly Arg Ser GlyPro Gln Pro His Lys Arg 1 5 10 15 Trp Val Phe Thr Leu Asn Asn Pro SerGlu Asp Glu Arg Lys Lys Ile 20 25 30 Arg Asp Leu Pro Ile Ser Leu Phe AspTyr Phe Ile Val Gly Glu Glu 35 40 45 Gly Asn Glu Glu Gly Arg Thr Pro HisLeu Gln Gly Phe Ala Asn Phe 50 55 60 Val Lys Lys Gln Thr Phe Asn Lys ValLys Trp Tyr Leu Gly Ala Arg 65 70 75 80 Cys His Ile Glu Lys Ala Lys GlyThr Asp Gln Gln Asn Lys Glu Tyr 85 90 95 Cys Ser Lys Glu Gly Asn Leu LeuMet Glu Cys Gly Ala Pro Arg Ser 100 105 110 Gln Gly Gln Arg Ser Asp LeuSer Thr Ala Val Ser Thr Leu Leu Glu 115 120 125 Ser Gly Ser Leu Val ThrVal Ala Glu Gln His Pro Val Thr Phe Val 130 135 140 Arg Asn Phe Arg GlyLeu Ala Glu Leu Leu Lys Val Ser Gly Lys Met 145 150 155 160 Gln Lys ArgAsp Trp Lys Thr Asn Val His Val Ile Val Gly Pro Pro 165 170 175 Gly CysGly Lys Ser Lys Trp Ala Ala Asn Phe Ala Asp Pro Glu Thr 180 185 190 ThrTyr Trp Lys Pro Pro Arg Asn Lys Trp Trp Asp Gly Tyr His Gly 195 200 205Glu Glu Val Val Val Ile Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp 210 215220 Asp Leu Leu Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu Thr Lys 225230 235 240 Gly Gly Thr Val Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr SerAsn 245 250 255 Gln Thr Pro Leu Glu Trp Tyr Ser Ser Thr Ala Val Pro AlaVal Glu 260 265 270 Ala Leu Tyr Arg Arg Ile Thr Ser Leu Val Phe Trp LysAsn Ala Thr 275 280 285 Glu Gln Ser Thr Glu Glu Gly Gly Gln Phe Val ThrLeu Ser Pro Pro 290 295 300 Cys Pro Glu Phe Pro Tyr Glu Ile Asn Tyr 305310 <210> SEQ ID NO 25 <211> LENGTH: 702 <212> TYPE: DNA <213> ORGANISM:Type B PWD circovirus <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION:(1)..(699) <400> SEQUENCE: 25 atg acg tat cca agg agg cgt tac cga agaaga aga cac cgc ccc cgc 48 Met Thr Tyr Pro Arg Arg Arg Tyr Arg Arg ArgArg His Arg Pro Arg 1 5 10 15 agc cat ctt ggc cag atc ctc cgc cgc cgcccc tgg ctc gtc cac ccc 96 Ser His Leu Gly Gln Ile Leu Arg Arg Arg ProTrp Leu Val His Pro 20 25 30 cgc cac cgt tac cgc tgg aga agg aaa aat ggcatc ttc aac acc cgc 144 Arg His Arg Tyr Arg Trp Arg Arg Lys Asn Gly IlePhe Asn Thr Arg 35 40 45 ctc tcc cgc acc ttc gga tat act gtc aag cga accaca gtc aga acg 192 Leu Ser Arg Thr Phe Gly Tyr Thr Val Lys Arg Thr ThrVal Arg Thr 50 55 60 ccc tcc tgg gcg gtg gac atg atg aga ttc aat att aatgac ttt ctt 240 Pro Ser Trp Ala Val Asp Met Met Arg Phe Asn Ile Asn AspPhe Leu 65 70 75 80 ccc cca gga ggg ggg tca aac ccc cgc tct gtg ccc tttgaa tac tac 288 Pro Pro Gly Gly Gly Ser Asn Pro Arg Ser Val Pro Phe GluTyr Tyr 85 90 95 aga ata aga aag gtt aag gtt gaa ttc tgg ccc tgc tcc ccgatc acc 336 Arg Ile Arg Lys Val Lys Val Glu Phe Trp Pro Cys Ser Pro IleThr 100 105 110 cag ggt gac agg gga gtg ggc tcc agt gct gtt att tta gatgat aac 384 Gln Gly Asp Arg Gly Val Gly Ser Ser Ala Val Ile Leu Asp AspAsn 115 120 125 ttt gta aca aag gcc aca gcc ctc acc tat gac ccc tat gtaaac tac 432 Phe Val Thr Lys Ala Thr Ala Leu Thr Tyr Asp Pro Tyr Val AsnTyr 130 135 140 tcc tcc cgc cat acc ata acc cag ccc ttc tcc tac cac tcccgg tac 480 Ser Ser Arg His Thr Ile Thr Gln Pro Phe Ser Tyr His Ser ArgTyr 145 150 155 160 ttt acc ccc aaa cct gtc cta gat ttc act att gat tacttc caa cca 528 Phe Thr Pro Lys Pro Val Leu Asp Phe Thr Ile Asp Tyr PheGln Pro 165 170 175 aac aac aaa aga aac cag ctg tgg ctg aga cta caa actgct gga aat 576 Asn Asn Lys Arg Asn Gln Leu Trp Leu Arg Leu Gln Thr AlaGly Asn 180 185 190 gta gac cac gta ggc ctc ggc act gcg ttc gaa aac agtata tac gac 624 Val Asp His Val Gly Leu Gly Thr Ala Phe Glu Asn Ser IleTyr Asp 195 200 205 cag gaa tac aat atc cgt gta acc atg tat gta caa ttcaga gaa ttt 672 Gln Glu Tyr Asn Ile Arg Val Thr Met Tyr Val Gln Phe ArgGlu Phe 210 215 220 aat ttt aaa gac ccc cca ctt aac cct taa 702 Asn PheLys Asp Pro Pro Leu Asn Pro 225 230 <210> SEQ ID NO 26 <211> LENGTH: 233<212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 26Met Thr Tyr Pro Arg Arg Arg Tyr Arg Arg Arg Arg His Arg Pro Arg 1 5 1015 Ser His Leu Gly Gln Ile Leu Arg Arg Arg Pro Trp Leu Val His Pro 20 2530 Arg His Arg Tyr Arg Trp Arg Arg Lys Asn Gly Ile Phe Asn Thr Arg 35 4045 Leu Ser Arg Thr Phe Gly Tyr Thr Val Lys Arg Thr Thr Val Arg Thr 50 5560 Pro Ser Trp Ala Val Asp Met Met Arg Phe Asn Ile Asn Asp Phe Leu 65 7075 80 Pro Pro Gly Gly Gly Ser Asn Pro Arg Ser Val Pro Phe Glu Tyr Tyr 8590 95 Arg Ile Arg Lys Val Lys Val Glu Phe Trp Pro Cys Ser Pro Ile Thr100 105 110 Gln Gly Asp Arg Gly Val Gly Ser Ser Ala Val Ile Leu Asp AspAsn 115 120 125 Phe Val Thr Lys Ala Thr Ala Leu Thr Tyr Asp Pro Tyr ValAsn Tyr 130 135 140 Ser Ser Arg His Thr Ile Thr Gln Pro Phe Ser Tyr HisSer Arg Tyr 145 150 155 160 Phe Thr Pro Lys Pro Val Leu Asp Phe Thr IleAsp Tyr Phe Gln Pro 165 170 175 Asn Asn Lys Arg Asn Gln Leu Trp Leu ArgLeu Gln Thr Ala Gly Asn 180 185 190 Val Asp His Val Gly Leu Gly Thr AlaPhe Glu Asn Ser Ile Tyr Asp 195 200 205 Gln Glu Tyr Asn Ile Arg Val ThrMet Tyr Val Gln Phe Arg Glu Phe 210 215 220 Asn Phe Lys Asp Pro Pro LeuAsn Pro 225 230 <210> SEQ ID NO 27 <211> LENGTH: 315 <212> TYPE: DNA<213> ORGANISM: Type B PWD circovirus <220> FEATURE: <221> NAME/KEY: CDS<222> LOCATION: (1)..(312) <400> SEQUENCE: 27 atg gta acc atc cca ccactt gtt tct agg tgg ttt cca gta tgt ggt 48 Met Val Thr Ile Pro Pro LeuVal Ser Arg Trp Phe Pro Val Cys Gly 1 5 10 15 ttc cgg gtc tgc aaa attagc agc cca ttt gct ttt acc aca ccc agg 96 Phe Arg Val Cys Lys Ile SerSer Pro Phe Ala Phe Thr Thr Pro Arg 20 25 30 tgg ccc cac aat gac gtg tacatt agt ctt cca atc acg ctt ctg cat 144 Trp Pro His Asn Asp Val Tyr IleSer Leu Pro Ile Thr Leu Leu His 35 40 45 ttt ccc gct cac ttt caa aag ttcagc cag ccc gcg gaa att tct gac 192 Phe Pro Ala His Phe Gln Lys Phe SerGln Pro Ala Glu Ile Ser Asp 50 55 60 aaa cgt tac agg gtg ctg ctc tgc aacggt cac cag act ccc gct ctc 240 Lys Arg Tyr Arg Val Leu Leu Cys Asn GlyHis Gln Thr Pro Ala Leu 65 70 75 80 caa caa ggt act cac agc agt aga caggtc act ccg ttg tcc ctg aga 288 Gln Gln Gly Thr His Ser Ser Arg Gln ValThr Pro Leu Ser Leu Arg 85 90 95 tct agg agc tcc aca ctc cat cag taa 315Ser Arg Ser Ser Thr Leu His Gln 100 <210> SEQ ID NO 28 <211> LENGTH: 104<212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 28Met Val Thr Ile Pro Pro Leu Val Ser Arg Trp Phe Pro Val Cys Gly 1 5 1015 Phe Arg Val Cys Lys Ile Ser Ser Pro Phe Ala Phe Thr Thr Pro Arg 20 2530 Trp Pro His Asn Asp Val Tyr Ile Ser Leu Pro Ile Thr Leu Leu His 35 4045 Phe Pro Ala His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser Asp 50 5560 Lys Arg Tyr Arg Val Leu Leu Cys Asn Gly His Gln Thr Pro Ala Leu 65 7075 80 Gln Gln Gly Thr His Ser Ser Arg Gln Val Thr Pro Leu Ser Leu Arg 8590 95 Ser Arg Ser Ser Thr Leu His Gln 100 <210> SEQ ID NO 29 <211>LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400>SEQUENCE: 29 Val Asp Met Met Arg Phe Asn Ile Asn Asp Phe Leu Pro Pro Gly1 5 10 15 <210> SEQ ID NO 30 <211> LENGTH: 15 <212> TYPE: PRT <213>ORGANISM: Type B PWD circovirus <400> SEQUENCE: 30 Gln Gly Asp Arg GlyVal Gly Ser Ser Ala Val Ile Leu Asp Asp 1 5 10 15 <210> SEQ ID NO 31<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus<400> SEQUENCE: 31 Gly Val Gly Ser Ser Ala Val Ile Leu Asp Asp Asn PheVal Thr 1 5 10 15 <210> SEQ ID NO 32 <211> LENGTH: 15 <212> TYPE: PRT<213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 32 Val Asp His ValGly Leu Gly Thr Ala Phe Glu Asn Ser Ile Tyr 1 5 10 15 <210> SEQ ID NO 33<211> LENGTH: 8 <212> TYPE: DNA <213> ORGANISM: Type A PWD circovirus<400> SEQUENCE: 33 tgtggcga 8 <210> SEQ ID NO 34 <211> LENGTH: 8 <212>TYPE: DNA <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 34agtttcct 8 <210> SEQ ID NO 35 <211> LENGTH: 20 <212> TYPE: DNA <213>ORGANISM: Type A PWD circovirus <400> SEQUENCE: 35 tcatttagag ggtctttcag20 <210> SEQ ID NO 36 <211> LENGTH: 8 <212> TYPE: DNA <213> ORGANISM:Type A PWD circovirus <400> SEQUENCE: 36 gtcaacct 8 <210> SEQ ID NO 37<211> LENGTH: 8 <212> TYPE: DNA <213> ORGANISM: Type A PWD circovirus<400> SEQUENCE: 37 gtggttgc 8 <210> SEQ ID NO 38 <211> LENGTH: 8 <212>TYPE: DNA <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 38agcccagg 8 <210> SEQ ID NO 39 <211> LENGTH: 8 <212> TYPE: DNA <213>ORGANISM: Type A PWD circovirus <400> SEQUENCE: 39 ttggctgg 8 <210> SEQID NO 40 <211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 40 tctagctctg gt 12 <210> SEQ ID NO 41 <211>LENGTH: 12 <212> TYPE: DNA <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 41 atctcagctc gt 12 <210> SEQ ID NO 42 <211> LENGTH: 12 <212>TYPE: DNA <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 42tgtcctcctc tt 12 <210> SEQ ID NO 43 <211> LENGTH: 8 <212> TYPE: DNA<213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 43 tctctaga 8<210> SEQ ID NO 44 <211> LENGTH: 8 <212> TYPE: DNA <213> ORGANISM: TypeA PWD circovirus <400> SEQUENCE: 44 tgtaccaa 8 <210> SEQ ID NO 45 <211>LENGTH: 8 <212> TYPE: DNA <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 45 tccgtctt 8 <210> SEQ ID NO 46 <211> LENGTH: 20 <212> TYPE:DNA <213> ORGANISM: Primer <400> SEQUENCE: 46 gtgtgctcga cattggtgtg 20<210> SEQ ID NO 47 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:Primer <400> SEQUENCE: 47 tggaatgtta acgagctgag 20 <210> SEQ ID NO 48<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Primer <400> SEQUENCE:48 ctcgcagcca tcttggaatg 20 <210> SEQ ID NO 49 <211> LENGTH: 20 <212>TYPE: DNA <213> ORGANISM: Primer <400> SEQUENCE: 49 cgcgcgtaatacgactcact 20 <210> SEQ ID NO 50 <211> LENGTH: 26 <212> TYPE: DNA <213>ORGANISM: Primer <400> SEQUENCE: 50 cctgtctact gctgtgagta ccttgt 26<210> SEQ ID NO 51 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM:Primer <400> SEQUENCE: 51 gcagtagaca ggtcactccg ttgtcc 26 <210> SEQ IDNO 52 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Primer <400>SEQUENCE: 52 tggaatgtta actacctcaa 20 <210> SEQ ID NO 53 <211> LENGTH:23 <212> TYPE: DNA <213> ORGANISM: Primer <400> SEQUENCE: 53 ggcggcgccatctgtaacgg ttt 23 <210> SEQ ID NO 54 <211> LENGTH: 23 <212> TYPE: DNA<213> ORGANISM: Primer <400> SEQUENCE: 54 gatggcgccg aaagacgggt atc 23<210> SEQ ID NO 55 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: TypeB PWD circovirus <400> SEQUENCE: 55 Asn Val Asn Glu Leu Arg Phe Asn IleGly Gln Phe Leu Pro Pro 1 5 10 15 <210> SEQ ID NO 56 <211> LENGTH: 14<212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 56Thr Ser Asn Gln Arg Gly Val Gly Ser Thr Val Val Ile Leu 1 5 10 <210> SEQID NO 57 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 57 Arg Gly Val Gly Ser Thr Val Val Ile LeuAsp Ala Asn Phe Val 1 5 10 15 <210> SEQ ID NO 58 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 58 PheThr Ile Asp Tyr Phe Gln Pro Asn Asn Lys Arg Asn Gln Leu 1 5 10 15 <210>SEQ ID NO 59 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 59 Asp Gln Thr Ile Asp Trp Phe Gln Pro AsnAsn Lys Arg Asn Gln 1 5 10 15 <210> SEQ ID NO 60 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 60 AsnVal Glu His Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Thr 1 5 10 15 <210>SEQ ID NO 61 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 61 His Arg Pro Arg Ser His Leu Gly Gln IleLeu Arg Arg Arg Pro 1 5 10 15 <210> SEQ ID NO 62 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 62 SerHis Leu Gly Gln Ile Leu Arg Arg Arg Pro Trp Leu Val His 1 5 10 15 <210>SEQ ID NO 63 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 63 Gln Ile Leu Arg Arg Arg Pro Trp Leu ValHis Pro Arg His Arg 1 5 10 15 <210> SEQ ID NO 64 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 64 ArgArg Pro Trp Leu Val His Pro Arg His Arg Tyr Arg Trp Arg 1 5 10 15 <210>SEQ ID NO 65 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 65 Leu Val His Pro Arg His Arg Tyr Arg TrpArg Arg Lys Asn Gly 1 5 10 15 <210> SEQ ID NO 66 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 66 ArgHis Arg Tyr Arg Trp Arg Arg Lys Asn Gly Ile Phe Asn Thr 1 5 10 15 <210>SEQ ID NO 67 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 67 Arg Trp Arg Arg Lys Asn Gly Ile Phe AsnThr Arg Leu Ser Arg 1 5 10 15 <210> SEQ ID NO 68 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 68 LysAsn Gly Ile Phe Asn Thr Arg Leu Ser Arg Thr Phe Gly Tyr 1 5 10 15 <210>SEQ ID NO 69 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 69 Phe Asn Thr Arg Leu Ser Arg Thr Phe GlyTyr Thr Val Lys Arg 1 5 10 15 <210> SEQ ID NO 70 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 70 LeuSer Arg Thr Phe Gly Tyr Thr Val Lys Arg Thr Thr Val Arg 1 5 10 15 <210>SEQ ID NO 71 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 71 Phe Gly Tyr Thr Val Lys Arg Thr Thr ValArg Thr Pro Ser Trp 1 5 10 15 <210> SEQ ID NO 72 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 72 ValLys Arg Thr Thr Val Arg Thr Pro Ser Trp Ala Val Asp Met 1 5 10 15 <210>SEQ ID NO 73 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 73 Thr Val Arg Thr Pro Ser Trp Ala Val AspMet Met Arg Phe Asn 1 5 10 15 <210> SEQ ID NO 74 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 74 ProSer Trp Ala Val Asp Met Met Arg Phe Asn Ile Asn Asp Phe 1 5 10 15 <210>SEQ ID NO 75 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 75 Arg Phe Asn Ile Asn Asp Phe Leu Pro ProGly Gly Gly Ser Asn 1 5 10 15 <210> SEQ ID NO 76 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 76 AsnAsp Phe Leu Pro Pro Gly Gly Gly Ser Asn Pro Arg Ser Val 1 5 10 15 <210>SEQ ID NO 77 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 77 Pro Pro Gly Gly Gly Ser Asn Pro Arg SerVal Pro Phe Glu Tyr 1 5 10 15 <210> SEQ ID NO 78 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 78 GlySer Asn Pro Arg Ser Val Pro Phe Glu Tyr Tyr Arg Ile Arg 1 5 10 15 <210>SEQ ID NO 79 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 79 Arg Ser Val Pro Phe Glu Tyr Tyr Arg IleArg Lys Val Lys Val 1 5 10 15 <210> SEQ ID NO 80 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 80 PheGlu Tyr Tyr Arg Ile Arg Lys Val Lys Val Glu Phe Trp Pro 1 5 10 15 <210>SEQ ID NO 81 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 81 Arg Ile Arg Lys Val Lys Val Glu Phe TrpPro Cys Ser Pro Ile 1 5 10 15 <210> SEQ ID NO 82 <211> LENGHT: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 82 ValLys Val Glu Phe Trp Pro Cys Ser Pro Ile Thr Gln Gly Asp 1 5 10 15 <210>SEQ ID NO 83 <211> LENGHT: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 83 Phe trp Pro Cys Ser Pro Ile Thr Gln GlyAsp Arg Gly Val Gly 1 5 10 15 <210> SEQ ID NO 84 <211> LENGHT: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 84 ThrArg Pro Arg Ser His Leu Gly Asn Ile Leu Arg Arg Arg Pro 1 5 10 15 <210>SEQ ID NO 85 <211> LENGHT: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 85 Ser His Leu Gly Asn Ile Leu Arg Arg ArgPro Tyr Leu Val His 1 5 10 15 <210> SEQ ID NO 86 <211> LENGHT: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 86 AsnIle Leu Arg Arg Arg Pro Tyr Leu Val His Pro Ala Phe Arg 1 5 10 15 <210>SEQ ID NO 87 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 87 Arg Arg Pro Tyr Leu Val His Pro Ala PheArg Asn Arg Tyr Arg 1 5 10 15 <210> SEQ ID NO 88 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 88 LeuVal His Pro Ala Phe Arg Asn Arg Tyr Arg Trp Arg Arg Lys 1 5 10 15 <210>SEQ ID NO 89 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 89 Ala Phe Arg Asn Arg Tyr Arg Trp Arg ArgLys Thr Gly Ile Phe 1 5 10 15 <210> SEQ ID NO 90 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 90 ArgTyr Arg Trp Arg Arg Lys Thr Gly Ile Phe Asn Ser Arg Leu 1 5 10 15 <210>SEQ ID NO 91 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 91 Arg Arg Lys Thr Gly Ile Phe Asn Ser ArgLeu Ser Arg Glu Phe 1 5 10 15 <210> SEQ ID NO 92 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 92 GlyIle Phe Asn Ser Arg Leu Ser Arg Glu Phe Val Leu Thr Ile 1 5 10 15 <210>SEQ ID NO 93 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 93 Ser Arg Leu Ser Arg Glu Phe Val Leu ThrIle Arg Gly Gly His 1 5 10 15 <210> SEQ ID NO 94 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 94 ArgGlu Phe Val Leu Thr Ile Arg Gly Gly His Ser Gln Pro Ser 1 5 10 15 <210>SEQ ID NO 95 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 95 Leu Thr Ile Arg Gly Gly His Ser Gln ProSer Trp Asn Val Asn 1 5 10 15 <210> SEQ ID NO 96 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 96 GlyGly His Ser Gln Pro Ser Trp Asn Val Asn Glu Leu Arg Phe 1 5 10 15 <210>SEQ ID NO 97 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 97 Gln Pro Ser Trp Asn Val Asn Glu Leu ArgPhe Asn Ile Gly Gln 1 5 10 15 <210> SEQ ID NO 98 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 98 AsnVal Asn Glu Leu Arg Phe Asn Ile Gly Gln Phe Leu Pro Pro 1 5 10 15 <210>SEQ ID NO 99 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 99 Leu Arg Phe Asn Ile Gly Gln Phe Leu ProPro Ser Gly Gly Thr 1 5 10 15 <210> SEQ ID NO 100 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 100 IleGly Gln Phe Leu Pro Pro Ser Gly Gly Thr Asn Pro Leu Pro 1 5 10 15 <210>SEQ ID NO 101 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type APWD circovirus <400> SEQUENCE: 101 Leu Pro Pro Ser Gly Gly Thr Asn ProLeu Pro Leu Pro Phe Gln 1 5 10 15 <210> SEQ ID NO 102 <211> LENGTH: 15<212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE:102 Gly Gly Thr Asn Pro Leu Pro Leu Pro Phe Gln Tyr Tyr Arg Ile 1 5 1015 <210> SEQ ID NO 103 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:Type A PWD circovirus <400> SEQUENCE: 103 Pro Leu Pro Leu Pro Phe GlnTyr Tyr Arg Ile Arg Lys Ala Lys 1 5 10 15 <210> SEQ ID NO 104 <211>LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 104 Pro Phe Gln Tyr Tyr Arg Ile Arg Lys Ala Lys Tyr Glu PheTyr 1 5 10 15 <210> SEQ ID NO 105 <211> LENGTH: 15 <212> TYPE: PRT <213>ORGANISM: Type A PWD circovirus <400> SEQUENCE: 105 Tyr Arg Ile Arg LysAla Lys Tyr Glu Phe Tyr Pro Arg Asp Pro 1 5 10 15 <210> SEQ ID NO 106<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus<400> SEQUENCE: 106 Lys Ala Lys Tyr Glu Phe Tyr Pro Arg Asp Pro Ile ThrSer Asn 1 5 10 15 <210> SEQ ID NO 107 <211> LENGTH: 15 <212> TYPE: PRT<213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 107 Glu Phe TyrPro Arg Asp Pro Ile Thr Ser Asn Gln Arg Gly Val 1 5 10 15 <210> SEQ IDNO 108 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 108 Arg Asp Pro Ile Thr Ser Asn Gln Arg GlyVal Gly Ser Thr Val 1 5 10 15 <210> SEQ ID NO 109 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 109 ThrSer Asn Gln Arg Gly Val Gly Ser Thr Val Val Ile Leu Asp 1 5 10 15 <210>SEQ ID NO 110 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type BPWD circovirus <400> SEQUENCE: 110 Gly Val Gly Ser Ser Ala Val Ile LeuAsp Asp Asn Phe Val Thr 1 5 10 15 <210> SEQ ID NO 111 <211> LENGTH: 15<212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE:111 Ser Ala Val Ile Leu Asp Asp Asn Phe Val Thr Lys Ala Thr Ala 1 5 1015 <210> SEQ ID NO 112 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:Type B PWD circovirus <400> SEQUENCE: 112 Leu Asp Asp Asn Phe Val ThrLys Ala Thr Ala Leu Thr Tyr Asp 1 5 10 15 <210> SEQ ID NO 113 <211>LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400>SEQUENCE: 113 Phe Val Thr Lys Ala Thr Ala Leu Thr Tyr Asp Pro Tyr ValAsn 1 5 10 15 <210> SEQ ID NO 114 <211> LENGTH: 15 <212> TYPE: PRT <213>ORGANISM: Type B PWD circovirus <400> SEQUENCE: 114 Ala Thr Ala Leu ThrTyr Asp Pro Tyr Val Asn Tyr Ser Ser Arg 1 5 10 15 <210> SEQ ID NO 115<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus<400> SEQUENCE: 115 Thr Tyr Asp Pro Tyr Val Asn Tyr Ser Ser Arg His ThrIle Thr 1 5 10 15 <210> SEQ ID NO 116 <211> LENGTH: 15 <212> TYPE: PRT<213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 116 Tyr Val AsnTyr Ser Ser Arg His Thr Ile Thr Gln Pro Phe Ser 1 5 10 15 <210> SEQ IDNO 117 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 117 Ser Ser Arg His Thr Ile Thr Gln Pro PheSer Tyr His Ser Arg 1 5 10 15 <210> SEQ ID NO 118 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 118 ThrIle Thr Gln Pro Phe Ser Tyr His Ser Arg Tyr Phe Thr Pro 1 5 10 15 <210>SEQ ID NO 119 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type BPWD circovirus <400> SEQUENCE: 119 Pro Phe Ser Tyr His Ser Arg Tyr PheThr Pro Lys Pro Val Leu 1 5 10 15 <210> SEQ ID NO 120 <211> LENGTH: 15<212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE:120 His Ser Arg Tyr Phe Thr Pro Lys Pro Val Leu Asp Phe Thr Ile 1 5 1015 <210> SEQ ID NO 121 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:Type B PWD circovirus <400> SEQUENCE: 121 Phe Thr Pro Lys Pro Val LeuAsp Phe Thr Ile Asp Tyr Phe Gln 1 5 10 15 <210> SEQ ID NO 122 <211>LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400>SEQUENCE: 122 Pro Val Leu Asp Phe Thr Ile Asp Tyr Phe Gln Pro Asn AsnLys 1 5 10 15 <210> SEQ ID NO 123 <211> LENGTH: 15 <212> TYPE: PRT <213>ORGANISM: Type B PWD circovirus <400> SEQUENCE: 123 Phe Thr Ile Asp TyrPhe Gln Pro Asn Asn Lys Arg Asn Gln Leu 1 5 10 15 <210> SEQ ID NO 124<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus<400> SEQUENCE: 124 Tyr Phe Gln Pro Asn Asn Lys Arg Asn Gln Leu Trp LeuArg Leu 1 5 10 15 <210> SEQ ID NO 125 <211> LENGTH: 15 <212> TYPE: PRT<213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 125 Asn Asn LysArg Asn Gln Leu Trp Leu Arg Leu Gln Thr Ala Gly 1 5 10 15 <210> SEQ IDNO 126 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 126 Asn Gln Leu Trp Leu Arg Leu Gln Thr AlaGly Asn Val Asp His 1 5 10 15 <210> SEQ ID NO 127 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 127 LeuArg Leu Gln Thr Ala Gly Asn Val Asp His Val Gly Leu Gly 1 5 10 15 <210>SEQ ID NO 128 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type BPWD circovirus <400> SEQUENCE: 128 Thr Ala Gly Asn Val Asp His Val GlyLeu Gly Thr Ala Phe Glu 1 5 10 15 <210> SEQ ID NO 129 <211> LENGTH: 15<212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400> SEQUENCE:129 Gly Leu Gly Thr Ala Phe Glu Asn Ser Ile Tyr Asp Gln Glu Tyr 1 5 1015 <210> SEQ ID NO 130 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:Type B PWD circovirus <400> SEQUENCE: 130 Ala Phe Glu Asn Ser Ile TyrAsp Gln Glu Tyr Asn Ile Arg Val 1 5 10 15 <210> SEQ ID NO 131 <211>LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus <400>SEQUENCE: 131 Ser Ile Tyr Asp Gln Glu Tyr Asn Ile Arg Val Thr Met TyrVal 1 5 10 15 <210> SEQ ID NO 132 <211> LENGTH: 15 <212> TYPE: PRT <213>ORGANISM: Type B PWD circovirus <400> SEQUENCE: 132 Gln Glu Tyr Asn IleArg Val Thr Met Tyr Val Gln Phe Arg Glu 1 5 10 15 <210> SEQ ID NO 133<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWD circovirus<400> SEQUENCE: 133 Ile Arg Val Thr Met Tyr Val Gln Phe Arg Glu Phe AsnPhe Lys 1 5 10 15 <210> SEQ ID NO 134 <211> LENGTH: 15 <212> TYPE: PRT<213> ORGANISM: Type B PWD circovirus <400> SEQUENCE: 134 Met Tyr ValGln Phe Arg Glu Phe Asn Phe Lys Asp Pro Pro Leu 1 5 10 15 <210> SEQ IDNO 135 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type B PWDcircovirus <400> SEQUENCE: 135 Val Gln Phe Arg Glu Phe Asn Phe Lys AspPro Pro Leu Asn Pro 1 5 10 15 <210> SEQ ID NO 136 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 136 ArgGly Val Gly Ser Thr Val Val Ile Leu Asp Ala Asn Phe Val 1 5 10 15 <210>SEQ ID NO 137 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type APWD circovirus <400> SEQUENCE: 137 Ser Thr Val Val Ile Leu Asp Ala AsnPhe Val Thr Pro Ser Thr 1 5 10 15 <210> SEQ ID NO 138 <211> LENGTH: 15<212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE:138 Ile Leu Asp Ala Asn Phe Val Thr Pro Ser Thr Asn Leu Ala Tyr 1 5 1015 <210> SEQ ID NO 139 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:Type A PWD circovirus <400> SEQUENCE: 139 Asn Phe Val Thr Pro Ser ThrAsn Leu Ala Tyr Asp Pro Tyr Ile 1 5 10 15 <210> SEQ ID NO 140 <211>LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 140 Pro Ser Thr Asn Leu Ala Tyr Asp Pro Tyr Ile Asn Tyr SerSer 1 5 10 15 <210> SEQ ID NO 141 <211> LENGTH: 15 <212> TYPE: PRT <213>ORGANISM: Type A PWD circovirus <400> SEQUENCE: 141 Leu Ala Tyr Asp ProTyr Ile Asn Tyr Ser Ser Arg His Thr Ile 1 5 10 15 <210> SEQ ID NO 142<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus<400> SEQUENCE: 142 Pro Tyr Ile Asn Tyr Ser Ser Arg His Thr Ile Arg GlnPro Phe 1 5 10 15 <210> SEQ ID NO 143 <211> LENGTH: 15 <212> TYPE: PRT<213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 143 Tyr Ser SerArg His Thr Ile Arg Gln Pro Phe Thr Tyr His Ser 1 5 10 15 <210> SEQ IDNO 144 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 144 His Thr Ile Arg Gln Pro Phe Thr Tyr HisSer Arg Tyr Phe Thr 1 5 10 15 <210> SEQ ID NO 145 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 145 GlnPro Phe Thr Tyr His Ser Arg Tyr Phe Thr Pro Lys Pro Glu 1 5 10 15 <210>SEQ ID NO 146 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type APWD circovirus <400> SEQUENCE: 146 Tyr His Ser Arg Tyr Phe Thr Pro LysPro Glu Leu Asp Gln Thr 1 5 10 15 <210> SEQ ID NO 147 <211> LENGTH: 15<212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE:147 Tyr Phe Thr Pro Lys Pro Glu Leu Asp Gln Thr Ile Asp Trp Phe 1 5 1015 <210> SEQ ID NO 148 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:Type A PWD circovirus <400> SEQUENCE: 148 Lys Pro Glu Leu Asp Gln ThrIle Asp Trp Phe Gln Pro Asn Asn 1 5 10 15 <210> SEQ ID NO 149 <211>LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 149 Asp Gln Thr Ile Asp Trp Phe Gln Pro Asn Asn Lys Arg AsnGln 1 5 10 15 <210> SEQ ID NO 150 <211> LENGTH: 15 <212> TYPE: PRT <213>ORGANISM: Type A PWD circovirus <400> SEQUENCE: 150 Asp Trp Phe Gln ProAsn Asn Lys Arg Asn Gln Leu Trp Leu His 1 5 10 15 <210> SEQ ID NO 151<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus<400> SEQUENCE: 151 Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu His Leu AsnThr His 1 5 10 15 <210> SEQ ID NO 152 <211> LENGTH: 15 <212> TYPE: PRT<213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 152 Arg Asn GlnLeu Trp Leu His Leu Asn Thr His Thr Asn Val Glu 1 5 10 15 <210> SEQ IDNO 153 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 153 Trp Leu His Leu Asn Thr His Thr Asn ValGlu His Thr Gly Leu 1 5 10 15 <210> SEQ ID NO 154 <211> LENGTH: 15 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 154 AsnThr His Thr Asn Val Glu His Thr Gly Leu Gly Tyr Ala Leu 1 5 10 15 <210>SEQ ID NO 155 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type APWD circovirus <400> SEQUENCE: 155 Asn Val Glu His Thr Gly Leu Gly TyrAla Leu Gln Asn Ala Thr 1 5 10 15 <210> SEQ ID NO 156 <211> LENGTH: 15<212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE:156 Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Thr Thr Ala Gln Asn 1 5 1015 <210> SEQ ID NO 157 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:Type A PWD circovirus <400> SEQUENCE: 157 Tyr Ala Leu Gln Asn Ala ThrThr Ala Gln Asn Tyr Val Val Arg 1 5 10 15 <210> SEQ ID NO 158 <211>LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 158 Asn Ala Thr Thr Ala Gln Asn Tyr Val Val Arg Leu Thr IleTyr 1 5 10 15 <210> SEQ ID NO 159 <211> LENGTH: 15 <212> TYPE: PRT <213>ORGANISM: Type A PWD circovirus <400> SEQUENCE: 159 Ala Gln Asn Tyr ValVal Arg Leu Thr Ile Tyr Val Gln Phe Arg 1 5 10 15 <210> SEQ ID NO 160<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus<400> SEQUENCE: 160 Val Val Arg Leu Thr Ile Tyr Val Gln Phe Arg Glu PheIle Leu 1 5 10 15 <210> SEQ ID NO 161 <211> LENGTH: 15 <212> TYPE: PRT<213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 161 Thr Ile TyrVal Gln Phe Arg Glu Phe Ile Leu Lys Asp Pro Leu 1 5 10 15 <210> SEQ IDNO 162 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Type A PWDcircovirus <400> SEQUENCE: 162 Tyr Val Gln Phe Arg Glu Phe Ile Leu LysAsp Pro Leu Asn Glu 1 5 10 15 <210> SEQ ID NO 163 <211> LENGTH: 1759<212> TYPE: DNA <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE:163 accagcgcac ttcggcagcg gcagcacctc ggcagcgtca gtgaaaatgc caagcaagaa 60aagcggcccg caaccccata agaggtgggt gttcaccctt aataatcctt ccgaggagga 120gaaaaacaaa atacgggagc ttccaatctc cctttttgat tattttgttt gcggagagga 180aggtttggaa gagggtagaa ctcctcacct ccaggggttt gcgaattttg ctaagaagca 240gacttttaac aaggtgaagt ggtattttgg tgcccgctgc cacatcgaga aagcgaaagg 300aaccgaccag cagaataaag aatactgcag taaagaaggc cacatactta tcgagtgtgg 360agctccgcgg aaccagggga agcgcagcga cctgtctact gctgtgagta cccttttgga 420gacggggtct ttggtgactg tagccgagca gttccctgta acgtatgtga gaaatttccg 480cgggctggct gaacttttga aagtgagcgg gaagatgcag aagcgtgatt ggaagacagc 540tgtacacgtc atagtgggcc cgcccggttg tgggaagagc cagtgggccc gtaattttgc 600tgagcctagg gacacctact ggaagcctag tagaaataag tggtgggatg gatatcatgg 660agaagaagtt gttgttttgg atgattttta tggctggtta ccttgggatg atctactgag 720actgtgtgac cggtatccat tgactgtaga gactaaaggg ggtactgttc cttttttggc 780ccgcagtatt ttgattacca gcaatcaggc cccccaggaa tggtactcct caactgctgt 840cccagctgta gaagctctct atcggaggat tactactttg caattttgga agactgctgg 900agaacaatcc acggaggtac ccgaaggccg atttgaagca gtggacccac cctgtgccct 960tttcccatat aaaataaatt actgagtctt ttttgttatc acatcgtaat ggtttttatt 1020tttatttatt tagagggtct tttaggataa attctctgaa ttgtacataa atagtcagcc 1080ttaccacata attttgggct gtggttgcat tttggagcgc atagcccagg cctgtgtgct 1140cgacattggt gtgggtattt aaatggagcc acagctggtt tcttttatta tttgggtgga 1200accaatcaat tgtttggtcc agctcaggtt tgggggtgaa gtacctggag tggtaggtaa 1260agggctgcct tatggtgtgg cgggaggagt agttaatata ggggtcatag gccaagttgg 1320tggagggggt tacaaagttg gcatccaaga taacaacagt ggacccaaca cctctttgat 1380tagaggtgat ggggtctctg gggtaaaatt catatttagc ctttctaata cggtagtatt 1440ggaaaggtag gggtaggggg ttggtgccgc ctgagggggg gaggaactgg ccgatgttga 1500atttcagcta gttaacattc caagatggct gcgagtatcc tccttttatg gtgagtacaa 1560attctgtaga aaggcgggaa ttgaagatac ccgtctttcg gcgccatctg taacggtttc 1620tgaaggcggg gtgtgccaaa tatggtcttc tccggaggat gtttccaaga tggctgcggg 1680ggcgggtcct tcttctgcgg taacgcctcc ttggccacgt catcctataa aagtgaaaga 1740agtgcgctgc tgtagtatt 1759 <210> SEQ ID NO 164 <211> LENGTH: 1759 <212>TYPE: DNA <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 164accagcgcac ttcggcagcg gcagcacctc ggcagcgtca gtgaaaatgc caagcaagaa 60aagcggcccg caaccccata agaggtgggt gttcaccctt aataatcctt ccgaggagga 120gaaaaacaaa atacgggagc ttccaatctc cctttttgat tattttgttt gcggagagga 180aggtttggaa gagggtagaa ctcctcacct ccaggggttt gctaattttg ctaagaagca 240gacttttaac aaggtgaagt ggtattttgg tgcccgctgc cacatcgaga aagcgaaagg 300aaccgaccag cagaataaag aatactgcag taaagaaggc cacatactta tcgagtgtgg 360agctccgcgg aaccagggga agcgcagcga cctgtctact gctgtgagta cccttttgga 420gacggggtct ttggtgactg tagccgagca gttccctgta acgtatgtga gaaatttccg 480cgggctggct gaacttttga aagtgagcgg gaagatgcag aagcgtgatt ggaagacagc 540tgtacacgtc atagtgggcc cgcccggttg tgggaagagc cagtgggccc gtaattttgc 600tgagcctagc gacacctact ggaagcctag tagaaataag tggtgggatg gatatcatgg 660agaagaagtt gttgttttgg atgattttta tggctggtta ccttgggatg atctactgag 720actgtgtgac cggtatccat tgactgtaga gactaaaggc ggtactgttc cttttttggc 780tcgcagtatt ttgattacca gcaatcaggc cccccaggaa tggtactcct caactgctgt 840cccagctgta gaagctctct atcggaggat tactactttg caattttgga agactgctgg 900agaacaatca acggaggtac ccgaaggccg atttgaagca gtggacccac cctgtgccct 960tttcccatat aaaataaatt actgagtctt ttttgttatc acatcgtaat ggtttttatt 1020tttatttatt tagagggtct tttaggataa attctctgaa ttgtacataa atagtcagcc 1080ttaccacata attttgggct gtggttgcat tttggagcgc atagcccagg cctgtgtgct 1140cgacattggt gtgggtattt aaatggagcc acagctggtt tcttttatta tttgggtgga 1200accattcaat tgtttggtcc agctcaggtt tgggggtgaa gtacctggag tggtaggtaa 1260agggctgcct tatggtgtgg cgggaggagt agttaatata ggggtcatag gccaagttgg 1320tggagggggt tacaaagttg gcatccaaga taacaacagt ggacccaaca cctctttcat 1380tagaggtgat ggggtctctg gggtaaaatt catatttagc ctttctaata cggtagtatt 1440ggaaaggtag gggtaggggg ttggtgccgc ctgagggggg gaggaactgg ccgatgttga 1500atctgaggtg gttaacatgc caagatggct gcgagtatcc tccttttatg gtgattacaa 1560attctttaga aaggcggcaa ttgaagatac ccgtctttcg gcgccatctg taacggtttc 1620tgaaggcggg gtgtgccaaa tatggtcttc tccggaggat gtttccaaga tggctgcggg 1680ggcgggtcct tcttctgcgg taacgcctcc ttggccacgt catcctataa aagtgaaaga 1740agtgcgctgc tgtagtatt 1759 <210> SEQ ID NO 165 <211> LENGTH: 312 <212>TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 165 MetPro Ser Lys Lys Ser Gly Pro Gln Pro His Lys Arg Trp Val Phe 1 5 10 15Thr Leu Asn Asn Pro Ser Gly Gly Gly Lys Asn Lys Ile Arg Gly Leu 20 25 30Pro Ile Ser Leu Phe Asp Tyr Phe Val Cys Gly Gly Gly Gly Leu Gly 35 40 45Gly Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe Ala Lys Lys 50 55 60Gln Thr Phe Asn Lys Val Lys Trp Tyr Phe Gly Ala Arg Cys His Ile 65 70 7580 Gly Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Gly Tyr Cys Ser Lys 85 9095 Gly Gly His Ile Leu Ile Gly Cys Gly Ala Pro Arg Asn Gln Gly Lys 100105 110 Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Gly Thr Gly Ser115 120 125 Leu Val Thr Val Ala Gly Gln Phe Pro Val Thr Tyr Val Arg AsnPhe 130 135 140 Arg Gly Leu Ala Gly Leu Leu Lys Val Ser Gly Lys Met GlnGln Arg 145 150 155 160 Asp Trp Lys Thr Ala Val His Val Ile Val Gly ProPro Gly Cys Gly 165 170 175 Lys Ser Gln Trp Ala Arg Asn Phe Ala Gly ProArg Asp Thr Tyr Trp 180 185 190 Lys Pro Ser Arg Asn Lys Trp Trp Asp GlyTyr His Gly Gly Gly Val 195 200 205 Val Val Leu Asp Asp Phe Tyr Gly TrpLeu Pro Trp Asp Asp Leu Leu 210 215 220 Arg Leu Cys Asp Arg Tyr Pro LeuThr Val Gly Thr Lys Gly Gly Thr 225 230 235 240 Val Pro Phe Leu Ala ArgSer Ile Leu Ile Thr Ser Asn Gln Ala Pro 245 250 255 Gln Gly Trp Tyr SerSer Thr Ala Val Pro Ala Val Gly Ala Leu Tyr 260 265 270 Arg Arg Ile ThrThr Leu Gln Phe Trp Lys Thr Ala Gly Gly Gln Ser 275 280 285 Thr Gly ValPro Gly Gly Arg Phe Gly Ala Val Asp Pro Pro Cys Ala 290 295 300 Leu PhePro Tyr Lys Ile Asn Tyr 305 310 <210> SEQ ID NO 166 <211> LENGTH: 312<212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE:166 Met Pro Ser Lys Lys Ser Gly Pro Gln Pro His Lys Arg Trp Val Phe 1 510 15 Thr Leu Asn Asn Pro Ser Gly Gly Gly Lys Asn Lys Ile Arg Gly Leu 2025 30 Pro Ile Ser Leu Phe Asp Tyr Phe Val Cys Gly Gly Gly Gly Leu Gly 3540 45 Gly Gly Arg Thr Ala His Leu Gln Gly Phe Ala Asn Phe Ala Lys Lys 5055 60 Gln Thr Phe Asn Lys Val Lys Trp Tyr Phe Gly Ala Arg Cys His Ile 6570 75 80 Gly Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Gly Tyr Cys Ser Lys85 90 95 Gly Gly His Ile Leu Ile Gly Cys Gly Ala Pro Arg Asn Gln Gly Lys100 105 110 Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Gly Thr GlySer 115 120 125 Leu Val Thr Val Ala Gly Gln Phe Pro Val Thr Tyr Val ArgAsn Phe 130 135 140 Arg Gly Leu Ala Gly Leu Leu Lys Val Ser Gly Lys MetGln Gln Arg 145 150 155 160 Asp Trp Lys Thr Ala Val His Val Ile Val GlyPro Pro Gly Cys Gly 165 170 175 Lys Ser Gln Trp Ala Arg Asn Phe Ala GlyPro Ser Asp Thr Tyr Trp 180 185 190 Lys Pro Ser Arg Asn Lys Trp Trp AspGly Tyr His Gly Gly Gly Val 195 200 205 Val Val Leu Asp Asp Phe Tyr GlyTrp Leu Pro Trp Asp Asp Leu Leu 210 215 220 Arg Leu Cys Asp Arg Tyr ProLeu Thr Val Gly Thr Lys Gly Gly Thr 225 230 235 240 Val Pro Phe Leu AlaArg Ser Ile Leu Ile Thr Ser Asn Gln Ala Pro 245 250 255 Gln Gly Trp TyrSer Ser Thr Ala Val Pro Ala Val Gly Ala Leu Tyr 260 265 270 Arg Arg IleThr Thr Leu Gln Phe Trp Lys Thr Ala Gly Gly Gln Ser 275 280 285 Thr GlyVal Pro Gly Gly Arg Phe Gly Ala Val Asp Pro Pro Cys Ala 290 295 300 LeuPhe Pro Tyr Lys Ile Asn Tyr 305 310 <210> SEQ ID NO 167 <211> LENGTH:233 <212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400>SEQUENCE: 167 Met Thr Trp Pro Arg Arg Arg Tyr Arg Arg Arg Arg Thr ArgPro Arg 1 5 10 15 Ser His Leu Gly Asn Ile Leu Arg Arg Arg Pro Tyr LeuAla His Pro 20 25 30 Ala Phe Arg Asn Arg Tyr Arg Trp Arg Arg Lys Thr GlyIle Phe Asn 35 40 45 Ser Arg Leu Ser Thr Glu Phe Val Leu Thr Ile Arg GlyGly His Ser 50 55 60 Gln Pro Ser Trp Asn Val Asn Tyr Leu Lys Phe Asn IleGly Gln Phe 65 70 75 80 Leu Pro Pro Ser Gly Gly Thr Asn Pro Leu Pro LeuPro Phe Gln Tyr 85 90 95 Tyr Arg Ile Arg Lys Ala Lys Tyr Glu Phe Tyr ProArg Asp Pro Ile 100 105 110 Thr Ser Asn Gln Arg Gly Val Gly Ser Thr ValVal Ile Leu Asp Ala 115 120 125 Asn Phe Val Thr Pro Ser Thr Asn Leu AlaTyr Asp Pro Tyr Ile Asn 130 135 140 Tyr Ser Ser Arg His Thr Ile Arg GlnPro Phe Thr Tyr His Ser Arg 145 150 155 160 Tyr Phe Thr Pro Lys Pro GluLeu Asp Gln Thr Ile Asp Trp Phe His 165 170 175 Pro Asn Asn Lys Arg AsnGln Leu Trp Leu His Leu Asn Thr His Thr 180 185 190 Asn Val Glu His ThrGly Leu Gly Tyr Ala Leu Gln Asn Ala Ala Thr 195 200 205 Ala Gln Asn TyrVal Val Arg Leu Thr Ile Tyr Val Gln Phe Arg Glu 210 215 220 Phe Ile LeuLys Asp Pro Leu Asn Lys 225 230 <210> SEQ ID NO 168 <211> LENGTH: 233<212> TYPE: PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE:168 Met Thr Trp Pro Arg Arg Arg Tyr Arg Arg Arg Arg Thr Arg Pro Arg 1 510 15 Ser His Leu Gly Asn Ile Leu Arg Arg Arg Pro Tyr Leu Val His Pro 2025 30 Ala Phe Arg Asn Arg Tyr Arg Trp Arg Arg Lys Thr Gly Ile Phe Asn 3540 45 Cys Arg Leu Ser Lys Glu Phe Val Ile Thr Ile Arg Gly Gly His Ser 5055 60 Gln Pro Ser Trp Ile Val Asn Ile Leu Arg Phe Asn Ile Gly Gln Phe 6570 75 80 Leu Pro Pro Ser Gly Gly Thr Asn Pro Leu Pro Leu Pro Phe Gln Tyr85 90 95 Tyr Arg Ile Arg Lys Ala Lys Tyr Glu Phe Tyr Pro Arg Asp Pro Ile100 105 110 Thr Ser Asn Glu Arg Gly Val Gly Ser Thr Val Val Ile Leu AspAla 115 120 125 Asn Phe Val Thr Pro Ser Thr Asn Leu Ala Tyr Asp Pro TyrIle Asn 130 135 140 Tyr Ser Ser Arg His Thr Ile Arg Gln Pro Phe Thr TyrHis Ser Arg 145 150 155 160 Tyr Phe Thr Pro Lys Pro Glu Leu Asp Gln ThrIle Glu Trp Phe His 165 170 175 Pro Asn Asn Lys Arg Asn Gln Leu Trp LeuHis Leu Asn Thr His Thr 180 185 190 Asn Val Glu His Thr Gly Leu Gly TyrAla Leu Gln Asn Ala Ala Thr 195 200 205 Ala Gln Asn Tyr Val Val Arg LeuThr Ile Tyr Val Gln Phe Arg Glu 210 215 220 Phe Ile Leu Lys Asp Pro LeuAsn Lys 225 230 <210> SEQ ID NO 169 <211> LENGTH: 206 <212> TYPE: PRT<213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 169 Met Ile SerIle Pro Pro Leu Ile Ser Thr Arg Leu Pro Val Gly Val 1 5 10 15 Pro ArgLeu Ser Lys Ile Thr Gly Pro Leu Ala Leu Pro Thr Thr Gly 20 25 30 Arg AlaHis Tyr Asp Val Tyr Ser Cys Leu Pro Ile Thr Leu Leu His 35 40 45 Leu ProAla His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser His 50 55 60 Ile ArgTyr Arg Glu Leu Leu Gly Tyr Ser His Gln Arg Pro Arg Leu 65 70 75 80 GlnLys Gly Thr His Ser Ser Arg Gln Val Ala Ala Leu Pro Leu Val 85 90 95 ProArg Ser Ser Thr Leu Asp Lys Tyr Val Ala Phe Phe Thr Ala Val 100 105 110Phe Phe Ile Leu Leu Val Gly Ser Phe Arg Phe Leu Asp Val Ala Ala 115 120125 Gly Thr Lys Ile Pro Leu His Leu Val Lys Ser Leu Leu Leu Ser Lys 130135 140 Ile Arg Lys Pro Leu Glu Val Arg Ser Ser Thr Leu Phe Gln Thr Phe145 150 155 160 Leu Ser Ala Asn Lys Ile Ile Lys Lys Gly Asp Trp Lys LeuPro Tyr 165 170 175 Phe Val Phe Leu Leu Leu Gly Arg Ile Ile Lys Gly GluHis Pro Pro 180 185 190 Leu Met Gly Leu Arg Ala Ala Phe Leu Ala Trp HisPhe His 195 200 205 <210> SEQ ID NO 170 <211> LENGTH: 206 <212> TYPE:PRT <213> ORGANISM: Type A PWD circovirus <400> SEQUENCE: 170 Met IleSer Ile Pro Pro Leu Ile Ser Thr Arg Leu Pro Val Gly Val 1 5 10 15 AlaArg Leu Ser Lys Ile Thr Gly Pro Leu Ala Leu Pro Thr Thr Gly 20 25 30 ArgAla His Tyr Asp Val Tyr Ser Cys Leu Pro Ile Thr Leu Leu His 35 40 45 LeuPro Ala His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser His 50 55 60 IleArg Tyr Arg Glu Leu Leu Gly Tyr Ser His Gln Arg Pro Arg Leu 65 70 75 80Gln Lys Gly Thr His Ser Ser Arg Gln Val Ala Ala Leu Pro Leu Val 85 90 95Pro Arg Ser Ser Thr Leu Asp Lys Tyr Val Ala Phe Phe Thr Ala Val 100 105110 Phe Phe Ile Leu Leu Val Gly Ser Phe Arg Phe Leu Asp Val Ala Ala 115120 125 Gly Thr Lys Ile Pro Leu His Leu Val Lys Ser Leu Leu Leu Ser Lys130 135 140 Ile Ser Lys Pro Leu Glu Val Ser Ser Ser Thr Leu Phe Gln ThrPhe 145 150 155 160 Leu Ser Ala Asn Lys Ile Ile Lys Lys Gly Asp Trp LysLeu Pro Tyr 165 170 175 Phe Val Phe Leu Leu Leu Gly Arg Ile Ile Lys GlyGlu His Pro Pro 180 185 190 Leu Met Gly Leu Arg Ala Ala Phe Leu Ala TrpHis Phe His 195 200 205

We claim:
 1. A vaccine comprising a nucleic acid having a nucleotidesequence with at least 90% sequence identity to SEQ ID No. 25 and anacceptable pharmaceutical vehicle, wherein said nucleic acid encodes animmunogenic protein that induces a protective response effective againstinfection by a piglet weight loss disease circovirus.
 2. A vaccineaccording to claim 1, wherein said nucleotide sequence is SEQ ID No. 25.3. A vaccine according to claim 1, further comprising an adjuvant.
 4. Avaccine according to claim 1, wherein said nucleic acid has a nucleotidesequence with at least 95% sequence identity to SEQ ID No.
 25. 5. Amethod of immunizing a mammal against piglet weight loss diseasecomprising administering to a mammal an effective amount of a vaccine,wherein said vaccine comprises a nucleic acid having a nucleotidesequence with at least 90% sequence identity to SEQ ID No. 25 and anacceptable pharmaceutical vehicle, wherein said nucleic acid encodes animmunogenic protein that induces a protective response effective againstinfection by a piglet weight loss disease circovirus.
 6. A methodaccording to claim 5, wherein said nucleotide sequence is SEQ ID No. 25.7. A method according to claim 5, wherein said vaccine further comprisesan adjuvant.
 8. A method according to claim 5, wherein said nucleic acidhas a nucleotide sequence with at least 95% sequence identity to SEQ IDNo.
 25. 9. A vaccine comprising a nucleic acid having a nucleotidesequence with at least 95% sequence identity to SEQ ID No. 25, anacceptable pharmaceutical vehicle, and an adjuvant, wherein said nucleicacid encodes an immunogenic protein that induces a protective responseeffective against infection by a piglet weight loss disease circovirus.10. A vaccine according to claim 9, wherein said nucleotide sequence isSEQ ID No.
 25. 11. A method of immunizing a mammal against piglet weightloss disease comprising administering to a mammal an effective amount ofa vaccine according to claim
 10. 12. A method of immunizing a mammalagainst piglet weight loss disease comprising administering to a mammalan effective amount of a vaccine according to claim 9.